Methods for producing blastogenic T cells, compositions containing the same, and methods for using the same
Patent Information
- Application Number
- JP2023531007
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-03-23
- Filing Date
- 2021-11-23
- Publication Date
- 2024-12-04
- Estimated Expiration
- Not applicable · inactive patent
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
Technical Field
[0001] Cross - reference to Related Applications This international patent application, filed in accordance with the Patent Cooperation Treaty (the "PCT"), claims priority to U.S. Provisional Patent Application No. 63 / 117,787, filed on November 24, 2020, U.S. Provisional Patent Application No. 63 / 153,881, filed on February 25, 2021, and U.S. Provisional Patent Application No. 63 / 165,093, filed on March 23, 2021, and incorporates the entire contents of each of them herein by reference.
Background Art
[0002] Tumor infiltrating lymphocytes ("TILs") are immune cells (e.g., T cells) found within tumors that can recognize and kill cancer cells. The adoptive transfer of autologous TILs has been widely studied, but one of the drawbacks of TIL - based therapies is that these cells often exhibit extensive differentiation and senescence cell markers along with loss of functionality. See, for example, Gurusamy, et al., 2020, Cancer Cell 37, 818 - 833; Jiang, et al., 2015, Cell Death Dis 6, e1792. Typically, TILs are mainly composed of TEM or TEMRA cells and have characteristics of exhaustion. Sakuishi et al., 2010, J Exp Med 207, 2187 - 2194. Furthermore, pre - clinical evidence strongly suggests that impairment of T cell function at the tumor site can contribute to the insufficient clinical efficacy of T cell products.
[0003] T cells (also called T lymphocytes) are a type of blood cell with unique characteristics that originates from stem cells found in the bone marrow. T cells prevent infection and fight cancer. T cells differ structurally and functionally from other cell types such as fibroblasts, requiring positive and negative selection in the thymus and undergoing complex development involving somatic gene rearrangement at the T cell receptor locus (see, for example, Kurd and Robey, Immunol Rev. 2016 May;271(1):114-126). While fibroblasts are also involved in the body's immune response, they are cells that synthesize the extracellular matrix and collagen, thereby creating the structural framework of animal tissues. Fibroblasts are primarily involved in the process of wound healing.
[0004] Tumor-responsive T cells, in addition to exhibiting increased depletion and differentiation, undergo induction of the cellular senescence pathway. Senescence is a process of progressive loss of potency and functionality resulting from aging and the repetition of the cell division cycle. Several features associated with cellular senescence are linked to T cell dysfunction, including epigenetic changes (Vodnala et al., 2019, Cancer Cell 37, 818-833 e819), reduced telomere length (Rosenberg et al., 2011, Clin Cancer Res 17, 4550-4557), and loss of functionality, proliferative capacity, and cell viability (Im et al., 2016, Nature 537, 417-421). While TIL-based cell therapies may mediate responses in some patients, clinical evidence indicates that TIL products with elevated CCR7 expression and increased telomere length are associated with improved treatment outcomes. Rosenberg et al., 2011, Clin Cancer Res 17, 4550-4557. Therefore, many groups have pursued methods of dedifferentiation or reprogramming of cells as a way to reverse T cell depletion, differentiation, and senescence.
[0005] Cell dedifferentiation (reprogramming) has been achieved in the past by using iPS cell technology to convert somatic cells back into pluripotent stem cells and then redifferentiate them into the desired cell lineage. (Takahashi et al., 2007, Cell 131, 861-872). iPS cell technology has been shown to be able to reprogram tumor antigen-specific tumor-infiltrating lymphocytes into iPS cells with the ability to generate T lineage cells in vitro. (Vizcardo et al., 2013, Cell Stem Cell 12, 31-36). Inducing cells into iPS cells has the advantage of completely resetting the cell's biological and epigenetic clocks.
[0006] However, iPS cells derived from T cells often exhibit abnormal ecology, such as immature phenotypes, non-MHC-dependent killing, inappropriate CD8αβ dimerization, dysregulation of gene expression, and a lack of ability to generate developmentally homogeneous T cell populations (see, for example, Vizcardo et al., 2018, Cell Rep 22, 3175-3190; Takada, K., Kondo, K., and Takahama, Y. 2017 J.Immunol. 198, 2215-2222; Yamagata, T., et al., (2004). Nat.Immunol. 5, 597-605; Fink, PJ (2013). Annu.Rev.Immunol. 31, 31-50; Kuderer, NM, et al., 2006 Cancer 106, 2258-2266). These limitations can be overcome by differentiating iPS cells in 3D thymic organoid cultures (see, e.g., Vizcardo et al., 2018, Cell Rep 22, 3175-3190), but these methods consume both a great deal of time and resources. To achieve commercially viable adoptive cell therapy using T cells, a more scalable method for reversing T cell depletion, differentiation, and senescence is desirable. [Overview of the Initiative]
[0007] Given that improving the antitumor function of T cells would be beneficial for all modalities of cellular immunotherapy, this disclosure relates to methods for improving the quality and antitumor capacity of therapeutic T cell products, compositions comprising such improved T cells, and methods for treating and other uses of improved T cell compositions. Accordingly, this system may be applicable to many other cancer treatment processes, such as T cells transduced with TCRs and CARs, in conjunction with cells genetically modified with anti-wasting or pro-functioning genes to improve the function of T cells in the tumor microenvironment.
[0008] This system is also suitable for novel methods of T cell augmentation in future culture medium repeats, as well as technological innovations devised with artificial neoproteins. In summary, the juvenile T cells of this disclosure can improve the efficiency of all modalities of cellular immunotherapy by generating T cells with improved growth capacity, improved metabolic quality, and enhanced persistence and ability to eliminate established solid tumors.
[0009] In various embodiments, the present disclosure relates to a method for producing juvenile T cells, comprising contacting a population of T cells with at least one reprogramming factor selected from the group consisting of KLF4, OCT3 / 4, SOX2, and C-MYC, and optionally SV40, for a period of time sufficient to form T cell-derived adherent cells, wherein the T cells are not transformed into iPS or pluripotent cells; and contacting the T cell-derived adherent cells with at least one T cell activator.
[0010] In various embodiments, the present disclosure provides a method for producing juvenile T cells, comprising contacting T cells with (i) at least one reprogramming factor selected from the group consisting of KLF4, OCT3 / 4, SOX2 and C-MYC, and (ii) optionally SV40 for a period of time sufficient to form T cell-derived adherent cells, wherein the T cells are not transformed into iPS or totipotent cells; and contacting the T cell-derived adherent cells with at least one T cell activator.
[0011] In various embodiments, the present disclosure relates to a method for producing T cells, comprising contacting a population of T cells in a first culture medium in a culture vessel with at least one reprogramming factor selected from the group consisting of KLF4, OCT3 / 4, SOX2, and C-MYC, and optionally SV40, for a period of time sufficient to cause at least one colony to form attached to the surface of the culture vessel, wherein the T cells are not transformed into iPS cells, and contacting at least one attached colony with at least one T cell activator.
[0012] In various embodiments, the present disclosure relates to a method for producing T cells, comprising contacting a population of isolated T cells in a first culture medium with at least one reprogramming factor selected from the group consisting of KLF4, OCT3 / 4, SOX2, and C-MYC, as well as SV40, for a period of at least about 5 to about 10 days, such that the T cells are not transformed into iPS cells or pluripotent cells, and contacting the contacted T cells with at least one T cell activator.
[0013] In various embodiments, the present disclosure relates to a method for producing at least one T cell, comprising contacting an isolated population of T cells with at least one reprogramming factor selected from the group consisting of KLF4, OCT3 / 4, SOX2, and C-MYC, as well as SV40, for a period of time sufficient to cause the T cells to express at least one marker selected from the group consisting of SSEA4, CD9, and CD90, wherein the T cells are not transformed into iPS cells or pluripotent cells, and contacting the contacted T cells with at least one T cell activator.
[0014] In various embodiments, isolated T cells are exposed to at least one reprogramming factor for a period of time sufficient to cause at least a portion of the T cells to express CD3 and at least one marker selected from the group consisting of SSEA4, CD9, and CD90. In various embodiments, the T cells are transiently exposed to at least one reprogramming factor for a period of time sufficient to cause at least a portion of the exposed T cells to express SSEA4 and CD3. In various embodiments, the T cells are transiently exposed to at least one reprogramming factor for a period of time sufficient to cause at least a portion of the exposed T cells to express CD3, CD9, and CD90. In various embodiments, the T cells are exposed to at least one reprogramming factor for a period of time sufficient to cause at least a portion of the exposed T cells to express CD3, SSEA4, CD9, and CD90.
[0015] In various embodiments, the isolated T cells are transiently exposed to IL-2 and at least one compound capable of activating the isolated T cells before contacting them with at least one reprogramming factor. In various embodiments, the T cells are TCRαβ T cells, TCRgd T cells, CD4+CD8αβ+ bipositive cells, CD4+ monopositive cells (Th1, Th2, Th17, Treg, etc.), naive T cells, central memory T cells, or effector memory T cells. In various embodiments, the T cells are TILs. In various embodiments, the isolated T cells are isolated from mammals.
[0016] In various embodiments, isolated T cells are transiently exposed to KLF4, OCT3 / 4, SOX2, and C-MYC. In various embodiments, isolated T cells are transiently exposed to KLF4, OCT3 / 4, SOX2, and C-MYC for at least about 4 to 10 days.
[0017] In various embodiments, isolated T cells are contacted with KLF4, OCT3 / 4, SOX2, and C-MYC for at least about 4 to 7 days. In various embodiments, isolated T cells are contacted with KLF4, OCT3 / 4, SOX2, and C-MYC for about 5 days.
[0018] In various embodiments, KLF4, OCT3 / 4, SOX2, and C-MYC are transiently expressed in T cells. In various embodiments, KLF4, OCT3 / 4, SOX2, and C-MYC are transiently expressed using non-integrated viral vectors. In this regard, T cells may be transduced with one or more viral vectors encoding reprogramming factors. In various embodiments, KLF4, OCT3 / 4, SOX2, and C-MYC are transiently expressed using Sendai virus. In various embodiments, KLF4, OCT3 / 4, SOX2, and C-MYC are constitutively expressed, and then their expression is inhibited by the addition of compounds that inhibit the expression of KLF4, OCT3 / 4, SOX2, and C-MYC. In various embodiments, the compounds are small molecule inhibitors that specifically inhibit the expression of one or more of KLF4, OCT3 / 4, SOX2, and C-MYC. In various embodiments, the compound is an siRNA or shRNA molecule that specifically inhibits the expression of one or more of KLF4, OCT3 / 4, SOX2, and C-MYC. In various embodiments, KLF4, OCT3 / 4, SOX2, and C-MYC are transiently expressed after delivery using nanoparticles.
[0019] In various embodiments, the disclosure provides further contact of contacted T cells (i.e., partially reprogrammed T cells) with at least one T cell activating compound and optionally at least one cytokine selected from the group consisting of IL-2, IL-7, IL-15, and IL-12. In various embodiments, the partially reprogrammed cells are T cell-derived adherent cells. In various embodiments, the at least one T cell activating compound comprises an antibody that binds to CD3, or an antibody that binds to CD28, or both, or the at least one T cell activating compound is a tumor antigen. In various embodiments, the disclosure provides further engineering of T cells to express a cell surface receptor, wherein the T cells are engineered before contacting the T cells with the at least one reprogramming factor. In various embodiments, the disclosure provides further engineering of T cells to express a cell surface receptor, wherein the T cells are engineered after transient contact with the at least one reprogramming factor.
[0020] In various embodiments, the cell surface receptor is either a chimeric antigen receptor, an engineered T cell receptor, or a hybrid receptor thereof. In various embodiments, the cell surface receptor recognizes a specific antigenic moiety on the surface of a target cell. In various embodiments, the antigenic moiety is MHC class I dependent. In various embodiments, the antigenic moiety is MHC class I independent.
[0021] In various embodiments, the resulting T cells contain an incomplete set of V, D, and J segments of the T cell receptor gene. In various embodiments, the disclosure provides further measurement of the epigenetic age of the resulting T cells. In various embodiments, the epigenetic age of the resulting T cells is at least 5% younger than the population of T cells before reprogramming. In various embodiments, the partially reprogrammed T cells can be increased by at least 25 times compared to the initially isolated cells. In various embodiments, the disclosure provides that a reduction in CD3 and CD8 expression is obtained by further contacting the isolated T cells with at least one factor selected from the group consisting of KLF4, OCT3 / 4, SOX2, and C-MYC, as well as SV40.
[0022] In various embodiments, the present disclosure provides a method for producing T cells, comprising: obtaining a plurality of isolated T cells from a source; culturing the isolated T cells in a first medium containing IL-2; activating the isolated T cells with at least one T cell activating compound or agent, as well as a co-stimulatory agent such as an antibody specific to CD3 and / or CD28; transiently contacting the activated T cells with KLF4, OCT3 / 4, SOX2 and C-MYC in a second culture medium not containing IL-2 or an antibody specific to CD3 or CD28 for a period of about 5 to about 10 days, such that the isolated T cells are not fully reprogrammed into iPS cells; and replacing the second culture medium with a third culture medium containing IL-2 and at least one antibody specific to CD3 and / or CD28, such that the transiently contacted T cells are cultured in the third culture medium for at least about 5 days.
[0023] In various embodiments, the disclosure provides a method for further increasing the partially reprogrammed and reactivated T cells. In various embodiments, the T cells are TCRαβ cells, TCRgd cells, CD4+CD8αβ+ double-positive cells, CD4+ mono-positive cells (Th1, Th2, Th17, Treg), naive T cells, central memory T cells, or effector memory T cells. In various embodiments, the T cells are tumor-infiltrating lymphocytes (TILs).
[0024] In various embodiments, the disclosure provides a population of T cells whose epigenetic age is at least 5% younger than their chronological age. In various embodiments, the disclosure provides a population of T cells whose epigenetic age is at least 25% younger than their chronological age. In various embodiments, the disclosure provides a population of T cell-derived adherent cells in which at least 70% of the cells express both CD3 and SSEA4. In various embodiments, the disclosure provides a population of T cell-derived adherent cells in which at least 30% of the cells express either CD9 or CD90 or both CD9 and CD90.
[0025] In various embodiments, the present invention provides a population of tumor-infiltrating lymphocytes in which at least 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the tumor-infiltrating lymphocytes express both CCR7 and CD62L. In various embodiments, the present invention provides a population of tumor-infiltrating lymphocytes in which at least 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the tumor-infiltrating lymphocytes express both CCR7 and TCF7.
[0026] In various embodiments, the present disclosure provides a population of T cells produced by a method comprising: contacting a population of T cells with at least one reprogramming factor selected from the group consisting of KLF4, OCT3 / 4, SOX2, and C-MYC, and optionally SV40, for a period sufficient to form T cell-derived adherent cells, wherein the isolated T cells are not transformed into iPS or totipotent cells; and contacting the T cell-derived adherent cells with at least one T cell activating compound.
[0027] In various embodiments, the present disclosure provides a population of T cells produced by a method comprising: contacting a population of isolated T cells in a first culture medium within a culture vessel with at least one reprogramming factor selected from the group consisting of KLF4, OCT3 / 4, SOX2, and C-MYC, and optionally SV40, for a period sufficient to form at least one colony of the isolated T cells attached to the surface of the culture vessel, wherein the isolated T cells are not transformed into iPS cells; and contacting the at least one attached colony with at least one T cell activating compound.
[0028] In various embodiments, the present disclosure provides a population of T cells produced by a method comprising: contacting a population of isolated T cells in a first culture medium with at least one reprogramming factor selected from the group consisting of KLF4, OCT3 / 4, SOX2, and C-MYC, and SV40, for a period of at least about 5 days and up to about 10 days, wherein the isolated T cells are not transformed into iPS cells; and contacting the transiently contacted T cells with at least one T cell activating compound.
[0029] In various embodiments, the present disclosure provides a population of T cells produced by a method comprising: contacting a population of isolated T cells with at least one reprogramming factor selected from the group consisting of KLF4, OCT3 / 4, SOX2, and C-MYC, and SV40 for a period sufficient to cause the isolated T cells to express at least one marker selected from the group consisting of SSEA4, CD9, and CD90, such that the isolated T cells are not transformed into iPS cells; and contacting the transiently contacted T cells with at least one T cell activating compound.
[0030] In various embodiments, isolated T cells are transiently contacted with at least one reprogramming factor for a period sufficient to cause at least a portion of the isolated T cells to express CD3 and at least one marker selected from the group consisting of SSEA4, CD9, and CD90. In various embodiments, isolated T cells are transiently contacted with at least one reprogramming factor for a period sufficient to cause at least a portion of the transiently contacted T cells to express SSEA4 and CD3. In various embodiments, isolated T cells are transiently contacted with at least one reprogramming factor for a period sufficient to cause at least a portion of the transiently contacted T cells to express CD3, CD9, and CD90. In various embodiments, isolated T cells are transiently contacted with at least one reprogramming factor for a period sufficient to cause at least a portion of the transiently contacted T cells to express CD3, SSEA4, CD9, and CD90.
[0031] In various embodiments, prior to contacting the isolated T cells with at least one reprogramming factor, the transiently contacted T cells are contacted with IL-2 and at least one compound capable of activating the isolated T cells.
[0032] In various embodiments, the T cells are TCRαβ cells, TCRγδ cells, CD4+CD8αβ+ double-positive cells, CD4+ mono-positive cells (Th1, Th2, Th17, Treg, etc.), naive T cells, central memory T cells, or effector memory T cells. In various embodiments, the T cells are TILs. In various embodiments, the isolated T cells are isolated from mammals. In various embodiments, the isolated T cells are transiently exposed to KLF4, OCT3 / 4, SOX2, and C-MYC.
[0033] In various embodiments, isolated T cells are transiently exposed to KLF4, OCT3 / 4, SOX2, and C-MYC for at least about 4 to 10 days. In various embodiments, isolated T cells are transiently exposed to KLF4, OCT3 / 4, SOX2, and C-MYC for at least about 4 to 7 days.
[0034] In various embodiments, isolated T cells are transiently exposed to KLF4, OCT3 / 4, SOX2, and C-MYC for approximately 5 days. In various embodiments, KLF4, OCT3 / 4, SOX2, and C-MYC are transiently expressed within T cells. In various embodiments, KLF4, OCT3 / 4, SOX2, and C-MYC are transiently expressed using a non-integrated viral vector. In various embodiments, KLF4, OCT3 / 4, SOX2, and C-MYC are transiently expressed using Sendai virus. In various embodiments, KLF4, OCT3 / 4, SOX2, and C-MYC are constitutively expressed, and then their expression is inhibited by the addition of a compound that inhibits the expression of KLF4, OCT3 / 4, SOX2, and C-MYC. In various embodiments, the compound is a small molecule inhibitor that specifically inhibits the expression of one or more of KLF4, OCT3 / 4, SOX2, and C-MYC. In various embodiments, the compound is an siRNA or shRNA molecule that specifically inhibits the expression of one or more of KLF4, OCT3 / 4, SOX2, and C-MYC. In various embodiments, KLF4, OCT3 / 4, SOX2, and C-MYC are transiently expressed using nanoparticles.
[0035] In various embodiments, the disclosure provides further contact of transiently contacted T cells (e.g., partially reprogrammed T cells) with at least one cytokine selected from the group consisting of IL-2, IL-7, IL-15, and IL-12, and / or at least one T cell activating agent, and / or at least one T cell costimulator (e.g., anti-CD3 and / or anti-CD28 antibodies). In various embodiments, the at least one T cell activating compound comprises an antibody that binds to CD3, or an antibody that binds to CD28, or both, or the at least one T cell activating compound is a tumor antigen.
[0036] In various embodiments, the disclosure provides further engineering of T cells to express a cell surface receptor, wherein the T cells are engineered before transient contact with the at least one reprogramming factor. In various embodiments, the disclosure provides further engineering of T cells to express a cell surface receptor, wherein the T cells are engineered after transient contact with the at least one reprogramming factor.
[0037] In various embodiments, the cell surface receptor is either a chimeric antigen receptor, a T cell receptor, or a hybrid receptor thereof. In various embodiments, the cell surface receptor recognizes a specific antigenic moiety on the surface of a target cell. In various embodiments, the antigenic moiety is MHC class I dependent. In various embodiments, the antigenic moiety is MHC class I independent. In various embodiments, the resulting T cells contain an incomplete set of V, D, and J segments of the T cell receptor gene. In various embodiments, the disclosure provides further measurement of the epigenetic age of the resulting T cells. In various embodiments, the epigenetic age of the resulting T cells is at least 5% younger than the population of T cells before reprogramming. In various embodiments, the partially reprogrammed T cells can be increased by at least 25 times compared to the initially isolated cells. In various embodiments, the disclosure provides that a reduction in CD3 and CD8 expression is obtained by further contacting the isolated T cells with at least one factor selected from the group consisting of KLF4, OCT3 / 4, SOX2, and C-MYC, as well as SV40.
[0038] In various embodiments, the present disclosure relates to a population of T cells produced by a method comprising: obtaining a plurality of isolated T cells from a source; culturing the isolated T cells in a first medium containing IL-2; activating the isolated T cells with at least one antibody specific to CD3 and / or CD28; transiently contacting the activated T cells with KLF4, OCT3 / 4, SOX2 and C-MYC in a second culture medium not containing IL-2 or an antibody specific to CD3 and / or CD28 for a period of about 5 to about 10 days, such that the isolated T cells are not fully reprogrammed into iPS cells; and exchanging the second culture medium with a third culture medium containing IL-2 and at least one antibody specific to CD3 and / or CD28, such that the transiently contacted T cells are cultured in the third culture medium for at least about 5 days.
[0039] In various embodiments, the disclosure relates to further increasing the transiently exposed T cells. In various embodiments, the T cells are TCRαβ cells, TCRγδ cells, CD4+CD8αβ+ double-positive cells, CD4+ mono-positive cells (Th1, Th2, Th17, Treg), naive T cells, central memory T cells, or effector memory T cells. In various embodiments, the T cells are tumor-infiltrating lymphocytes (TILs).
[0040] In various embodiments, this disclosure relates to a method for treating a patient in need using or by a population of T cells produced by the method disclosed herein. In various embodiments, the treatment method is a method for treating cancer, viral conditions, or autoimmune disorders.
[0041] In various embodiments, cancers include acute lymphoblastic carcinoma, acute myeloid leukemia, alveolar rhabdomyosarcoma, bone cancer, brain cancer, breast cancer, cancer of the anus, anal canal, or anorectal cancer, eye cancer, intrahepatic cholangiocarcinoma, joint cancer, cancer of the neck, gallbladder, or pleura, head and neck cancer (e.g., cancer of the nose, nasal cavity, or middle ear, oral cancer), vulvar cancer, chronic lymphoblastic leukemia, chronic bone marrow cancer, colon cancer, esophageal cancer, and children. These include cervical cancer, gastrointestinal carcinoid tumors, Hodgkin lymphoma, hypopharyngeal cancer, kidney cancer, laryngeal cancer, liver cancer, lung cancer, malignant mesothelioma, melanoma, multiple myeloma, nasopharyngeal cancer, non-Hodgkin lymphoma, ovarian cancer, pancreatic cancer, cancers of the peritoneum, retinoplasm, and mesentery, pharyngeal cancer, prostate cancer, rectal cancer, kidney cancer (e.g., renal cell carcinoma (RCC)), small intestine cancer, soft tissue cancer, gastric cancer, testicular cancer, thyroid cancer, ureteral cancer, or bladder cancer.
[0042] In various embodiments, the present invention relates to a method for producing at least one juvenile T cell, comprising: a) isolating T cells from a tumor, wherein the T cells are tumor-infiltrating lymphocytes and the tumor-infiltrating lymphocytes express CD137; b) activating the tumor-infiltrating lymphocytes with at least one T cell activating compound, wherein the T cell activating compound is a tumor antigen; c) transiently contacting the isolated population of T cells with at least one reprogramming factor selected from the group consisting of KLF4, OCT3 / 4, SOX2, and C-MYC, and optionally SV40, for a period of time sufficient to form T cell-derived adherent cells, wherein the isolated T cells are not transformed into iPS cells or pluripotent cells; and d) contacting the T cell-derived adherent cells with at least one T cell activating compound.
[0043] In various embodiments, the present invention relates to a method for producing at least one immature tumor-infiltrating lymphocyte (TIL), the method comprising: (a) isolating the TIL from a tumor such that the TIL expresses CD137; (b) activating the TIL with at least one first tumor antigen; and (c) transiently contacting the isolated population of TILs with (i) at least one reprogramming factor selected from the group consisting of KLF4, OCT3 / 4, SOX2 and C-MYC, and (ii) optionally SV40 for a period of time sufficient to form TIL-derived adherent cells, such that the isolated TIL is not transformed into iPS or pluripotent cells.
[0044] In various embodiments, the present invention relates to a method for producing juvenile T cells, comprising: contacting a population of T cells with (i) at least one reprogramming factor selected from the group consisting of KLF4, OCT3 / 4, SOX2 and C-MYC, and (ii) optionally SV40 for a period of time sufficient to cause at least 20% of the contacted T cells to express α6β1 integrin, wherein the contacted T cells are not transformed into iPS cells; isolating the at least 20% of the contacted T cells with a binding molecule that specifically binds to α6β1 integrin; and (b) contacting the isolated cells with a T cell activating agent and / or a T cell costimulating agent to produce juvenile T cells.
[0045] In various embodiments, the present invention relates to a method for producing at least one juvenile T cell, comprising: transiently contacting a population of T cells with (i) at least one reprogramming factor selected from the group consisting of KLF4, OCT3 / 4, SOX2 and C-MYC, and (ii) optionally SV40 for a period of time sufficient to form T cell-derived adherent cells, wherein the T cells are not transformed into iPS or totipotent cells; isolating a subpopulation of T cell-derived adherent cells expressing either or both a6(CD49f) or b1(CD29) integrins; and contacting the isolated subpopulation with at least one T cell activating compound.
[0046] In various embodiments, the present invention relates to a population of juvenile T cells produced by a method comprising: contacting the population of T cells with (i) at least one reprogramming factor selected from the group consisting of KLF4, OCT3 / 4, SOX2 and C-MYC, and (ii) SV40 for a period of time sufficient to form T cell-derived adherent cells, wherein the T cells are not transformed into iPS or totipotent cells; isolating a subpopulation of T cell-derived adherent cells expressing a6 integrin, b1 integrin, or both; and contacting the subpopulation of T cell-derived adherent cells with at least one T cell activating compound.
[0047] In various embodiments, the present invention relates to a population of T cell-derived adherent cells in which at least 70% of the cells express integrin α6 or integrin β1.
[0048] In various embodiments, the present invention relates to a population of T cell-derived adherent cells in which at least 50% of the cells express both integrin α6 and integrin β1.
[0049] In various embodiments, the present invention relates to a population of T cell-derived adherent cells in which at least 70% of the cells express both integrin α6 and integrin β1.
[0050] Additional features and aspects of the present invention will be understood by those skilled in the art in consideration of the following disclosure and the appended claims and drawings. [Brief explanation of the drawing]
[0051] [Figure 1]This paper describes an experimental design for partial reprogramming using Sendai virus transduction. T cells isolated from peripheral blood mononuclear cells (PBMCs) were activated for 3 days in CD3, CD28-activated culture medium containing IL2 (-2 to 0 days). On day 0, the cells were (i) left undisturbed (Group 1); (ii) placed in stem cell culture medium without IL2 (Group 2); (iii) placed in stem cell culture medium without IL2 and transduced with two Sendai viruses (one expressing EmGFP and the other expressing SV40) (Group 3); or (iv) placed in stem cell culture medium without IL2 and transduced with four Sendai viruses expressing KOS (KLF4, OCT3 / 4, SOX2), KLF4, cMyc, and SV40 (Group 4). Expression continued for 5 days. [Figure 2] The fourth group of colonies was formed starting on day 4 after transduction of a Sendai virus expressing OSKM+SV40, and continued until day 9. [Figure 3A] The differences in morphology of T cells cultured under different conditions as described in Example 1 are shown. Figure 3A shows colony formation of adherent cells from Group 4, Figure 3B shows T cells from Group 3 that do not show adhesion or colony formation, and Figure 3C shows the same panel as Figure 3A for comparison with Figure 3D. Figure 3D shows T cells after 3 days in standard T cell culture medium stimulated with anti-CD3 antibody (100 ng / ml) and anti-CD28 antibody (2 μg / ml), and Figure 3E is the same panel as Figure 3A for comparison with Figure 3F. Figure 3F shows a normal iPS cell colony. The adherent cells shown in Figures 3A, 3C, and 3E are referred to herein as T cell-derived adherent cells. [Figure 3B]The differences in morphology of T cells cultured under different conditions as described in Example 1 are shown. Figure 3A shows colony formation of adherent cells from Group 4, Figure 3B shows T cells from Group 3 that do not show adhesion or colony formation, and Figure 3C shows the same panel as Figure 3A for comparison with Figure 3D. Figure 3D shows T cells after 3 days in standard T cell culture medium stimulated with anti-CD3 antibody (100 ng / ml) and anti-CD28 antibody (2 μg / ml), and Figure 3E is the same panel as Figure 3A for comparison with Figure 3F. Figure 3F shows a normal iPS cell colony. The adherent cells shown in Figures 3A, 3C, and 3E are referred to herein as T cell-derived adherent cells. [Figure 3C] The differences in morphology of T cells cultured under different conditions as described in Example 1 are shown. Figure 3A shows colony formation of adherent cells from Group 4, Figure 3B shows T cells from Group 3 that do not show adhesion or colony formation, and Figure 3C shows the same panel as Figure 3A for comparison with Figure 3D. Figure 3D shows T cells after 3 days in standard T cell culture medium stimulated with anti-CD3 antibody (100 ng / ml) and anti-CD28 antibody (2 μg / ml), and Figure 3E is the same panel as Figure 3A for comparison with Figure 3F. Figure 3F shows a normal iPS cell colony. The adherent cells shown in Figures 3A, 3C, and 3E are referred to herein as T cell-derived adherent cells. [Figure 3D] The differences in morphology of T cells cultured under different conditions as described in Example 1 are shown. Figure 3A shows colony formation of adherent cells from Group 4, Figure 3B shows T cells from Group 3 that do not show adhesion or colony formation, and Figure 3C shows the same panel as Figure 3A for comparison with Figure 3D. Figure 3D shows T cells after 3 days in standard T cell culture medium stimulated with anti-CD3 antibody (100 ng / ml) and anti-CD28 antibody (2 μg / ml), and Figure 3E is the same panel as Figure 3A for comparison with Figure 3F. Figure 3F shows a normal iPS cell colony. The adherent cells shown in Figures 3A, 3C, and 3E are referred to herein as T cell-derived adherent cells. [Figure 3E]The differences in morphology of T cells cultured under different conditions as described in Example 1 are shown. Figure 3A shows colony formation of adherent cells from Group 4, Figure 3B shows T cells from Group 3 that do not show adhesion or colony formation, and Figure 3C shows the same panel as Figure 3A for comparison with Figure 3D. Figure 3D shows T cells after 3 days in standard T cell culture medium stimulated with anti-CD3 antibody (100 ng / ml) and anti-CD28 antibody (2 μg / ml), and Figure 3E is the same panel as Figure 3A for comparison with Figure 3F. Figure 3F shows a normal iPS cell colony. The adherent cells shown in Figures 3A, 3C, and 3E are referred to herein as T cell-derived adherent cells. [Figure 3F] The differences in morphology of T cells cultured under different conditions as described in Example 1 are shown. Figure 3A shows colony formation of adherent cells from Group 4, Figure 3B shows T cells from Group 3 that do not show adhesion or colony formation, and Figure 3C shows the same panel as Figure 3A for comparison with Figure 3D. Figure 3D shows T cells after 3 days in standard T cell culture medium stimulated with anti-CD3 antibody (100 ng / ml) and anti-CD28 antibody (2 μg / ml), and Figure 3E is the same panel as Figure 3A for comparison with Figure 3F. Figure 3F shows a normal iPS cell colony. The adherent cells shown in Figures 3A, 3C, and 3E are referred to herein as T cell-derived adherent cells. [Figure 4] The images show CD3 expression on days 3, 4, and 5 of partial reprogramming. Notably, the reprogrammed cells in group 4 showed CD3 loss during the partial reprogramming process. [Figure 5] The lateral scatter / forward scatter (SSC / FSC) FACS plot of adherent cells in group 4 is shown, indicating that adherent cells are larger and have a more complex structure compared to cells in groups 1 and 3. [Figure 6] This is an SSC / FSC FACS contour plot showing that adherent cells grow larger and develop a more complex structure on day 5. [Figure 7]This study demonstrates that adherent cells in Group IV regain CD3 and CD8 expression after 2 days of T cell activation followed by a further 5 days of culture in T cell culture medium. T cells were activated on day 5 in a 96-well plate using 1:100 diluted (1:100) T cell TRANSACT® (Miltenyi Biotec) in T cell culture medium over 2 days. Cells under Group IV conditions were separated into two wells on day 5 by pipetting, separating suspension and adherent cells. All cells were cultured in T cell culture medium for a further 5 days after activation. [Figure 8] The phenotype of CD3-positive cells on day 12 is shown. CCR7 and CD62L are markers for detecting certain T cell types, such as naive, memory stem cells, and central memory T cells. The cells regained CD3 expression on day 12, showing a return to the T cell phenotype. [Figure 9] The bar graphs show cell growth on days 0, 5, and 12. Cell growth was measured by counting beads (123 count eBeads Counting beads, Thermo) using flow cytometry. Adherent cells in group 4 showed an abnormal appearance and reduced CD3 expression on day 5, but responded to activation and grew after activation from day 5. The ratio of change from day 5 to day 12 showed increased growth in group 4 compared to group 1, particularly for adherent cells. This indicates that the partial rejuvenation method used herein increases T cell growth capacity, especially in adherent cells. [Figure 10] This is a FACS contour plot analysis of SSEA4 and CD3 expression in partially reprogrammed T cells. Sendai virus-infected T cells described in Example 2 were transferred to iMatrix coated dishes on day 1 and cultured in iPS cell medium + 60 IU / ml IL2 for 3 days, then switched to iPS cell medium without IL2 from day 4. FACS analysis was performed on day 8 of reprogramming. This figure shows that partially reprogrammed T cells express the hiPS cell marker SSEA4 and lose the expression of the CD3 T cell marker. [Figure 11] This is a schematic diagram outlining the partial reprogramming of PBMC-derived CD8 T cells (see Example 4 and Table 4). [Figure 12] A and B show the results from flow cytometry measuring CD8a, CD8b, and CD3 in cells partially reprogrammed over the number of days indicated before reactivation. A shows FACS plots for CD8a and CD8b expression on days 7, 9, and 10, and B is a graph plotting the percentage of cells positive for CD8a and CD8ab from days 6 to 10. See Example 4. The CD4-CD8a+ population was gated for further analysis of CD8B and CD3. "No Sendai infection" means that CD8 T cells received the first and second stimulation but were not infected with Sendai virus (no reprogramming factors). [Figure 13] This is a schematic diagram outlining the partial reprogramming and reactivation of NY-ESO-1+ T cells. For clarity, different stages of the entire process are labeled. [Figure 14] Graphs A-D show the results of cytokine production and degranulation assays of juvenile NY-ESO-1 TCR transduction T cells. FACS results were analyzed using FlowJo software. For NY-ESO-1 Tg T cells, gating was performed as follows: single cell > live cell > CD3+ > CD8+CD4-> NY-ESO-1 tetramer+ cell. For mock control T cells, gating was performed as follows: single cell > live cell > CD3+ > CD8+CD4-> NY-ESO-1 tetramer- cell. The frequencies of IFNg+ (A), TNFa+ (B), IL-2+ (C), and CD107a+ (D) were calculated and plotted as shown in the figure. [Figure 15] This is a waterfall plot of the ratio of cell surface marker expression levels in stimulated T cells to those in T cell-derived iPS cells (see also Table 5). [Figure 16] This is a waterfall plot of the ratio of cell surface marker expression levels in unstimulated T cells to those in T cell-derived iPS cells (see also Table 5). [Figure 17] This suggests that CD9 and CD90 are potential cell surface marker indicators in the early stages of partially reprogrammed T cells. The figure shows flow cytometry analysis of CD9 and CD90 expression in stimulated T cells, unstimulated T cells, and adherent partially reprogrammed T cells (T cell-derived adherent cells) on day 5. Unlike CD9 and CD90 expression, the expression of the early iPS cell surface marker SSEA4 did not significantly change in T cell-derived adherent cells on day 5. [Figure 18A] This shows that stimulus signaling is crucial for partially reprogrammed T cells to regain expression of conventional T cell markers CD3 and CD8a, and to survive and proliferate. The FACS contour plot shows the percentage of partially reprogrammed cells expressing CD3 and CD8a on day 7 (shedding day). [Figure 18B] This study demonstrates that stimulus signaling is crucial for partially reprogrammed T cells to regain expression of conventional T cell markers CD3 and CD8a, and to survive and proliferate. The FACS contour plots show the percentage of cells expressing CD3 and CD8a after 20 days of either activation with TRANSACT at a dilution of 1:500 or 1:1000, or T cell culture medium (TCM + IL2 60 IU / ml) alone. [Figure 18C] This study demonstrates that stimulus signaling is crucial for partially reprogrammed T cells to regain expression of conventional T cell markers CD3 and CD8a, and to survive and proliferate. It also shows proliferation in different groups. [Figure 18D] This study demonstrates that stimulus signaling is crucial for partially reprogrammed T cells to regain expression of conventional T cell markers CD3 and CD8a, and to survive and proliferate. Survival rates for different groups are shown. [Figure 19]Figures A and B show that immature T cells exhibit dramatically improved sustained proliferation in vitro. T cells were obtained from a 37-year-old female (37y F), a 42-year-old male (42y M), and a 52-year-old male (52y M) donor. [Figure 20A] This study demonstrates the effect of IL-2 on juvenified T cells. Juvenified T cells were co-cultured in IL-2-free TCM 45 days after juvenation. FACS results were analyzed using FlowJo software. Gating was performed for all cell populations: single cells > viable cells > CD3+ cells. [Figure 20B] This study demonstrates the effect of IL-2 on juvenified T cells. 45 days after juvenation, juvenified T cells were co-cultured in a TCM without IL-2. FACS results were analyzed using FlowJo software. Gating was performed for all cell populations: single cells > viable cells > CD3+ cells. As can be seen in Figures 20B and 20C, cells co-cultured without IL-2 died within 6 days. [Figure 20C] This study demonstrates the effect of IL-2 on juvenified T cells. 45 days after juvenation, juvenified T cells were co-cultured in a TCM without IL-2. FACS results were analyzed using FlowJo software. Gating was performed for all cell populations: single cells > viable cells > CD3+ cells. As can be seen in Figures 20B and 20C, cells co-cultured without IL-2 died within 6 days. [Figure 21] The results from T-cell cytokine production assays of juvenified 37-year-old women, 42-year-old men, and 52-year-old men are shown. FACS results were analyzed using FlowJo software. For all cell populations, single-cell > viable cell > CD3+ > CD8+CD4- cell gating was performed. The frequencies of IL2+ and IFNg+ were calculated and plotted as shown in the figure. [Figure 22]Figures A-C show that immature T cells exhibit an effector phenotype after prolonged growth. Sendai virus-infected T cells were transferred to iMatrix-coated dishes on day 1 and cultured for 3 days in T cell medium + 60 IU / ml IL-2 or iPS cell medium + 60 IU / ml IL-2. From day 4, the culture was switched to iPS cell medium without IL-2. FACS analysis was performed on days 7 and 26 after reprogramming. [Figure 23] This is a FACS contour plot analysis of cell markers (CD3, CD45RA, CD45RO, CD62L, and CCR7) used to define the differentiation state of T cells. [Figure 24] This shows the growth rate of NY-ESO-1 immature cells or control cells from two different donors (#3 and #4) after stimulation with TRANSACT. Immature T cells proliferate longer than controls, surpassing the control level after approximately 2-3 weeks of culture. [Figure 25] This is a FACS contour plot analysis of the expression of NY-ESO-1-CD3, CD4-CD8b, CCR7-CD62L, and CD45RO-CD45RA in partially reprogrammed NY-ESO-1 T cells. [Figure 26A] This graph shows the results of cytokine production and degranulation assays of juvenile NY-ESO-1 TCR transduced T cells. FACS results were analyzed using FlowJo software. For NY-ESO-1 Tg T cells, gating was performed as follows: single cell > live cell > CD3+ > CD8+CD4-> NY-ESO-1 tetramer+ cell. For mock control T cells, gating was performed as follows: single cell > live cell > CD3+ > CD8+CD4-> NY-ESO-1 tetramer- cell. The frequencies of IFNg+ (A), TNFa+ (B), IL-2+ (C), and CD107a+ (D) were calculated and plotted as shown in the figure. No target (control), T2P-: T2 target cells without peptide (-control), T2P+: T2 target cells pulsed with NYESO1 peptide, Mel624: HLA-A2+ tumor cells expressing endogenous NYESO1, PMA / I: cells activated with PMA / ionomycin (+control). [Figure 26B]This graph shows the results of cytokine production and degranulation assays of juvenile NY-ESO-1 TCR transduced T cells. FACS results were analyzed using FlowJo software. For NY-ESO-1 Tg T cells, gating was performed as follows: single cell > live cell > CD3+ > CD8+CD4-> NY-ESO-1 tetramer+ cell. For mock control T cells, gating was performed as follows: single cell > live cell > CD3+ > CD8+CD4-> NY-ESO-1 tetramer- cell. The frequencies of IFNg+ (A), TNFa+ (B), IL-2+ (C), and CD107a+ (D) were calculated and plotted as shown in the figure. No target (control), T2P-: T2 target cells without peptide (-control), T2P+: T2 target cells pulsed with NYESO1 peptide, Mel624: HLA-A2+ tumor cells expressing endogenous NYESO1, PMA / I: cells activated with PMA / ionomycin (+control). [Figure 26C] This graph shows the results of cytokine production and degranulation assays of juvenile NY-ESO-1 TCR transduced T cells. FACS results were analyzed using FlowJo software. For NY-ESO-1 Tg T cells, gating was performed as follows: single cell > live cell > CD3+ > CD8+CD4-> NY-ESO-1 tetramer+ cell. For mock control T cells, gating was performed as follows: single cell > live cell > CD3+ > CD8+CD4-> NY-ESO-1 tetramer- cell. The frequencies of IFNg+ (A), TNFa+ (B), IL-2+ (C), and CD107a+ (D) were calculated and plotted as shown in the figure. No target (control), T2P-: T2 target cells without peptide (-control), T2P+: T2 target cells pulsed with NYESO1 peptide, Mel624: HLA-A2+ tumor cells expressing endogenous NYESO1, PMA / I: cells activated with PMA / ionomycin (+control). [Figure 26D]This graph shows the results of cytokine production and degranulation assays of juvenile NY-ESO-1 TCR transduced T cells. FACS results were analyzed using FlowJo software. For NY-ESO-1 Tg T cells, gating was performed as follows: single cell > live cell > CD3+ > CD8+CD4-> NY-ESO-1 tetramer+ cell. For mock control T cells, gating was performed as follows: single cell > live cell > CD3+ > CD8+CD4-> NY-ESO-1 tetramer- cell. The frequencies of IFNg+ (A), TNFa+ (B), IL-2+ (C), and CD107a+ (D) were calculated and plotted as shown in the figure. No target (control), T2P-: T2 target cells without peptide (-control), T2P+: T2 target cells pulsed with NYESO1 peptide, Mel624: HLA-A2+ tumor cells expressing endogenous NYESO1, PMA / I: cells activated with PMA / ionomycin (+control). [Figure 27] Figures A and B show that the rejuvenation of tumor-infiltrating lymphocytes (TILs) enhances their proliferation and yields more stem cell-like products. Figure A is a graph plotting cell growth and comparing the magnification of rejuvenated TILs with that of control cells. Figure B shows FACS plots for the expression of CCR7-CD62L and CCR7-TCF7, indicating that rejuvenated TILs exhibited high expression of stem cell-related markers. [Figure 28] An exemplary and non-limiting scheme of the juvenation protocol used in Example 12, described later, is shown below. [Figure 29] Figures A and B show the phenotypic analysis performed in relation to the juvenation protocol of Example 12. Figure A shows a representative FACS plot for Donor 1, showing the frequency of CD3+CD8b+ (singlet, negative for cell death staining, and gated for lymphocyte SSCs / FSCs). Figure B is a bar graph of the CD3+CD8b+ frequency, gated as in Figure A. Each bar represents the mean for Donors 1-3. Error bars represent ±1SD. [Figure 30]A-C show the skin and blood clock results for donors 1-3 of Example 12 before Sev transduction and at 7, 13, and 18 days after transduction. "Before Sev transduction" refers to the sample before activation for Sendai virus transduction. Error bars represent 1 standard deviation. [Figure 31] This shows the results of ny-ESO-1 transcatheterization of CD4 and CD8 T cells. CD4 or CD8 T cells were stimulated with Transact and transduced with the NY-ESO-1 TCR before reprogramming. [Figure 32A] The results show that juvenile NY-ESO-1 Tg CD4 and CD8 T cells exhibited a poorly differentiated phenotype. [Figure 32B] The results show that juvenile NY-ESO-1 Tg CD4 and CD8 T cells exhibited a poorly differentiated phenotype. [Figure 33] The results show that juvenile NY-ESO-1 Tg CD4 and CD8 T cells proliferated more significantly than control NY-ESO-1 Tg CD4 and CD8 T cells. [Figure 34] A and B are bar graphs showing eAge values from two donors: a 24-year-old male (A) and a 35-year-old male (B). This figure shows that the juvenile NY-ESO-1 Tg CD4 and CD8 T cells exhibited a younger phenotype than control NY-ESO-1 Tg CD4 and CD8 T cells, as well as the donor's chronological age, based on epigenetic age analysis. The graph shows the mean and SD of age values analyzed from the methylation status of a specific CpG site. [Figure 35] This bar graph shows intracellular cytokine staining from juvenile cells and control NY-ESO-1 cells. This graph indicates that juvenile NY-ESO-1 Tg CD4 and CD8 T cells produced more cytokines (IFNg(A), IL-2(B), and TNFa(C)) when co-cultured with T2 cells containing NY-ESO-1 peptide. Statistical significance of p-values in the t-test: *<0.05, **<0.005, ***<0.0005, ****<0.0001. [Figure 36]The results show that juvenile NY-ESO-1 Tg CD8 T cells, when repeatedly co-cultured with NY-ESO-1 expressing target cells (A375-NLR), persist longer and retain cytotoxic activity. [Figure 37] This shows the increased cytotoxicity of juvenile NY-ESO-1 Tg CD8 T cells due to the addition of juvenile NY-ESO-1 Tg CD4 T cells. [Figure 38A] The graph shows the expression levels of adaptive immunity-related cytokines in juvenated cells and control cells from two different donors at the indicated time points. The y-axis represents the cytokine concentration in pg / mL. [Figure 38B] The graph shows the expression levels of adaptive immunity-related cytokines in juvenated cells and control cells from two different donors at the indicated time points. The y-axis represents the cytokine concentration in pg / mL. [Figure 39A] The graph shows the expression levels of innate immunity-related cytokines in juvenated cells from two different donors and control cells at the indicated time points. The y-axis represents the cytokine concentration in pg / mL. [Figure 39B] The graph shows the expression levels of innate immunity-related cytokines in juvenated cells from two different donors and control cells at the indicated time points. The y-axis represents the cytokine concentration in pg / mL. [Figure 40] Representative FACS plots of NY-ESO-1 TCR-transduced T cells are used to illustrate the NY-ESO-1 TCR transduction efficiency in CD8 T cells: (left) CD4×CD8b, (right) CD3×NY-ESO-1 TCR TE. See Example 15. [Figure 41] A summary of the procedure for Example 15 is presented. [Figure 42] A bar graph is presented showing the magnification of the change in the number of exfoliated cells collected under each condition on day 7 compared to day 0. Please refer to Example 15. [Figure 43]This shows the restimulation of partially reprogrammed NY-ESO-1 TCR Tg T cells. A representative FACS plot at day 14 is presented. The frequency of NY-ESO-1 TCR TE+ cells is shown. See Example 15. [Figure 44] This represents the restimulation of partially reprogrammed NY-ESO-1 TCR Tg T cells. A representative bar graph of the frequency of NY-ESO-1 TCR TE+ cells on day 14 is shown. See Example 15. [Figure 45] This growth curve shows that juvenile NY-ESO-1 Tg T cells have higher proliferative capacity than non-juvenile controls (see Example 15). [Figure 46] This shows the efficiency of CD19 CAR transduction in CD8 T cells. See Example 16. Cells were gated as lymphocytes > single cells > Live / Dead- and plotted as CD3 × CD8a (second from the right) and CAR idiotype × EGFR (far right). tEGFR was expressed as a marker of successful transduction. [Figure 47] This shows that the juvenile CD19 CAR T cells exhibited a poorly differentiated phenotype. On day 13, control and juvenile CD19 CAR Tg T cells were analyzed by FACS for surface markers and Tcf1 expression. Cells were gated as Lymphocytes > Single Cell > Live / Dead -> CD19 CAR+ and plotted as CD4×CD8a (second from the left), CCR7×CD62L (second from the right), and CCR7×Tcf1 (far right). [Figure 48] This shows that juvenile CD19 CAR T cells proliferated more significantly than control CD19 CAR T cells. See Example 16. CD19 CAR Tg T cells were juvenated and cultured as described in Section 3, and cell numbers were counted every 3-4 days. The graph shows the rate of change over time in two healthy donors, 7 days after transduction with reprogramming factors, and compared to their corresponding control cells. [Figure 49]This demonstrates that juvenile CD19 CAR T cells produced equivalent levels of cytokines when co-cultured with CD19-expressing target cells. See Example 16. On day 20, control or juvenile CD19 CAR Tg T cells were cultured alone or with PMA / ionomycin, Colo205 (CD19-), or Nalm6 (CD19+) in the presence of Golgi transporter inhibitors. After staining surface antigens, cells were fixed, permeabilized, and stained with intracellular antibodies (Abs). The frequency of each cytokine-positive CAR+ cell is shown. [Figure 50A] This shows that juvenile CD19 CAR T cells, when repeatedly co-cultured with CD19-expressing target cells, persisted longer and retained cytotoxic activity. See Example 16. Results of co-culturing control or juvenile CD19 CAR Tg T cells with Nalm6-NLR cell lines are shown. Every 3-4 days, 25% (10% in the 4th and 5th co-cultures) of the previous culture was transferred to a new plate containing fresh targets. Target growth was monitored using the Incucyte® live cell analysis system and analyzed using the Base Software Analysis Module. The graph shows the Nalm6-NLR count / image under donor #1 conditions. [Figure 50B] This shows that juvenile CD19 CAR T cells, when repeatedly co-cultured with CD19-expressing target cells, persisted longer and retained cytotoxic activity. See Example 16. Results of co-culturing control or juvenile CD19 CAR Tg T cells with Nalm6-NLR cell lines are shown. Every 3-4 days, 25% (10% in the 4th and 5th co-cultures) of the previous culture was transferred to a new plate containing fresh targets. Target growth was monitored using the Incucyte® live cell analysis system and analyzed using the Base Software Analysis Module. The graph shows Nalm6-NLR count / image under donor #2 conditions. [Figure 51] This is an illustrative and non-limiting experimental design of the juvenation protocol described in Example 17, for illustrative purposes. [Figure 52A]The results of phenotypic analysis of cells detached on day 11 (Figure 52A) and the same cells (i.e., detached on day 11) on day 17 (Figure 52B) in the Sev group and mSev group, respectively, as described in Example 17. The provided FACS plots show the frequency of CD3+CD8b+ (singlet, negative for cell death stain, and gated for lymphocyte SSC / FSC). [Figure 52B] The results of phenotypic analysis of cells detached on day 11 (Figure 52A) and the same cells (i.e., detached on day 11) on day 17 (Figure 52B) in the Sev group and mSev group, respectively, as described in Example 17. The provided FACS plots show the frequency of CD3+CD8b+ (singlet, negative for cell death stain, and gated for lymphocyte SSC / FSC). [Figure 53A] This is a proliferation curve showing the rate of change at various times after exfoliation (see Example 17). The rate of change in cell count after exfoliation, performed on day 7, is shown. Each dot in the figure represents the average of two donors. Error bars indicate ±1SD. [Figure 53B] This is a proliferation curve showing the rate of change at various days after exfoliation (see Example 17). The rate of change in cell count after exfoliation, performed on day 9, is shown. Each dot in the figure represents the average of two donors. Error bars indicate ±1SD. [Figure 53C] This is a proliferation curve showing the rate of change at various days after exfoliation (see Example 17). The rate of change in cell count after exfoliation, performed on day 11, is shown. Each dot in the figure represents the average of two donors. Error bars indicate ±1SD. [Figure 54A] The stem cell phenotype shown 6 days after detachment of reprogrammed T cells in Example 17 is shown. The bar graph shows the mean TCF1+CCR7+ frequency (gated for singlet, death stain negative, lymphocyte SSC / FSC, and CD3+CD8b+) in the technical double-series study. Error bars represent ±1SD. [Figure 54B]The stem cell phenotype of reprogrammed T cells 6 days after detachment in Example 17 is shown. The bar graph shows the mean CCR7+CD62L+ frequency (singlet, negative for cell death stain, lymphocyte SSC / FSC, and gated for CD3+CD8b+) in a technical double-series study. Error bars represent ±1SD. [Figure 55] As described in Example 17, the epigenetic age of T cells transiently reprogrammed with either Sev or mSev and exfoliated on days 7, 9, and 11 is shown. Epigenetic age was measured using the Horvath skin blood clock. [Figure 56] The proliferation curves of the juvenified cells and control cells from Example 18 are shown. [Figure 57A] Transcriptome profiling of healthy donor CD8+ T cells from control and immature cells at days 7 and 13 of Example 18 is shown. Single-cell RNA-seq data of CD8+ T cells from control and immature cells derived from all four donors, visualized by UMAP, are shown. [Figure 57B] The transcriptome profiling of healthy donor CD8+ T cells from control and immature cells at days 7 and 13 of Example 18 is shown. The expression levels of transcripts encoding Yamanaka factor in immature cells are shown in single-cell RNA-seq data of CD8+ T cells from control and immature cells. [Figure 57C] The transcriptome profiling of healthy donor CD8+ T cells from control and immature cells at days 7 and 13 of Example 18 is shown. The expression levels of transcripts encoding Yamanaka factor in bulk RNA-seq data of CD8+ T cells from control and immature cells are shown. [Figure 57D] The transcriptome profiling of healthy donor CD8+ T cells from control and immature cells at days 7 and 13 of Example 18 is shown. Visualization of genomic alignment of reads aligned to the endogenous cMYC gene in healthy donor CD8+ T cells from control and immature cells at days 7 and 13 is shown. [Figure 58A] This shows the enrichment of metabolic gene sets in juvenated cells compared to control cells at day 7 and day 13 in bulk RNA-seq data from three donors (i.e., donor numbers 11347, 12254, and 26221) in Example 18. The difference on the x-axis scale represents the adjusted p-values at day 7 and day 13. The gray solid line indicates the significance threshold (adjusted p-value < 0.05). [Figure 58B] The AddModule scores for the gene sets for glycolysis and oxidative phosphorylation in the same UMAP representation as shown in Figure 59A are shown (see Example 18). [Figure 59A] This UMAP shows that the naive gene set (Gattinoni) is enriched in the immature cells on day 13 compared to the control cells (see Example 18). [Figure 59B] This bar graph shows that the naive gene set (Gattinoni) is enriched in immature cells compared to control cells on day 13 (see Example 18). [Figure 60A] This graph shows the proliferation curves of donors 1 and 2 after juvenation. All juvenated cells showed a significantly higher growth rate than the control group. In one donor, the TransAct-stimulated group showed a higher growth rate than the CD137+ selected group, while the growth rate in the other donor was lower. This suggests that the tumor-responsive populations had different affinities to the stimulation. Growth decreased after 33 days. This may be due to insufficient nutrient and oxygen supply because the seeding cell density of the culture was not optimal for the culture plate. See Example 19. [Figure 60B]This graph shows the proliferation curves of donors 1 and 2 after juvenation. All juvenated cells showed a significantly higher growth rate than the control group. In one donor, the TransAct-stimulated group showed a higher growth rate than the CD137+ selected group, while the growth rate in the other donor was lower. This suggests that the tumor-responsive populations had different affinities to the stimulation. Growth decreased after 33 days. This may be due to insufficient nutrient and oxygen supply because the seeding cell density of the culture was not optimal for the culture plate. See Example 19. [Figure 61A] This graph shows the time course of CD62L and CCR7 expression in juvenile cells and control cells. CD62L+CCR7+ cells were preserved in the early stages of juvenation. Cells were harvested on the indicated days, stained with fluorescently labeled antibodies, and analyzed by flow cytometry. The results showed that in these two donors, juvenile cells highly expressed CD62L+CCR7+ on days 14 and 17. See Example 19. [Figure 61B] This graph shows the time course of CD62L and CCR7 expression in juvenile cells and control cells. CD62L+CCR7+ cells were preserved in the early stages of juvenation. Cells were harvested on the indicated days, stained with fluorescently labeled antibodies, and analyzed by flow cytometry. The results showed that in these two donors, juvenile cells highly expressed CD62L+CCR7+ on days 14 and 17. See Example 19. [Figure 62] This graph shows the proliferation curve of donor 3 after juvenation. TILs were enriched with CD45+, then stimulated with TransAct, and subsequently juvenated. Cells were counted on the indicated days. Juvenated CD45+ cells showed significantly improved proliferation compared to control cells, while the CD45- group showed very limited growth. See Example 19. [Figure 63]The FACS contour plots showing the expression of stem cell-related markers in the control and donor 3 cells on day 15 are shown. Young CD45+ TIL cells showed significantly higher expression of CD62L+CCR7+ and TCF7+CCR7+, whereas CD45- cells did not. See Example 19. [Figure 64] This graph shows the growth curves of control and donor 4 cells after juvenation. Cells were stimulated with either 1:500 (HI) or 1:2000 (LO) TransAct. Juvenated cells (both HI and LO groups) showed a similar growth rate to the control after redirection to T cells. [Figure 65] FACS contour plots showing the expression of stem cell-related markers in control cells, donor 4, and 21 days after juvenation are shown. Juvenated cells (both HI and LO groups) showed higher expression of CD62L+CCR7+ and TCF7+CCR7+ than control cells. See Example 19. [Figure 66] This graph shows the epigenetic age (eAge) of control cells or juvenile cells from donor 7 at the indicated time points. The epigenetic age of control cells was similar to the donor's chronological age, while juvenile cells showed a significantly lower age at day 15, which gradually increased with growth time. See Example 19. [Figure 67] This graph shows the epigenetic age (eAge) of control cells or juvenile cells from donor 9 at the indicated time points. The epigenetic age of the control group was similar to the donor's chronological age, but the juvenile cells showed a significantly lower epigenetic age on day 15, which gradually returned to control levels with time of growth in culture. See Example 19. [Figure 68] This graph shows the proliferation of control and juvenile cells from donors 7 and 9. The juvenile cells showed a similar rate of growth to the control after redirection to T cells. See Example 19. [Figure 69A]Phenotypic analysis of cells detached on day 11 from donor 6 in Example 20 at days 14 and 18 is shown. The FACS plot shows the frequency of CD3+ (gated for singlet, death-negative, and CD3+ cells). Immature cells showed higher TCF7+CCR7+ at days 14 and 18. See Example 20 and Table 10. [Figure 69B] Phenotypic analysis of cells detached on day 11 from donor 8 in Example 20 at days 14 and 18 is shown. The FACS plot shows the frequency of CD3+ (gated for singlet, death-negative, and CD3+ cells). Immature cells showed higher TCF7+CCR7+ at days 14 and 18. See Example 20 and Table 10. [Figure 70] This shows that adherent cells (weakly adherent, adherent, and strongly adherent) express higher levels of integrin a6 and integrin b1 than activated T cell controls on day 10. Strongly adherent cells express higher levels of integrin a6 and integrin b1 than weakly adherent and adherent cells. Plots were obtained after gating of singlets and live cells. [Figure 71] This shows that the expression of integrin a6 and integrin b1 decreased after T cell activation on day 10. The bar graph shows the MFI (mean fluorescence intensity) of the plot in Figure 70. The values were normalized by the MFI of activated T cells control at each time point. The control value was 1. [Figure 72] This shows that adherent cells lost CD3 expression on day 10 but regained it on day 17. [Figure 73] Weakly adherent cells, adherent cells, and strongly adherent cells all exhibited high proliferation. Strongly adherent cells showed a delayed onset of cell growth. [Figure 74A] This shows that adherent cells (especially strongly adherent cells) exhibited high TCF1 and CCR7 expression on day 10. MFI was obtained from singlet and live cell gating data. [Figure 74B]This shows that adherent cells (especially strongly adherent cells) exhibited high TCF1 and CCR7 expression on day 17. MFI was obtained from singlet and live cell gating data. [Figure 75] The Simpson clonal distribution of single-cell TCR sequences from control and juvenile cells on days 7 and 13 is shown (see Example 18). [Modes for carrying out the invention]
[0052] The descriptions herein are illustrative and descriptive only and should not be understood as limiting the scope of the claimed disclosures. In this application, the use of the singular includes the plural unless otherwise explicitly stated.
[0053] The section headings used herein are for organizational purposes only and should not be construed as limiting the subjects described.
[0054] Throughout this disclosure, various patents, patent applications, and published documents are referenced. The disclosures of these patents, patent applications, and published documents are incorporated by reference in whole to better illustrate the current state of the art as known to those skilled in the art as of the date of this disclosure. In the event of any inconsistency between the cited patents, patent applications, and published documents and this disclosure, this disclosure shall prevail.
[0055] For convenience, certain terms used in this specification, examples, and claims are set forth herein. Unless otherwise defined, all technical and scientific terms used in this disclosure have the same meanings as those generally understood by those skilled in the art to which this disclosure belongs. The following terms, when used in accordance with this disclosure, shall be understood to have the following meanings unless otherwise stated.
[0056] In this application, the use of “or” means “and / or” unless otherwise specified. Furthermore, the use of the term “including,” as well as other forms such as “includes” and “included,” is not limited. Also, terms such as “element” or “component” encompass both elements and components containing one unit and elements and components containing two or more subunits, unless otherwise explicitly stated.
[0057] This disclosure relates, in part, to a method for generating juvenile T cells by a process of partial reprogramming and reactivation to revert the partially reprogrammed cells back into juvenile, functional T cells. In certain embodiments, partial reprogramming involves transient expression of a reprogramming factor in T cells. The partial reprogramming process results in the formation of “T cell-derived adherent” cells that express one or more markers of dedifferentiated cells but retain phenotypic markers of the T cell lineage. Thus, T cell-derived adherent cells are partially dedifferentiated T cells that revert back to functional T cells upon contact with a T cell-activating compound agent. The T cells generated by this process retain lineage stability and antigen specificity, as described in further detail herein, and exhibit the characteristics of cell juvenation.
[0058] As used herein, the term “immune cells” means any type of immune cell, including, for example, T cells, B cells, monocytes, macrophages, dendritic cells, and so on. In certain exemplary embodiments, the immune cells disclosed herein are T cells.
[0059] The terms “polynucleotide,” “nucleotide,” or “nucleic acid” include both single-stranded and double-stranded nucleotide polymers. The nucleotides constituting a polynucleotide may be ribonucleotides or deoxyribonucleotides, or modified forms of either type of nucleotide. Such modifications include base modifications such as bromouridine and inosine derivatives, ribose modifications such as 2',3'-dideoxyribose, and internucleotide bond modifications such as phosphorothioates, phosphorodithioates, phosphoroselenoates, phosphorodiselenoates, phosphoranilothioates, phosphoraniladetes, and phosphoramidates.
[0060] The term "oligonucleotide" refers to a polynucleotide containing 200 or fewer nucleotides. Oligonucleotides can be single-stranded or double-stranded, for example, for use in constructing mutant genes. Oligonucleotides can be sense or antisense oligonucleotides. Oligonucleotides can be labeled, including radiolabeling, fluorescent labeling, hapten, or antigenic labeling, for detection assays. Oligonucleotides can be used, for example, as PCR primers, cloning primers, or hybridization probes.
[0061] The term “regulatory sequence” refers to a polynucleotide sequence that can influence the expression and processing of a linked coding sequence. The properties of such a regulatory sequence may be host organism-dependent. In certain embodiments, a prokaryotic regulatory sequence may include a promoter, a ribosome binding site, and a transcription termination sequence. For example, a eukaryotic regulatory sequence may include a promoter containing one or more recognition sites for a transcription factor, a transcription enhancer sequence, and a transcription termination sequence. A “regulatory sequence” may include a leader sequence (signal peptide) and / or a fusion partner sequence.
[0062] As used herein, “operably linked” means that the components to which this term applies are in a relationship that allows them to perform specific functions under preferred conditions.
[0063] The term “vector” means any molecule or entity (e.g., nucleic acid, plasmid, bacteriophage, or virus) used to transmit protein-coding information to a host cell. The terms “expression vector” or “expression construct” refer to a vector containing nucleic acid sequences that are suitable for transforming host cells and that, in conjunction with the host cell, direct and / or control the expression of one or more heterogeneous coding regions operably ligated thereto. An expression construct may, but is not limited to, contain sequences that affect or control transcription, translation, and, where introns are present, affect the RNA splicing of the coding regions operably ligated thereto.
[0064] The term "host cell" refers to a cell that has been transformed by a nucleic acid sequence, or can be transformed, to express the gene of interest. This term includes offspring of a parent cell, regardless of whether the offspring are morphologically or genetically identical to the original parent cell, as long as the gene of interest is present.
[0065] The term "transformation" refers to a change in the genetic characteristics of a cell, and a cell is transformed if it is modified to contain new DNA or RNA. For example, a cell is transformed if it is genetically modified from its native state by introducing new genetic material through transfection, transduction, delivery using nanoparticles (e.g., lipid nanoparticles), or other techniques. After transfection or transduction, the transformed DNA can be rejoined with the cell's DNA by being physically incorporated into the cell's chromosomes, or it can be transiently maintained as an episomal element without replication, or it can replicate independently as a plasmid. If the transformed DNA replicates with cell division, the cell is considered "stablely transformed."
[0066] The term "transfection" refers to the uptake of foreign or exogenous genetic material (DNA or RNA) by cells. Several transfection techniques are well known in the art and are disclosed herein. See, for example, Graham et al., 1973, Virology, 1973, 52:456; Sambrook et al., Molecular Cloning: A Laboratory Manual, 2001 (see above); Davis et al., Basic Methods in Molecular Biology, 1986, Elsevier; and Chu et al., 1981, Gene, 13:197.
[0067] The term "transduction" refers to the process by which foreign DNA or RNA is introduced into cells via a viral vector. For example, see Jones et al., Genetics: Principles and Analysis, 1998, Boston: Jones & Bartlett Publ.
[0068] The terms “polypeptide” or “protein” refer to macromolecules having an amino acid sequence of a protein, including the deletion, addition, and / or substitution of one or more amino acids from the native sequence. The terms “polypeptide” and “protein” specifically encompass antigen-binding molecules, antibodies, or sequences having the deletion, addition, and / or substitution of one or more amino acids from an antigen-binding protein. The term “polypeptide fragment” refers to a polypeptide having amino-terminal deletions, carboxyl-terminal deletions, and / or internal deletions compared to a full-length native protein. Such fragments may also contain modified amino acids compared to the native protein. Useful polypeptide fragments include immunologically functional fragments of antigen-binding molecules.
[0069] The term “isolated” means (i) not containing at least some other proteins that are normally found together; (ii) essentially not containing other proteins from the same source, e.g., from the same species; (iii) isolated from at least about 50 percent of the polynucleotides, lipids, carbohydrates, or other substances that are related in nature; (iv) operably related (by covalent or non-covalent interactions) with polypeptides that are not related in nature; or (v) not occurring in nature.
[0070] A "variant" of a polypeptide (e.g., an antigen-binding molecule) includes an amino acid sequence in which one or more amino acid residues are inserted, deleted, and / or substituted compared to another polypeptide sequence. Variants include fusion proteins.
[0071] The term "identity" refers to the relationship between the sequences of two or more polypeptide molecules or two or more nucleic acid molecules, determined by aligning and comparing their sequences. "Identity percentage" means the percentage of identical residues between amino acids or nucleotides in the multiple molecules being compared, and is calculated based on the size of the smallest of the molecules being compared. In these calculations, any gaps in the alignment (if any) are preferably addressed by a specific mathematical model or computer program (i.e., an "algorithm").
[0072] To calculate the percentage of identity, the sequences being compared are typically aligned to obtain the greatest possible match between them. An example of a computer program that can be used to determine the percentage of identity is the GCG program package, which includes GAP (Devereux et al., Nucl. Acid Res., 1984, 12, 387, Genetics Computer Group, University of Wisconsin, Madison, Wis.). The computer algorithm GAP is used to align two polypeptides or polynucleotides whose sequence identity percentage is to be determined. Multiple sequences are aligned for the best possible match of each amino acid or nucleotide (the "matched span" determined by the algorithm). In certain embodiments, standard comparison matrices (for example, see Dayhoff et al., 1978, Atlas of Protein Sequence and Structure, 5:345-352 for the PAM 250 comparison matrix, and Henikoff et al., 1992, Proc. Natl. Acad. Sci. USA, 89, 10915-10919 for the BLO-SUM 62 comparison matrix) are also used by the algorithm.
[0073] Where used herein, the 20 conventional (e.g., naturally occurring) amino acids and their abbreviations follow conventional usage. See, for example, Immunology A Synthesis (2nd Edition, Golub and Green, Eds., Sinauer Assoc., Sunderland, Mass. (1991)), which is incorporated herein by reference for all purposes. Stereoisomers of the 20 conventional amino acids (e.g., D-amino acids), unnatural amino acids, such as α-,α-disubstituted amino acids, N-alkyl amino acids, lactic acid, and other unconventional amino acids may also be preferred components of the polypeptides of this disclosure. Examples of unconventional amino acids include 4-hydroxyproline, γ-carboxyglutamic acid, epsilon-N,N,N-trimethyllysine, eN-acetyllysine, 0-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, sigma-N-methylarginine, and other similar amino acids and imino acids (e.g., 4-hydroxyproline). In the polypeptide notation used herein, the left-hand direction is towards the amino terminus and the right-hand direction is towards the carboxy terminus, in accordance with standard usage and convention.
[0074] Conservative amino acid substitutions can include non-spontaneous amino acid residues that are typically incorporated by chemical peptide synthesis rather than synthesis in biological systems. These include peptide mimetic compounds and other inverted or reversed forms of the amino acid moiety. Spontaneously occurring residues can be classified into the following classes based on common side-chain properties: a) Hydrophobic: norleucine, Met, Ala, Val, Leu, Ile; b) Neutral hydrophilic: Cys, Ser, Thr, Asn, Gln; c) Acidic: Asp, Glu; d) Basicity: His, Lys, Arg; e) Residues that affect chain orientation: Gly, Pro; and f) Aromatics: Trp, Tyr, Phe.
[0075] For example, non-conservative substitution may involve exchanging a member of one of these classes for a member of another class.
[0076] When modifying the antigen-binding molecule, costimulatory domain, or activating domain of engineered T cells, according to certain embodiments, the hydroxyl index of amino acids may be taken into consideration. Each amino acid is assigned a hydroxyl index based on its hydrophobic and charge properties. These are as follows: isoleucine (+4.5), valine (+4.2), leucine (+3.8), phenylalanine (+2.8), cysteine / cystine (+2.5), methionine (+1.9), alanine (+1.8), glycine (-0.4), threonine (-0.7), serine (-0.8), tryptophan (-0.9), tyrosine (-1.3), proline (-1.6), histidine (-3.2), glutamic acid (-3.5), glutamine (-3.5), aspartic acid (-3.5), asparagine (-3.5), lysine (-3.9), and arginine (-4.5). See, for example, Kyte et al., 1982, J. Mol. Biol., 157, 105-131. Certain amino acids can be substituted with other amino acids having a similar hydropathic index or score, and it is known that similar biological activity is still retained. It is also understood in the art that similar amino acid substitutions can be effectively carried out on a hydrophilic basis, especially when the resulting biologically functional protein or peptide is intended for use in immunological embodiments, as in this case. Exemplary amino acid substitutions are listed in Table 1. [Table 1]
[0077] The term "derivative" refers to a molecule that includes chemical modifications other than insertion, deletion, or substitution of amino acids (or nucleic acids). In certain embodiments, derivatives include covalent modifications that include, but are not limited to, chemical bonding with polymers, lipids, or other organic or inorganic moieties. In certain embodiments, chemically modified antigen-binding molecules may have a longer cyclic half-life than chemically modified antigen-binding molecules. In some embodiments, derivative antigen-binding molecules are covalently modified to include one or more water-soluble polymer bonds, including but not limited to polyethylene glycol, polyoxyethylene glycol, or polypropylene glycol.
[0078] Peptide analogs are commonly used in the pharmaceutical industry as non-peptide drugs that possess properties similar to those of a template peptide. These types of non-peptide compounds are called "peptide mimes" or "peptide mimes." (Fauchere, JL, 1986, Adv. Drug Res., 1986, 15, 29; Veber, DF & Freidinger, RM, 1985, Trends in Neuroscience, 8, 392-396; and Evans, BE, et al., 1987, J. Med. Chem., 30, 1229-1239 - these are incorporated herein by reference for all purposes.)
[0079] The term "therapeutic effective dose" refers to the amount of immune cells (e.g., T cells) or other therapeutic agent determined to produce a therapeutic response in a mammal. Such a therapeutic effective dose is readily verifiable by those skilled in the art.
[0080] The terms “patient” and “subject” are used synonymously and include human and non-human animal subjects, as well as those with a formally diagnosed disability, those without a formally recognized disability, those receiving medical treatment, and those at risk of developing a disability.
[0081] The terms "to treat" and "treatment" include therapeutic treatment, preventive treatment, and uses that reduce the risk of an object developing a disorder or other risk factor. Treatment does not require complete cure of the disorder and includes embodiments that reduce symptoms or potential risk factors. The term "prevent" does not require 100% elimination of the possibility of an event; rather, it means that the likelihood of the event occurring is reduced in the presence of the compound or method.
[0082] Standard techniques may be used for recombinant DNA and oligonucleotide synthesis, as well as for tissue culture and transformation (e.g., electroporation, lipofection). Enzymatic reactions and purification techniques may be performed according to the manufacturer's specifications, as commonly achieved in the art, or as described herein. The aforementioned techniques and procedures may generally be performed according to conventional methods well known in the art and as described in the various general and more specific references cited and mentioned throughout this specification. For example, see Sambrook et al., Molecular Cloning: A Laboratory Manual (2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989)), which is incorporated herein by reference for all purposes.
[0083] As used herein, the terms “substantially” or “essentially” refer to a quantity, level, value, number, frequency, percentage, dimension, size, volume, weight, or length that is about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% higher than the quantity, level, value, number, frequency, percentage, dimension, size, volume, weight, or length of reference. In certain embodiments, the terms “essentially the same” or “substantially the same” refer to a range of quantities, levels, values, numbers, frequencies, percentages, dimensions, size, volume, weight, or length that is approximately the same as the quantity, level, value, number, frequency, percentage, dimension, size, volume, weight, or length of reference.
[0084] As used herein, the terms “substantially absent” and “essentially absent” are used synonymously and, when used to describe a composition such as a cell population or culture medium, refer to a composition that does not contain a particular substance, for example, a composition that is 95%, 96%, 97%, 98%, 99%, or undetectable by conventional means. The same meaning may apply to the term “absence of” which refers to the absence of a particular substance or component in a composition.
[0085] As used herein, the term “recognizable” means a range of quantities, levels, values, numbers, frequencies, percentages, dimensions, sizes, quantities, weights, or lengths, or events, that are readily detectable by one or more standard methods. “Unrecognizable” and “unrecognizable” and equivalent terms mean a range of quantities, levels, values, numbers, frequencies, percentages, dimensions, sizes, quantities, weights, or lengths, or events, that are not readily detectable or undetectable by standard methods. In certain embodiments, an event is unrecognizable if it occurs with a probability of less than 5%, 4%, 3%, 2%, 1%, 0.1%, 0.001%, or less.
[0086] Throughout this specification, unless contextually required, the terms “comprise,” “comprises,” and “comprising” are understood to mean including the described step or element or group of steps or elements, but not to mean excluding any other step or element or group of steps or elements. In certain embodiments, the terms “include,” “has,” “contains,” and “comprise” are used synonymously.
[0087] As used herein, "consisting of" means including and limiting to everything associated with the phrase "consisting of." Therefore, the phrase "consisting of" indicates that the listed elements are necessary or essential, and that other elements cannot be present.
[0088] "Essentially derived from" means that it includes all elements listed after it, and that other elements are limited to those that do not interfere with or contribute to the activity or action specified in the disclosure of the listed elements. Therefore, the phrase "essentially derived from" indicates that the listed elements are necessary or essential, but the other elements are not optional and may or may not be present depending on whether or not they affect the activity or action of the listed elements.
[0089] Any portion of the entire scope of this disclosure may be claimed for any reason, provided that the right to exclude or remove any individual member of any such group (including any partial scope or combination of partial scopes within such group) which may be claimed in accordance with a certain scope or in a similar manner. Furthermore, any portion of the entire scope of this disclosure may be claimed for any reason, provided that the right to exclude or remove any individual substituent, analogue, compound, ligand, structure, or any group thereof, or any member of the claimed group.
[0090] Throughout this specification, any reference to “one embodiment,” “a specific embodiment,” “a related embodiment,” “a particular embodiment,” “an additional embodiment,” or “a further embodiment,” or any combination thereof, means that any specific feature, structure, or characteristic described in relation to that embodiment is included in at least one embodiment of this disclosure. Therefore, references to the aforementioned terms in various parts of this specification do not necessarily all refer to the same embodiment. Furthermore, specific features, structures, or characteristics may be combined in a preferred manner in one or more embodiments.
[0091] As used herein, the terms “about” or “approximately” refer to a quantity, level, value, number, frequency, percentage, dimension, size, volume, weight, or length that differs by approximately 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1% from the quantity, level, value, number, frequency, percentage, dimension, size, volume, weight, or length of reference. In certain embodiments, the terms “about” or “approximately” preceding a number indicate a value plus or minus 15%, 10%, 5%, or 1%, or any range between them.
[0092] As used herein, “related” means the relationship between two events, entities and / or phenomena. As used herein, two events, entities and / or phenomena are “related” to one another if the existence, level and / or form of one correlates with that of the other.
[0093] As used herein, the term “memory” T cells refer to T cells that have previously encountered and responded to a congeneral antigen (e.g., in vivo, in vitro, or ex vivo) or that have been stimulated (e.g., in vitro or ex vivo) by an anti-CD3 antibody. Such memory T cells, which are immune cells that have a “memory-like” phenotype at the time of secondary exposure, may replicate to develop a more rapid and robust immune response than during the primary exposure. In some embodiments, memory T cells include central memory T cells (TCM cells), effector memory T cells (TEM cells), tissue-resident memory T cells (TRM cells), stem cell-like memory T cells (TSCM cells), or any combination thereof.
[0094] As used herein, the terms “stem cell-like memory T cell,” “T memory stem cell,” or “TSCM cell” refer to memory T cells that express CD95, CD45RA, CCR7, and CD62L, possess stem cell-like ability to self-replicate, and have the ability to reconstitute an entire range of memory T cells and effector T cells.
[0095] As used herein, the terms “central memory T cells” or “TCM cells” refer to memory T cells expressing CD45RO, CCR7, and CD62L. Central memory T cells are commonly found in lymph nodes and peripheral circulation.
[0096] As used herein, the terms “effector memory T cells” or “TEM cells” refer to memory T cells that express CD45RO but lack expression of CCR7 and CD62L. Because effector memory T cells lack lymph node homing receptors (e.g., CCR7 and CD62L), these cells are typically found in peripheral circulation and non-lymphatic tissues.
[0097] As used herein, the terms “tissue-resident memory T cells” or “TRM cells” refer to memory T cells that do not circulate and are commensal to peripheral tissues such as the skin, lungs, and gastrointestinal tract. In some embodiments, tissue-resident memory T cells are also effector memory T cells.
[0098] As used herein, the terms “naive T cell” or “TN cell” refer to T cells that express CD45RA, CCR7, and CD62L but not CD95. TN cells are the most undifferentiated cells in the T cell lineage. Interactions between TN cells and antigen-presenting cells (APCs) induce the differentiation of TN cells into activated TEFF cells and the immune response.
[0099] As used herein, the terms “stem cell-like,” “stem cell-like,” “stem-like,” or “poorly differentiated” refer to immune cells (e.g., T cells or TILs) that express markers consistent with a more naive phenotype. For example, poorly differentiated T cells may express one or more markers characteristic of TN cells or TSCM cells. In some embodiments, “poorly differentiated” or “stem-like” T cells express CD45RA, CCR7, and CD62L. In some embodiments, “poorly differentiated” or “stem-like” T cells express CD45RA, CCR7, CD62L, and TCF7. In some embodiments, “poorly differentiated” or “stem-like” T cells do not express CD45RO, or have CD45ROlow. In some embodiments, the methods disclosed herein promote immune cells (e.g., T cells) having a poorly differentiated phenotype. While not bound to any particular mechanism, in some embodiments, the methods disclosed herein can inhibit, block, or limit the differentiation of poorly differentiated immune cells (e.g., T cells), resulting in an increase in the number of stem-like cells in culture. For example, adoptive transfer of poorly differentiated immune cells with stem cell-like memory or central memory phenotypes, such as T cells, is generally considered preferable for effectively controlling tumors. Gattinoni,L.,et al.,J.Clin.Invest.115:1616-1626(2005), Gattinoni,L.,et al.Nat Med 15(7):808-814(2009),Lynn,RC,et al.,Nature 576(7786):293-300(2019), Gattinoni, L., et al. Nat Rev 12:671-684(2012), Klebanoff, C., et al., J. Immunother 35(9):651-670(2012), and Gattinoni, L., et al., Nat Med 17(10):1290-1297 (2011).
[0100] Stem cell characteristics are characterized by self-renewal ability, pluripotency, and persistence of proliferative capacity. In some embodiments, stem cell characteristics are characterized by a specific gene signature, e.g., a combination of expression patterns across a number of genes. In some embodiments, stem-like cells can be identified by transcriptome analysis, for example, using stem cell gene signatures disclosed herein. In some embodiments, gene signatures include ACTN1, DSC1, TSHZ2, MYB, LEF1, TIMD4, MAL, KRT73, SESN3, CDCA7L, LOC283174, TCF7, SLC16A10, LASS6, UBE2E2, IL7R, GCNT4, TAF4B, SULT1B1, SELP, KRT72, STXBP1, TCEA3, FCGBP, CXCR5, GPA33, NEL L2, APBA2, SELL, VIPR1, FAM153B, PPFIBP2, FCER1G, GJB6, OCM2, GCET2, LRRN1, IL6ST, LRRC16A, IGSF9B, EFHA2 , LOC129293, APP, PKIA, ZC3H12D, CHMP7, KIAA0748, SLC22A17, FLJ13197, NRCAM, C5orf13, GIPC3, WNT7A, FAM11 7B, BEND5, LGMN, FAM63A, FAM153B, ARHGEF11, RBM11, RIC3, LDLRAP1, PELI1, PTK2, KCTD12, LMO7, CEP68, SDK2, MCOLN3, ZNF238, EDAR, FAM153C, FAAH2, BCL9, C17orf48, MAP1D, ZSWIM1, SORBS3, IL4R, SERPINF1, C16orf45, SP This includes one or more genes selected from TBN1, KCNQ1, LDHB, BZW2, NBEA, GAL3ST4, CRTC3, MAP3K1, HLA-DOA, RAB43, SGTB, CNN3, CWH43, KLHL3, PIM2, RGMB, C16orf74, AEBP1, SNORD115-11, SNORD115-11, GRAP, and any combination thereof (see, for example, Gattinoni et al., Nature Medicine 17(10):1290-97(2011)).In some embodiments, the gene signatures are NOG, TIMD4, MYB, UBE2E2, FCER1G, HAVCR1, FCGBP, PPFIBP2, TPST1, ACTN1, IGF1R, KRT72, SLC16A10, GJB6, LRRN1, PRAGMIN, GIPC3, FLNB, ARRB1, SLC7A8, NUCB2, LRRC7, MYO15B, MAL, AEBP1, SDK2, BZW2, GAL3ST4, PI TPNM2, ZNF496, FAM117B, C16orf74, TDRD6, TSPAN32, C18orf22, C3orf44, LOC129293, ZC3H12D, MLXIP, C7orf10, STXBP 1, KCNQ1, FLJ13197, LDLRAP1, RAB43, RIN3, SLC22A17, AGBL3, TCEA3, NCRNA00185, FAM153B, FAM153C, VIPR1, MMP19, HB S1L, EEF2K, SNORA5C, UBASH3A, FLJ43390, RP6-213H19.1, INPP5A, PIM2, TNFRSF10D, SNRK, LOC100128288, PIGV, LOC1 00129858, SPTBN1, PROS1, MMP28, HES1, CACHD1, NSUN5C, LEF1, TTTY14, SNORA54, HSF2, C16orf67, NSUN5B, KIAA1257, N This includes one or more genes selected from RG2, CAD, TARBP1, STRADB, MT1F, TMEM41B, PDHX, KDM6B, LOC100288322, UXS1, LGMN, NANOS2, PYGB, RASGRP2, C14orf80, XPO6, SLC24A6, FAM113A, MRM1, FBXW8, NDUFS2, KCTD12, and any combination thereof (see, for example, Gattinoni, L., et al., Nat Med 17(10):1290-1297 (2011)).
[0101] As used herein, the term “mononuclear cell” refers to a cell found in the blood that has a single round nucleus.
[0102] As used herein, the term “pluripotency” refers to the ability of a cell to give rise to any cell type found in embryonic and extraembryonic (placental) cells.
[0103] As used herein, the term “pluripotency” refers to the ability of a cell to form all lineages of the body or somatic cells (i.e., a true embryo and not a placenta). For example, embryonic stem cells are a type of pluripotent stem cell that is available to form cells from each of the three germ layers: ectoderm, mesoderm, and endoderm. Pluripotency can be determined in part by evaluating the pluripotent properties of a cell. Pluripotent properties may include, but are not limited to, (i) the morphology of a pluripotent stem cell; (ii) the potential for unrestricted self-renewal; (iii) the ability to differentiate into all three somatic cell lineages (ectoderm, mesoderm, and endoderm); (iv) the formation of a teratoma consisting of the three somatic cell lineages; and (v) the formation of an embryoid body consisting of cells from the three somatic cell lineages; (vi) SSEA1 (mouse only), SSEA3 / 4, SSEA5, TRA1-60 / 81, TRA2-54 (ALP), TRA1-85, GCTM-2, TG343, TRA2-49, CD (vii) Expression of one or more pluripotent stem cell markers, including but not limited to 340, CD326, podoplanin, and TG30 (CD9); (vii) Expression of certain other markers associated with somatic stem cells or early differentiated cells from embryonic stem cells, including but not limited to integrin α6β1, CD29, CD133 / prominin, CD140a, CD56, CD73, CD90, CD105, CD30, and / or LD50; (viii) Expression of certain pluripotent genes, including OCT4, NANOG, and SOX2.
[0104] As used herein, the term "multipotency" refers to the ability of cells in a particular lineage to develop into a limited number of cell types.
[0105] As used herein, the term “non-pluripotent cells” refers to any cells that do not possess full pluripotency, including incomplete or partial pluripotent stem cells, multipotent cells, minor pluripotent cells, unipotent cells (e.g., progenitor cells), and terminally differentiated cells.
[0106] As used herein, the term “introduce” refers to a process that involves bringing cells into contact with polynucleotides, polypeptides, or small molecules. The introduction step may also include microinjection of polynucleotides or polypeptides into cells, the use of liposomes to deliver polynucleotides or polypeptides into cells, or their fusion into a cell-permeable portion for introducing polynucleotides or polypeptides into cells.
[0107] One embodiment of this disclosure provides a method for preparing a population of isolated or purified immune cells (e.g., T cells) in vitro. The isolated or purified population of immune cells (e.g., T cells) may be included in pharmaceutical compositions useful for treating or preventing various different pathological conditions described herein.
[0108] "Differentiation" is the process by which cells lose their efficacy and ability to self-replicate, ultimately becoming mature, distinct cell types within distinct lineages (see, for example, Crompton 2014, Trends in Immunol. 35:178-185).
[0109] Dedifferentiation refers to the process by which cells become less specialized. In certain embodiments, dedifferentiation is the loss of specialized characteristics within a normal developmental pathway or within the same cell lineage. In certain embodiments, dedifferentiation is dedifferentiation within the same cell lineage (hierarchical dedifferentiation). However, as described herein, in other embodiments, dedifferentiation may not be within the same cell lineage. For example, in certain embodiments, partial reprogramming of T cells as described herein results in cells that dedifferentiate by acquiring the expression of CD9 and / or CD90 and / or SSEA4, markers not normally associated with conventional human T cell lineages, and these cells begin to lose the expression of T cell markers CD3 and / or CD4 and / or CD8. Such dedifferentiation does not follow the standard hierarchical lineage of T cells. These cells can be reverted to conventional T cells after stimulation with T cell activating agents. CD90 expression is associated only with rare human T cell populations, such as cortical thymocytes and some Th17s.
[0110] Rejuvenation is the process by which cellular functions lost due to cellular aging are restored. Cellular age can be described as the sum of the donor's chronological age plus an alpha coefficient determined by a combination of several factors that induce stress within the cellular microenvironment. These factors can be observed in vivo (e.g., heavy smoking, chronic diseases including autoimmune diseases, infections, obesity, metabolic disorders, and possibly depression) and can be artificially induced in vitro (e.g., prolonged exposure to tumor antigens or other stimuli, high levels of cytokines, hypoxia, etc.). Cells that have aged due to chronological age or as a result of continuous strong stress stimuli are known as senescent cells. Several cellular processes have been identified as being impaired by cellular age, including chronological age, tumor antigen specificity, killer cell properties, proliferative capacity, metabolism, inhibition of DNA repair systems, telomere length, and loss of stem cell characteristics.
[0111] As used herein, “immature T cells” refers to T cells that have been exposed to one or more reprogramming factors for a period of time sufficient for the T cells to begin to adhere to the surface of the culture vessel in order to form T cell-derived adherent cells that revert to functional T cells after stimulation with T cell activating agents and optionally immunomodulatory molecules.
[0112] For example, the methods described herein produce juvenile T cells that result in one or more of the following compared to terminally differentiated T cells: increased in vivo proliferation, survival, persistence, and / or cytotoxicity; reduced epigenetic age; increased telomere length; improved metabolism; decreased other markers associated with apoptosis and cellular senescence; and improved antitumor activity. In certain embodiments, the juvenile T cells exhibit a polyclonal TCR repertoire and long-term in vivo engraftment ability. The juvenile T cells may exhibit the biological and phenotypic features of younger T cells with respect to epigenetic signature, telomere length, metabolic activity, and functionality. In various embodiments, the partial reprogramming processes described herein may partially dedifferentiate T cells, for example, resulting in the loss of certain aspects of the T cell phenotype (which can be restored by T cell activation via TCR signaling and / or culture in appropriate media).
[0113] In various embodiments, juvenile T cells can be used to target cancer, viruses, or autoimmune diseases. In various embodiments, partially reprogrammed T cells can be used to reconfigure the entire adaptive immune system or alleviate the condition of immunocompromised patients.
[0114] In certain embodiments, T cells are partially reprogrammed and rejuvenated by transient expression of reprogramming factors. In various embodiments, the morphology and cell surface expression profiles of the T cells begin to change. In particular, in certain embodiments, the cells begin to express certain cell surface markers and the expression of T cell markers decreases. In certain embodiments, from about 5 days after partial reprogramming, the cells begin to express certain cell surface markers and the expression of T cell markers decreases, indicating that the dedifferentiation process has begun. In various embodiments, the dedifferentiated T cells (also referred to herein as “T cell-derived adherent” cells) are stimulated with one or more T cell activating molecules, such as anti-CD3 antibodies or other CD3 agonists, and cultured under T cell culture conditions. In certain embodiments, this T cell stimulation, also referred to herein as “reactivation,” can drive the dedifferentiated cells back into T lineage cells. Notably, the reactivated T cells, based on epigenetic clock analysis, exhibit significantly younger cell characteristics, have a more stem-like phenotype, and acquire high proliferative capacity.
[0115] As used herein, “transient” means a period of time sufficient to achieve partial reprogramming of one or more T cells (for example, a period of time sufficient to cause the formation of T cell-derived adherent cells, but not long enough to transform one or more T cells into iPS cells or pluripotent cells).
[0116] For example, “transient contact” with one or more reprogramming factors means contact with one or more reprogramming factors for a period of time that is sufficient to cause T cell-derived adherent cells to form, or for one or more T cells to form at least one colony attached to the surface of the culture vessel, but not long enough for one or more T cells to transform into iPS cells or pluripotent cells. In various embodiments, “transient contact” could mean contact for a period of up to 1 day, or up to 2 days, or up to 3 days, or up to 4 days, or up to 6 days, or up to 7 days, or up to 8 days, or up to 9 days, or up to 10 days, or up to 11 days, or up to 12 days, or up to 13 days, or up to 14 days.
[0117] For example, "transient expression" or "transient expression" means the expression of one or more Yamanaka factors, or the inducing such expression, that achieves partial reprogramming of one or more T cells (i.e., transformation into iPS cells or pluripotent cells is not achieved).
[0118] As used herein, “epigenetic age” (or “eAge”) means the age of a cell as determined using a known epigenetic clock, e.g., the Horvath clock, the Hannum clock, or the Levine clock (see, e.g., Horvath et al., 2018, Aging 10, 1758-1775; Hannum et al., 2013, Mol. Cell. 49(2), 359-367; Levine et al., 2018, Aging, 10(4):573-592). In certain embodiments, eAge is the age of a cell as determined using the Horvath clock method, which measures methylation status at 353 CpGs (Horvath and Raj, 2018 Nature Reviews Genetics, 19:371-385). These results demonstrate that the partial reprogramming and reactivation methods described herein can generate juvenile T cells without going through the iPS cell stage, which requires time-consuming and complex differentiation steps. Furthermore, T cells differentiated from iPS cells in the absence of education by autologous thymus lack true T cell function and exhibit abnormalities including immature phenotype, non-MHC-dependent killing, improper CD8αβ dimerization, dysregulation of gene expression, and a lack of ability to generate a developmentally homogeneous T cell population. Vizcardo et al., 2018, Cell Rep 22, 3175-3190. Therefore, juvenile T cells generated using the partial reprogramming method described herein offer unexpectedly advantageous properties compared to T cells generated using methods known in the art.
[0119] I. Method for producing immature T cells The following are non-limiting and exemplary embodiments of the present invention. Additional embodiments of the compositions and methods of the present invention will become apparent to those skilled in the art based on the disclosures provided herein.
[0120] In various embodiments, the present disclosure relates to a method for producing juvenile T cells. In various embodiments, the method comprises (i) transiently exposing a population of T cells to at least one reprogramming factor for a period of time sufficient to achieve partial reprogramming, such that the T cells are not transformed into iPS cells; and (ii) exposing the partially reprogrammed T cells to at least one T cell activating compound or agent, and optionally one or more immunomodulators.
[0121] In various embodiments, the present disclosure relates to a method for producing juvenile T cells. In various embodiments, the method comprises (i) transiently contacting a population of T cells with at least one reprogramming factor selected from the group consisting of KLF4, OCT3 / 4, SOX2, NANOG, LIN28, L-MYC and C-MYC, and optionally SV40, for a period of time sufficient to achieve partial reprogramming, such that the T cells are not transformed into iPS cells; and (ii) contacting the partially reprogrammed T cells with at least one T cell activating compound or agent, and optionally one or more immunomodulators.
[0122] In various embodiments, the present disclosure relates to a method for producing juvenile T cells. In various embodiments, the method comprises (i) contacting a population of T cells with at least one reprogramming factor selected from the group consisting of KLF4, OCT3 / 4, SOX2, NANOG, LIN28, L-MYC and C-MYC, and optionally SV40, for a period of time sufficient for the formation of T cell-derived adherent cells, such that the T cells are not transformed into iPS cells; and (ii) contacting T cell-derived adherent cells with at least one T cell activating compound or agent and / or a T cell costimulatory agent, and optionally one or more immunomodulators.
[0123] As used herein, “reprogramming” refers to the process of erasing and / or re-establishing epigenetic modifications acquired during the development or in cell culture of mammalian cells. For example, muscle cells can be reprogrammed into neurons. Reprogramming is not intrinsically related to aging and rejuvenation (see, for example, Takahashi et al., Cell (2007) 131, 861-872).
[0124] "Complete reprogramming" refers to the reprogramming of somatic cells into pluripotent stem (iPS) cells or totipotent stem cells.
[0125] "Partial reprogramming" refers to a reprogramming process that does not reach the state of totipotent stem cells or pluripotent stem cells (iPS cells). Therefore, partial preprogramming is any reprogramming that is not complete reprogramming. "Partial," "incomplete," or "transient" reprogramming is reprogramming that is not complete reprogramming compared to cells that have been completely reprogrammed, for example, to iPS cells. In certain embodiments, partial reprogramming is reprogramming that takes place over approximately 1 to approximately 20 days. In certain embodiments, partial reprogramming is reprogramming that takes place over approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or approximately 25 days.
[0126] In certain embodiments, partial T cell reprogramming is a reprogramming process that continues until T cell reactivation is initiated. In other embodiments, partial T cell reprogramming is a reprogramming process that continues until T cells begin to lose the expression of at least one T cell marker and / or begin to express markers associated with non-T cell lineages. In certain embodiments, partial T cell reprogramming is a reprogramming process that continues over a period of time until T cells are no longer able to revert to cells expressing CD3, CD4 and / or CD8 through reactivation with a T cell activating agent.
[0127] "Partially reprogrammed T cells" refers to T cells that have been reprogrammed without reaching a totipotent stem cell state or a pluripotent stem cell state (iPS cells). In further embodiments, partial reprogramming of T cells is incomplete, and / or partial, and / or transient reprogramming compared to iPS cells. Partially reprogrammed T cells refer to T cells that have been reprogrammed by contacting T cells with one or more reprogramming factors for a period of time such that the T cells form T cell-derived adherent cells. In certain embodiments, T cell-derived adherent cells are loosely attached to the surface of the culture vessel. The T cell-derived adherent cells described herein maintain lineage stability and return to the T cell lineage after stimulation (reactivation), for example, with T cell activating agents and optionally immunomodulatory molecules (e.g., cytokines). In certain embodiments, T cell-derived adherent cells are semi-adherent, loosely adherent, adherent, or strongly adherent (firmly attached).
[0128] 1. Source and isolation of T cells In some embodiments, the cells useful in the partial reprogramming methods described herein are derived from primary cells, such as primary human cells. Samples include tissues, bodily fluids, and other samples taken directly from a subject, as well as samples obtained from one or more processing steps such as separation, centrifugation, genetic engineering operations (e.g., transduction with a viral vector), washing, and / or incubation. Biological samples may be samples obtained directly from a biological source or processed samples. Biological samples include, but are not limited to, bodily fluids such as blood, plasma, serum, cerebrospinal fluid, synovial fluid, urine, and sweat, as well as tissue and organ samples, and processed samples derived therefrom.
[0129] In some embodiments, the sample from which cells are derived or isolated is blood or a blood-derived sample, or a product of apheresis or leukocyte apheresis, or derived therefrom. Exemplary samples include whole blood, peripheral blood mononuclear cells (PBMCs), leukocytes, bone marrow, thymus, tissue biopsy, tumors, leukemia, lymphoma, lymph nodes, intestinal lymphoid tissue, mucosa-associated lymphoid tissue, spleen, other lymphoid tissue, liver, lungs, stomach, intestines, colon, kidneys, pancreas, breast, bone, prostate, cervix, testes, ovaries, tonsils, or other organs, and / or cells derived therefrom. In the context of cell therapy, for example adoptive cell therapy, samples may include samples from autologous and allogeneic sources.
[0130] In some embodiments, the cells for use in the partial reprogramming method are derived from a cell line, such as a T cell line. In some embodiments, the cells are obtained from heterologous sources, such as mice, rats, non-human primates, and pigs.
[0131] In various embodiments, this disclosure relates to isolating T cells from a source and partially reprogramming the T cells to improve aging and enhance T cell function. Examples of suitable source cells include, but are not limited to, peripheral blood mononuclear cells (PBMCs). T cells for use in the methods herein may include, but are not limited to, cultured T cells, e.g., primary T cells or T cells from cultured T cell lines, e.g., Jurkat, SupT1, etc., or T cells obtained from mammals. When obtained from mammals, source cells can be obtained from a number of sources, including, but not limited to, blood, bone marrow, lymph nodes, tumors, thymus, spleen, or other tissues or body fluids. Source cells may also be concentrated or purified. T cells can be any type of T cell and at any developmental stage, including but not limited to CD4+CD8αβ+ double-positive T cells, CD4+ helper T cells (e.g., Th1 and Th2 cells), CD4+ T cells, CD8+ T cells (e.g., cytotoxic T cells), peripheral blood mononuclear cells (PBMCs), peripheral blood leukocytes (PBLs), tumor-infiltrating cells (TILs), memory T cells, naive T cells, etc.
[0132] In various embodiments, T cells are isolated from tumors, and in particular, T cells for use in the partial reprogramming methods described herein are TILs. As used herein, “tumor-infiltrating lymphocytes” or “TIL” means a population of cells originally obtained as cells that have migrated from the bloodstream of the subject into the tumor. TILs include, but are not limited to, CD8+ cytotoxic T cells (lymphocytes), Th1 and Th17 CD4+ T cells, natural killer cells, dendritic cells, and M1 macrophages. TILs include both primary and secondary TILs. “Primary TILs” are those obtained from patient tissue samples as outlined herein (sometimes referred to as “freshly recovered”). In some embodiments, TILs may be classified by expressing one or more of the following biomarkers: CD4, CD8, TCRαβ, CD27, CD28, CD56, CCR7, CD45Ra, CD95, PD-1, and CD25.
[0133] In various embodiments of this disclosure, source cells may have a naive T cell (TN) phenotype, a central memory T cell (TCM) phenotype, or an effector memory T cell (TEM) phenotype, or stem-like T cells (Tscm). The phenotypes of TN, TCM, and TEM cells are known in the art and described elsewhere in this specification. For example, CCR7 and CD62L are expressed in TN and TCM cells but not in TEM cells. The transcription factors LEF1, FOXP1, and KLF7 are expressed in TN and TCM cells but not in TEM cells. CD45RO and KLRG1 are not expressed in TN cells but are expressed in TEM cells. Gattinoni et al., 2012, Nat. Rev. Cancer, 12:671-84. Alternatively, TN and TCM cells may be characterized by longer telomeres compared to those of TEM cells.
[0134] Specific subpopulations of T cells, such as CD3+, CD45+, CD137+, CD25+, CD28+, CD4+, CD8+, CD45RA+, GITR+, and / or CD45RO+ T cells, can be isolated by positive or negative selection techniques (e.g., using fluorescence-based or magnetic-based cell sorting). For example, T cells can be isolated by incubation with any of the various commercially available antibody-conjugated beads, such as Dynabeads®, CELLection®, DETACHaBEAD® (Thermo Fisher), or MACS® cell isolation products (Miltenyi Biotec), for a sufficient period of time for positive selection of desired T cells or negative selection for removal of unwanted cells.
[0135] In various embodiments herein, T cells are cultured in appropriate culture media for isolation, pre-activation, reactivation, or growth stages. T cell culture conditions are known in the art. In certain embodiments, the medium for culturing T cells herein may be a starting medium referred to as a “basic” medium. A basic medium refers to any starting medium supplemented with one or more of the additional elements disclosed herein, e.g., glucose, one of various salts, one or more cytokines, e.g., IL-2, IL-7, IL-15, IL-21, or any combination thereof. A basic medium may be any medium for culturing immune cells, e.g., T cells. In some embodiments, the basic medium is an equilibrium salt solution (e.g., PBS, DPBS, HBSS, EBSS), Dulbecco's Modified Eagle Medium (DMEM), Crick Medium, Minimum Essential Medium (MEM), Basic Eagle Medium (BME), F-10, F-12, RPMI 1640, Glasgow Minimum Essential Medium (GMEM), Alpha Minimum Essential Medium (AlphaMEM), Iskov Modified Dulbecco's Medium (IMDM), M199, OPTMIZER® Pro, OPTMIZER® CTS® T Cell Growth Basic Medium (ThermoFisher), OPTMIZER®, OPTMIZER® Complete, IMMUNOCULT® XF (STEMCELL® Technologies), AIM V®, TEXMACS® Medium, PRIME-XV® T cell CDM, X-VIVO™ The medium comprises 15(Lonza), TRANSACT® TIL augmentation medium, or any combination thereof. In some embodiments, the basal medium is serum-free. In some embodiments, the basal medium contains PRIME-XV® T cell CDM. In some embodiments, the basal medium contains OPTMIZER®. In some embodiments, the basal medium contains OPTMIZER® Pro. In some embodiments, the basal medium further contains an immune cell serum substitute (ICSR).
[0136] As used herein, the term “cytokine” refers to small secreted proteins released by cells that have a specific effect on intercellular interactions and communication. Non-limiting examples of cytokines include interleukins (e.g., interleukin (IL)-1, IL-2, IL-4, IL-7, IL-9, IL-13, IL-15, IL-3, IL-5, IL-6, IL-11, IL-10, IL-20, IL-14, IL-16, IL-17, IL-21, and IL-23), interferons (IFNs; e.g., IFN-α, IFN-β, and IFN-γ), tumor necrosis factor (TNF) family members, and transforming growth factor (TGF) family members. Some aspects of this disclosure relate to methods for culturing and / or growing immune cells, e.g., T cells as disclosed herein or one or more engineered immune cells, in a medium containing cytokines. In some aspects, the cytokines are interleukins. In some embodiments, the cytokines include IL-2, IL-7, IL-15, IL-21, or any combination thereof.
[0137] In various embodiments of this disclosure, the T cells for use in the partial reprogramming methods described herein are TCRαβ cells. In this regard, TCRαβ cells may express a functional antigen-specific T cell receptor (TCR) comprising both alpha (α) and beta (β) chains. The alpha and beta chains of TCRs are known in the art. A TCR may contain any amino acid sequence, as long as it specifically binds to the antigen and is immunologically recognizable. A TCR may have antigen specificity for any desired antigen. As used herein, the terms “antigen-specific” and “antigen-specific” mean that a TCR can specifically bind to an antigen, such as a disease-specific antigen or its epitope, and be immunologically recognizable, such that the binding of the TCR to the antigen or its epitope triggers an immune response.
[0138] In various embodiments, the mammals from which T cells are isolated are immunized with an antigen of a certain disease state, or an antigen specific to a certain disease state. Preferably, the mammals are immunized before T cells are obtained from them. In this way, the isolated T cells may contain T cells induced to have specificity for the disease state to be treated, or may contain a higher proportion of cells specific to that disease state.
[0139] Alternatively, T cells containing endogenous antigen-specific TCRs may be T cells within a mixed population of cells isolated from mammals. In certain embodiments, the mixed population may be exposed to an antigen recognized by the endogenous TCR while being cultured in vitro. In this way, T cells containing TCRs that recognize disease-specific antigens increase or proliferate in vitro, thereby increasing the number of T cells with endogenous antigen-specific receptors.
[0140] Antigen-specific TCRs may be exogenous TCRs, i.e., antigen-specific TCRs that are not specific to T cells (do not occur naturally). Recombinant TCRs are TCRs produced by the recombinant expression of genes encoding the α, β, γ, and / or δ chains of one or more exogenous TCRs. Recombinant TCRs may contain polypeptide chains derived entirely from a single mammalian species, or antigen-specific TCRs may be chimeric or hybrid TCRs consisting of amino acid sequences derived from TCRs of two different mammalian species. For example, an antigen-specific TCR may contain a variable region derived from a mouse TCR and a constant region from a human TCR so that the TCR is "humanized". Methods for producing recombinant TCRs are known in the art. See, for example, U.S. Patents 7,820,174, 8,785,601, 8,216,565, and U.S. Patent Application Publication 2013 / 0274203.
[0141] T cells containing an endogenous antigen-specific TCR can also be transformed, e.g., transduced or transfected, by one or more nucleic acids encoding an exogenous (e.g., recombinant) TCR or other recombinant chimeric receptor. Such exogenous chimeric receptors, e.g., chimeric CRs, can confer specificity to additional antigens to transformed T cells beyond the antigen to which the endogenous TCR is inherently specific. This may, but is not necessarily, result in the production of T cells with dual antigen specificity.
[0142] T cells containing an endogenous antigen-specific TCR can also be transformed, for example, transduced or transfected, with one or more nucleic acids encoding a “chimeric antigen receptor” (CAR). Typically, a CAR comprises an antigen-binding domain of an antibody, such as a single-chain variable fragment (scFv), fused to the transmembrane and intracellular domains of the TCR, and in some embodiments, one or more costimulatory domains, such as an intracellular signaling region of a T cell costimulatory molecule. Thus, the antigen specificity of the TCR may be encoded by an scFv that specifically binds to the antigen or its epitope. Methods for constructing such CARs are known in the art. See, for example, U.S. Patents 8,465,743, 10,533,055, 10,603,380, and U.S. Patent Application Publications 2014 / 0037628 and 2014 / 0274909.
[0143] Any suitable nucleic acid encoding a CAR, an engineered TCR, or a TCR-like protein or polypeptide can be used. In these embodiments, the partial reprogramming process, further described below, may occur before, after, or concurrently with the genetic modification of T cells by the CAR, engineered TCR, or TCR-like protein or polypeptide. The CAR or engineered TCR encoded by the nucleic acid may be any suitable form, including, for example, a fusion with a single-chain CAR or TCR or other protein or polypeptide (e.g., a co-stimulatory molecule, but not limited to these).
[0144] Antigens recognized by T cells in this specification, whether by endogenous antigen-specific TCRs, engineered TCRs, or CARs, can be any antigen associated with a disease state. For example, an antigen may be, but is not limited to, a cancer antigen (also called a tumor antigen or tumor-associated antigen) or an infectious disease antigen (e.g., a viral antigen). Viral antigens may be, but are not limited to, any viral protein known in the art (e.g., env, gag, pol, gp120, thymidine kinase, etc.).
[0145] In certain embodiments, the antigens are CD19, TRAC, TCRβ, BCMA, CLL-1, CS1, CD38, CD19, TSHR, CD123, CD22, CD30, CD70, CD171, CD33, EGFRvIII, GD2, GD3, Tn Ag, PSMA, ROR1, ROR2, GPC1, GPC2, FLT3, FAP, TAG72, CD44v6, CEA, EPCAM, B7H3, KIT, IL-13Ra2, Mesothelin, IL-llRa, PSCA, PRSS21, VEGFR2, LewisY, CD24, PDGFR-beta, SSEA-4, CD20, Folate receptor alpha, ERBB2 (Her2 / neu), MUC1, MUC16, EGFR, NCAM, Prostase, PAP, ELF2M, Ephrin B2, IGF-I receptor, CAIX, LMP2, gpl OO, bcr-abl, tyrosinase, EphA2, fucosyl GM1, sLe, GM3, TGS5, HMWMAA, o-acetyl-GD2, folate receptor beta, TEM1 / CD248, TEM7R, CLDN6, GPRC5D, CXORF61, CD97, CD179a, ALK, polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WTl, NY-ESO-1, LAGE-la, MAGE-Al, regmine, HPV E6,E7, MAGE Al, ETV6-AML, sperm protein 17, XAGE1, Tie 2, MAD-CT-1, MAD-CT-2, Fos-related antigen 1, p53, p53 variant, prostain, survivor, telomerase, PCTA-1 / galectin 8, melan A / MARTl, Ras variant, hTERT, sarcoma translocation breakpoint, ML-IAP, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, androgen receptor, cyclin Bl, MYCN, RhoC, TRP-2, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, RAGE-1, human telomerase reverse transcriptase, RU1, RU2, intestinal carboxylesterase, mut hsp70-2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5, IGLL1, CD2, CD3ε, CD4, CD5, CD7, the extracellular components of APRIL proteins, or any combination thereof, or derived from them.
[0146] In certain embodiments, CAR or engineered TCR is AFP, CD19, TRAC, TCRβ, BCMA, CLL-1, CS1, CD38, CD19, TSHR, CD123, CD22, CD30, CD171, CD33, EGFRvIII, GD2, GD3, Tn Ag, PSMA, ROR1, ROR2, GPC1, GPC2, FLT3, FAP, TAG72, CD44v6, CEA, EPCAM, B7H3, KIT, IL-13Ra2, Mesothelin, IL-llRa, PSCA, PRSS21, VEGFR2, LewisY, CD24, PDGFR-beta, SSEA-4, CD20, Folate receptor alpha, ERBB2 (Her2 / neu), MUC1, MUC16, EGFR, NCAM, Prostase, PAP, ELF2M, Ephrin B2, IGF-I receptor, CAIX, LMP2, gpl OO, bcr-abl, tyrosinase, EphA2, fucosyl GM1, sLe, GM3, TGS5, HMWMAA, o-acetyl-GD2, folate receptor beta, TEM1 / CD248, TEM7R, CLDN6, GPRC5D, CXORF61, CD97, CD179a, ALK, polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WTl, NY-ESO-1, LAGE-la, MAGE-Al, regmine, HPV E6,E7, MAGE Al, ETV6-AML, sperm protein 17, XAGE1, Tie 2, MAD-CT-1, MAD-CT-2, Fos-related antigen 1, p53, p53 variant, prostain, survivor, telomerase, PCTA-1 / galectin 8, melan A / MARTl, Ras variant, hTERT, sarcoma translocation breakpoint, ML-IAP, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, androgen receptor, cyclin Bl, MYCN, RhoC, TRP-2, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, RAGE-1, human telomerase reverse transcriptase, RU1, RU2, intestinal carboxylesterase, mut The extracellular components of hsp70-2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5, IGLL1, CD2, CD3ε, CD4, CD5, CD7, APRIL proteins, or any combination thereof are targeted.
[0147] As used herein, the terms “cancer antigen” or “tumor-associated antigen” refer to any molecule (e.g., protein, polypeptide, peptide, lipid, carbohydrate, etc.) that is expressed or overexpressed exclusively or primarily by tumor cells or cancer cells, so that the antigen is associated with tumor or cancer. A cancer antigen may be, for example, a variant tumor antigen or neoantigen. Cancer antigens may also be expressed by normal cells, non-tumor cells, or non-cancerous cells. However, in such cases, the expression of cancer antigens by normal cells, non-tumor cells, or non-cancerous cells is not as robust as the expression by tumor or cancer cells. In this regard, tumor or cancer cells can overexpress antigens, i.e., express antigens at significantly higher levels, compared to the expression of antigens by normal cells, non-tumor cells, or non-cancerous cells. Furthermore, cancer antigens may also be expressed by cells in different stages of development or maturation. For example, cancer antigens may be further expressed by embryonic or fetal cells not typically found in adult mammals. Alternatively, cancer antigens may be further expressed by stem cells or progenitor cells not typically found in adult mammals. Cancer antigens are known in the art and include, for example, the cancer antigens listed above, common tumor antigens, such as mesothelin, CD19, CD22, CD276 (B7H3), gp100, MART-1, epidermal growth factor receptor variant III (EGFRVIII), TRP-1, KRAS, TRP-2, tyrosinase, NY-ESO-1 (also known as CAG-3), MAGE-1, MAGE-3, etc. In one embodiment of this disclosure, the cancer antigen is a patient-specific neoantigen. Patient-specific neoantigens may arise as a result of tumor-specific mutations.
[0148] A cancer antigen may be an antigen expressed by any cell of any cancer or tumor, including cancers and tumors described herein. A cancer antigen may be a cancer antigen of only one type of cancer or tumor, such that the cancer antigen is associated with or characteristic of only one type of cancer or tumor. Alternatively, a cancer antigen may be a cancer antigen of multiple types of cancers or tumors (for example, characteristic of them). For example, a cancer antigen may be expressed by both breast cancer cells and prostate cancer cells, and may not be expressed at all by normal cells, non-tumor cells, or non-cancerous cells.
[0149] The pathological condition associated with or characterized by an antigen recognized by a TCR or CAR may be any such condition. For example, this condition may be cancer or an infectious condition, such as a viral condition, as described herein.
[0150] Cancers include sarcomas, carcinomas, acute lymphoblastic carcinomas, acute myeloid leukemia, alveolar rhabdomyosarcoma, bone cancer, brain cancer, breast cancer, cancer of the anus, anal canal, or anorectal area, eye cancer, intrahepatic cholangiocarcinoma, joint cancer, cancer of the neck, gallbladder, or pleura, head and neck cancers (e.g., cancer of the nose, nasal cavity, or middle ear, or oral cancer), vulvar cancer, chronic lymphocytic leukemia, chronic bone marrow cancer, colon cancer, esophageal cancer, cervical cancer, and gastrointestinal carcinoma. It may be any cancer, including any of the following: noid tumor, Hodgkin lymphoma, hypopharyngeal cancer, kidney cancer, laryngeal cancer, liver cancer, lung cancer, malignant mesothelioma, melanoma, multiple myeloma, nasopharyngeal cancer, non-Hodgkin lymphoma, ovarian cancer, pancreatic cancer, cancer of the peritoneum, retinoplasm, and mesentery, pharyngeal cancer, prostate cancer, rectal cancer, kidney cancer (e.g., renal cell carcinoma (RCC)), small intestine cancer, soft tissue cancer, gastric cancer, testicular cancer, thyroid cancer, ureteral cancer, and bladder cancer.
[0151] For the purposes of this specification, “viral condition” means a condition caused by a virus that may be transmitted from person to person or from organism to organism. In one embodiment of this disclosure, a viral condition is caused by a virus selected from the group consisting of herpesviruses, poxviruses, hepadnaviruses, papillomaviruses, adenoviruses, coronaviruses, orthomyxoviruses, paramyxoviruses, flaviviruses, and caliciviruses. For example, a viral condition may be caused by a virus selected from the group consisting of respiratory syncytial virus (RSV), influenza virus, herpes simplex virus, Epstein-Barr virus, varicella virus, cytomegalovirus, hepatitis A virus, hepatitis B virus, hepatitis C virus, human immunodeficiency virus (HIV), human T lymphotropic virus, calicivirus, adenovirus, and arenavirus.
[0152] Viral conditions may include, for example, influenza, pneumonia, herpes, hepatitis, hepatitis A, hepatitis B, hepatitis C, chronic fatigue syndrome, idiopathic acute respiratory syndrome (SARS), gastroenteritis, enteritis, carditis, encephalitis, bronchiolitis, respiratory papillomatosis, meningitis, HIV / AIDS, and mononucleosis.
[0153] T cells for use in the partial reprogramming methods of the present disclosure can be isolated or purified from a source using any suitable technique known in the art. For example, immune cells (e.g., T cells) can be obtained from a subject. Immune cells (e.g., T cells) can be obtained from several sources, including peripheral blood mononuclear cells (PBMCs), bone marrow, lymph node tissue, umbilical cord blood, thymic tissue, tissue from the site of infection, ascites, pleural fluid, spleen tissue, and tumors. In certain embodiments, immune cells (e.g., T cells) can be obtained from units of blood collected from a subject using any number of techniques known to those skilled in the art, such as FICOLL® isolation. Cells can preferably be obtained from the circulating blood of an individual by apheresis. Apheresis products typically include lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated leukocytes, erythrocytes, and platelets. In certain embodiments, cells collected by apheresis may be washed to remove the plasma fraction and placed in a suitable buffer or culture medium for further processing. The cells may be washed with PBS. As understood, the washing step may be performed by, for example, using a semi-automatic flow-through centrifuge such as a Cobe® 2991 cell processor or a Baxter Cyto-Mate®. After washing, the cells may be resuspended in various biocompatible buffers, or other saline solutions with or without buffers. In certain embodiments, undesirable components of the apheresis sample may be removed.
[0154] 2. Partial reprogramming of T cells This disclosure relates in part to a method for partially reprogramming T cells. In a particular embodiment, T cells are partially reprogrammed by exposing the T cells to one or more reprogramming factors over a period of days such that one or more T cells form colonies that adhere (or partially adhere) to the surface of a culture vessel (forming T cell-derived adherent cell colonies), and such adherent cells are reactivated after stimulation (reactivation) with a T cell activating agent and optionally immunomodulatory molecules (e.g., cytokines).
[0155] As used herein, the term “reprogramming factor” refers to any protein, polypeptide, amino acid, mRNA, DNA, or small molecule capable of erasing and / or re-establishing epigenetic modifications acquired during development or in cell culture of mammalian cells. Reprogramming factors can alter the differentiation state of cells. Such reprogramming factors may include, but are not limited to, the transcription factors discovered by Yamanaka et al. (see, e.g., Takahashi and Yamanaka, 2006, Cell, 136, 364-377), OCT4 (or OCT3 / 4), SOX3, KLF4, and C-MYC, which are referred herein to as “OSKM” or “Yamanaka factors.” Reprogramming factors also refer to other factors that may alter the differentiation state of cells or improve or alter the efficiency of cell reprogramming. Such factors are known in the art. Exemplary reprogramming factors are described in Feng et al. 2009, Cell Stem Cell Review, 4:301-313.
[0156] In various embodiments, the reprogramming factor is at least one from the group consisting of KLF4, OCT3 / 4, SOX2, C-MYC, and SV40. In various embodiments, not all four Yamanaka factors are strictly required (see, e.g., Genome Biol. 2012;13(10):251, Cell Stem Cell, 2019, 25(6):737-753, Nature Communications (2018) 9:2865). In various embodiments, isolated immune cells (e.g., T cells) are contacted with OCT3 / 4 and SOX2. In various embodiments, isolated immune cells (e.g., T cells) are contacted with OCT3 / 4, SOX2, and C-MYC. In various embodiments, isolated cells are contacted with OCT3 / 4, SOX2, and KLF4. In certain embodiments, T cells are contacted with OCT3 / 4, SOX2, and KLF4, as well as either C-MYC or SV40.
[0157] In various embodiments, additional reprogramming factors may be used to partially reprogram isolated immune cells (e.g., T cells). Such factors include, but are not limited to, LIN28, NANOG, Esrrb, Pax5 shRNA, C / EBPa, p53 siRNA, UTF1, DNMT shRNA, Wnt3a, GLIS1, DLX4, CDH1, SV40 LT(T), and hTERT. In various embodiments, the reprogramming factors may upmodulate or downmodulate certain miRNAs involved in reprogramming. In certain embodiments, the reprogramming factors may upmodulate or downmodulate the expression of one or more upstream or downstream genes of one or more Yamanaka factors. In various embodiments, one or more reprogramming factors may include, but are not limited to, histone methyltransferase inhibitors, L-type calcium channel agonists, G9a methyltransferase inhibitors, DNA methyltransferase inhibitors, histone deacetylase inhibitors, MEK inhibitors, GSK3 inhibitors, or TGF-B inhibitors. Any factor that modulates the upstream or downstream molecular pathway of a reprogramming transcription factor is intended for use in the partial reprogramming methods described herein. Exemplary inhibitors include, but are not limited to, BIX01294, BayK 8644, CHIR 99021, forskolin, and RepSox. In certain embodiments, serine / threonine-protein kinase B-Raf (BRAF) inhibitors, epidermal growth factor receptor (EGFR) inhibitors, vascular endothelial growth factor 1 (VEGFR1) inhibitors, and / or fibroblast growth factor receptor 1 (FGFR1) inhibitors may be used in the reprogramming methods described herein (see, for example, US2017114323).
[0158] In various embodiments, the Disclosure relates to a method for producing juvenile T cells by transiently exposing T cells to at least one reprogramming factor selected from the group selected from KLF4, OCT3 / 4, SOX2, and C-MYC. In various embodiments of the Disclosure, isolated immune cells (e.g., T cells) are transiently exposed to KLF4, OCT3 / 4, SOX2, and C-MYC, and optionally SV40.
[0159] In this field, many strategies are known for delivering reprogramming factors to cells. These strategies include the use of single-stranded negative sense RNA viruses (Vizcardo et al., 2013), episomal plasmid systems such as those described in Nat. Methods 2011, 8(5):409-412, mRNA transfection using nanoparticles (Moffett et al., 2017), and the use of small molecules known to induce gene expression of pluripotency-constituting factors (Feng et al., 2009, Hou et al., 2013).
[0160] In various embodiments, one or more reprogramming factors are transiently expressed in isolated immune cells (e.g., T cells). In various embodiments, the one or more reprogramming factors may include one or all of KLF4, OCT3 / 4, SOX2, and C-MYC, or further include one or more other reprogramming factors. In various embodiments, the reprogramming factors may be expressed in isolated T cells using gene editing techniques known in the art (e.g., TALENS, CRISPR / cas). In various embodiments, the gene editing technique delivers a set of inducible reprogramming factors to be expressed in isolated T cells. In various embodiments, nucleic acids encoding stem cell-related genes are carried in one or more recombinant expression vectors. Recombinant expression vectors may include, but are not limited to, DNA and RNA, and may contain any type of nucleotides, which may be single-stranded or double-stranded, synthetic or partially derived from natural sources, and may contain natural, non-natural, or modified nucleotides. Recombinant expression vectors may contain naturally occurring nucleotide bonds, non-naturally occurring nucleotide bonds, or both types of bonds. Vectors may contain regulatory nucleic acid sequences that result in the expression of stem cell-related genes.
[0161] In some embodiments, the recombinant expression vector is a viral vector. Preferred viral vectors, though not limited to, include, sendai virus vectors, retroviral vectors, lentiviral vectors, alphaviral vectors, vaccinia vectors, adenovirus vectors, adeno-associated virus vectors, herpesvirus vectors, and fowlpox virus vectors, and preferably have the native ability or the ability to be engineered to transform immune cells (e.g., T cells). In certain embodiments, the viral vector is pseudotyped with a heterologous viral envelope protein. In certain embodiments, the viral vector is a lentivirus or sendai virus vector pseudotyped with a preferred envelope, e.g., a viral envelope (see, e.g., Blood Adv 2017 Oct 24;1(23):2088-2104, Mol Ther 2012 Sep;20(9):1699-712). In certain embodiments, the viral vector is an embedded-defective lentiviral vector. Suitable viral vectors are known in the art and are described, for example, in J. Biol. Chem. (2011) 286:4760-4771 and Stem Cell Research & Therapy (2019) 10:185.
[0162] In various embodiments, recombinant expression vectors are delivered by nanoparticles. In various embodiments, reprogramming factors are delivered using nanoparticles. Such nanoparticles can be designed to deliver specific mRNA or other macromolecules to lymphocytes in a transient and dose-controlled manner. These nanoparticles can be designed to target specific cell subtypes and, upon binding to them, stimulate receptor-mediated endocytosis, thereby introducing the synthetic mRNA they carry, which the cells can then express. This process is rapid and efficient because nuclear transport and transcription of the transgene are not required.
[0163] In various embodiments, one or more reprogramming vectors are delivered to immune cells (e.g., T cells) in separate vectors. In various embodiments, KLF4, OCT3 / 4, and SOX2 (KOS) are delivered in a single vector. In various embodiments, the vector expressing KOS is a viral vector and is delivered with a titer of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, or 30 MOI (multiple levels of infection). In various embodiments, KLF4 is delivered in a viral vector with a titer of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, or 30 MOI. In various embodiments, cMyc is delivered in a viral vector with a titer of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, or 30 MOI. In various embodiments, a vector expressing SV40 is further delivered to the cells, which is a viral vector delivered with a titer of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, or 30 MOI. In various embodiments, immune cells (e.g., T cells) are contacted with a Sendai vector expressing KOS at 10 MOI, a Sendai vector expressing KLF4 at 10 MOI, a Sendai vector expressing C-MYC at 3 MOI, and a Sendai vector expressing SV40 at 5 MOI. In certain embodiments, T cells are contacted with a multi-cistronic vector, such as a lentiviral vector, Sendai virus vector, or non-viral vector expressing KOSM.
[0164] In certain embodiments, T cells are stimulated with a T cell activator and optionally one or more immunomodulatory molecules for a sufficient time to stimulate and activate them before contact with one or more reprogramming factors. In certain embodiments, T cells are stimulated with tumor antigens or with autologous tumor cells or tumor cell lines. In some embodiments, T cells are TILs, and TILs are stimulated with tumor target cells derived from cancer patients or tumor antigens derived therefrom, or with one or more tumor-associated antigens.
[0165] Non-limiting examples of tumor-associated antigens include AFP (alpha-fetoprotein), αvβ6 or other integrins, BCMA, BRAF, B7-H3, B7-H6, CA9 (carbonic anhydrase 9), (carcinoembryonic antigen), claudin 18.2, claudin 6, c-MET, DLL3 (delta-like protein 3), DLL4, ENPP3 (ectonucleotide pyrophosphatase / phosphodiesterase family member 3), EpCAM, EPG-2 (epithelial glycoprotein 2), EPG-40, ephrin B2, EPHa2 (ephrin B2). Phosphate receptor A2, ERBB dimer, estrogen receptor, ETBR (endothelin B receptor), FAP-α (fibroblast-activating protein α), fetal AchR (fetal acetylcholine receptor), FBP (folate-binding protein), FCRL5, FR-α (folate receptor alpha), GCC (guanylic acid cyclase C), GD2, GD3, GPC2 (glypican-2), GPC3, gp100 (glycoprotein 100), GPNMB (glycoprotein NMB), GPRC5D (G protein-binding receptor 5D), HER2, HER3, HER4, hepatitis B Surface antigens, melanoma-associated antigens (MAGE)-A1, MAGE-A3, MAGE-A6, MART-1 (Melan A), mesothelin, mucin 1 (MUC1), MUC16, MHC / peptide complexes (e.g., HLA-A complexed with peptides derived from AFP, KRAS, NY-ESO, MAGE-A, and WT1), NCAM (neuronal cell adhesion molecule), nectin-4, NY-ESO, carcinoembryonic antigen, PRAME (preferentially expressed melanoma antigen), progesterone receptor, PSA (prostate-specific antigen), PSCA (prostate stem cell antigen), PSM A (prostate-specific membrane antigen), ROR1, ROR2, SIRPα (signal regulatory protein alpha), SLIT, SLITRK6 (NTRK-like protein 6), Survivin, TAG72 (tumor-associated glycoprotein 72), TPBG (trophoblast glycoprotein), Trop-2, VEGFR1 (vascular endothelial growth factor receptor 1), p53, p53 variant, prostain, Survivin, telomerase, PCTA-1 / galectin 8, Melan A / MARTl, Ras variant, hTERT, sarcoma translocation breakpoint, ML-IAP, ERG (TMPRSS2)This includes ETS fusion genes, NA17, PAX3, androgen receptor, cyclin Bl, MYCN, RhoC, TRP-2, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, RAGE-1, human telomerase reverse transcriptase, RU1, RU2, intestinal carboxylesterase, mut hsp70-2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5, IGLL1, CD2, CD3ε, CD4, CD5, CD7, extracellular components of APRIL protein, neoantigens, or any combination thereof.
[0166] In this way, polyclonal antigen-specific (e.g., tumor-specific) T cells derived from cancer patients can be partially reprogrammed and rejuvenated. In certain embodiments, T cells are selected, sorted, or otherwise enriched after stimulation with an antigen such as a tumor antigen, tumor organoid, autologous tumor cell, or tumor cell lineage. In certain embodiments, T cells are enriched, selected, or sorted by selecting cells that express one or more cell surface markers such as 4-1BB(CD137), PD1, LAG3, CD45, CD39, TIGIT, TIM3, CD69, OX40, CD28, CD25, CD49d, and CTLA4. In certain embodiments, T cells are enriched, selected, or sorted before activation with any of the T cell activators described herein. In certain embodiments, CD45+ T cells are selected or enriched before activation with any of the activators described herein.
[0167] In some embodiments, the method of this invention involves activating cells before, during, and / or after incubation with viral vector particles. In some embodiments, the stimulation conditions may include incubation of cells in the presence of a T cell costimulatory molecule (e.g., TRANSACT, Miltenyi) that specifically binds to CD28, CD27, CD137(4-1BB), OX40, or ICOS, including a primary agent capable of activating one or more intracellular signaling domains of one or more components of the TCR complex, e.g., CD3, and a secondary agent (e.g., TRANSACT, Miltenyi) that specifically binds to CD28, CD27, CD137(4-1BB), OX40, or ICOS, e.g., an antibody present on the surface of a solid support such as beads. While not bound by theory, stimulating T cells in this manner (pre-activation step) enhances the efficiency of viral transduction and reprogramming factor delivery. Similarly, when nucleic acid transfection is used for reprogramming factor delivery, pre-stimulation of T cells enhances the efficiency of gene delivery.
[0168] In certain embodiments, T cells are pre-activated, reactivated, and / or enlarged with one or more T cell activating compounds and / or co-stimulating compounds and / or immunomodulatory compounds.
[0169] In certain embodiments, T cells are exposed to one or more reprogramming factors for a period of approximately 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or approximately 21 days. In certain embodiments, T cells are exposed to one or more reprogramming factors for a period of approximately 7 days. In certain embodiments, T cells are exposed to one or more reprogramming factors for a period of approximately 8 days. In certain embodiments, T cells are exposed to one or more reprogramming factors for a period of approximately 9 days. In certain embodiments, T cells are exposed to one or more reprogramming factors for a period of approximately 10 days. In certain embodiments, T cells are exposed to one or more reprogramming factors for a period of approximately 11 days. In certain embodiments, T cells are exposed to one or more reprogramming factors for a period of approximately 12 days. In certain embodiments, T cells are exposed to one or more reprogramming factors for a period of approximately 13 days. In certain embodiments, T cells are exposed to one or more reprogramming factors for a period of approximately 14 days.
[0170] In certain embodiments, T cells are exposed to one or more reprogramming factors for a period of at least about 5 days and no more than about 10 days. In certain embodiments, T cells are exposed to one or more reprogramming factors for a period of at least about 5 days and no more than about 11 days. In certain embodiments, T cells are exposed to one or more reprogramming factors for a period of at least about 5 days and no more than about 12 days. In certain embodiments, T cells are exposed to one or more reprogramming factors for a period of at least about 5 days and no more than about 12 days. In certain embodiments, T cells are exposed to one or more reprogramming factors for a period of at least about 5 days and no more than about 13 days.
[0171] In certain embodiments, T cells are exposed to one or more reprogramming factors for a period of at least about 6 days and no more than about 10 days. In certain embodiments, T cells are exposed to one or more reprogramming factors for a period of at least about 6 days and no more than about 11 days. In certain embodiments, T cells are exposed to one or more reprogramming factors for a period of at least about 6 days and no more than about 12 days. In certain embodiments, T cells are exposed to one or more reprogramming factors for a period of at least about 6 days and no more than about 12 days. In certain embodiments, T cells are exposed to one or more reprogramming factors for a period of at least about 6 days and no more than about 13 days.
[0172] The duration for which T cells are exposed to one or more reprogramming factors may vary depending on the amount or level of expression of the reprogramming factors. For example, in one embodiment in which a viral vector expressing one or more reprogramming factors at high levels is transduced into T cells, a shorter period may be required to achieve the desired partial reprogramming (formation of T cell-derived adherent cells). In another embodiment, a viral vector expressing one or more reprogramming factors at low levels is transduced into T cells, and a longer period may be required to achieve the desired partial reprogramming (formation of T cell-derived adherent cells). In this regard, in certain embodiments, the expression vector, such as a viral vector encoding one or more reprogramming factors, may include an inducible promoter that can adjust the expression of the partial reprogramming factors to a desired expression level.
[0173] In certain embodiments, T cells are exposed to one or more reprogramming factors for a period of approximately 5 to 30 days. In certain embodiments, T cells are exposed to one or more reprogramming factors for a period of approximately 5 to 25 days. In certain embodiments, T cells are exposed to one or more reprogramming factors for a period of approximately 5 to 20 days. In certain embodiments, T cells are exposed to one or more reprogramming factors for a period of approximately 5 to 15 days. In certain embodiments, T cells are exposed to one or more reprogramming factors for a period of approximately 5 to 13 days. In certain embodiments, T cells are exposed to one or more reprogramming factors for a period of approximately 5 to 12 days. In certain embodiments, T cells are exposed to one or more reprogramming factors for a period of approximately 6 to 12 days. In certain embodiments, T cells are exposed to one or more reprogramming factors for a period of approximately 6 to 13 days. In certain embodiments, T cells are exposed to one or more reprogramming factors for a period of approximately 7 to 12 days. In certain embodiments, T cells are exposed to one or more reprogramming factors for a period of approximately 7 to 13 days. In certain embodiments, T cells are exposed to one or more reprogramming factors over a period of approximately 7 to 14 days. In certain embodiments, T cells are exposed to one or more reprogramming factors over a period of approximately 6 to 20, 7 to 20, 8 to 20, 9 to 20, 10 to 20, 5 to 18, 6 to 18, 7 to 18, 8 to 18, 9 to 18, or 10 to 18 days.
[0174] During the reprogramming of somatic cells into totipotent or pluripotent stem cells (TSCs or PSCs), the somatic cells begin to dedifferentiate and lose their lineage-specific epigenetic status, but also begin to acquire the PSC phenotype. Because these changes progress gradually, the longer somatic cells remain in the reprogramming process, the more of the PSC phenotype they acquire. In various embodiments of this disclosure, the reprogramming process is stopped before the somatic cells dedifferentiate too much, so as to prevent the somatic cells from losing the function of the source cells. In various embodiments, partial reprogramming is sufficient to cause immune cells (e.g., T cells) to form at least one cell attached to the surface of the culture vessel and transform into an intermediate cell type referred to herein as “T cell-derived adherent cells.”
[0175] As used herein, “T cell-derived adherent cells” refers to intermediate cells in the partial reprogramming process of T cells. During the partial reprogramming process, T cell-derived adherent cells adhere (at least partially) to the surface of the culture vessel and form colonies. In certain embodiments, the T cell-derived adherent cells are loosely attached to the surface of the culture vessel. T cell-derived adherent cells differ from iPS cells (and iTSCs) in that they are not fully reprogrammed. In certain embodiments, the T cell-derived adherent cell colonies are loosely attached to the surface of the culture vessel. The T cell-derived adherent cells described herein retain lineage stability and, for example, the T cell-derived adherent cells of this disclosure retain the ability to revert to the T cell lineage after culture under T cell activation / stimulation conditions (e.g., using T cell culture media in the presence of activating molecules and / or immunomodulatory molecules such as anti-CD3, anti-CD28, anti-CD27 antibodies and cytokines such as IL2, IL7, IL15). In certain embodiments, the T cell-derived adherent cells are not multipotent. In certain embodiments, T cell-derived adherent cells are larger than partially reprogrammed or activated T cells. In certain embodiments, T cell-derived adherent cells are larger and have a more complex structure when measured by FACS analysis. In certain embodiments, T cell-derived adherent cells are SSEA4+CD3+. In another embodiment, T cell-derived adherent cells express one or more of the following cell surface markers, as determined by flow cytometry or transcriptome analysis: CD50, CD352, CD31, integrin β7, CD49e, CD122, CD314, HLA-DR, CD134, CD245, CD105 (endoglin), CD366, CD39, integrin α6β1, integrin β5, CD71, CD164, CD10, CD63, XCR1, CD298, CD201, CD151, CD325, CD324, CD147, SSEA-3, TRA-1-81, TRA-2-54, podoplanin, CD9, CD340, CD24, CD90, CD326, SSEA-5, SSEA-4, TRA-1-60-R.
[0176] As will be readily apparent to those skilled in the art, iPS cells can be distinguished from T cell-derived adherent cells by their morphology. In particular, as shown in Figure 3F, iPS cell colonies are significantly larger and have a more distinct colony structure. iPS cells are well known in the art and are described, for example, by Nishimura 2013, Cell Stem Cell 12, 114-126 and Vizcardo et al., 2013, Cell Stem Cell 12, 31-36).
[0177] In certain embodiments, at least 10% of T cell-derived adherent cells express one or more of the following cell surface markers, as determined by flow cytometry or transcriptome analysis: CD50, CD352, CD31, integrin α6β1, integrin β7, CD49e, CD122, CD314, HLA-DR, CD134, CD245, CD105 (endoglin), CD366, CD39, integrin β5, CD71, CD164, CD10, CD63, XCR1, CD298, CD201, CD151, CD325, CD324, CD147, SSEA-3, TRA-1-81, TRA-2-54, podoplanin, CD9, CD340, CD24, CD90, CD326, SSEA-5, SSEA-4, TRA-1-60-R.
[0178] In certain embodiments, at least about 10% to about 80% of T cell-derived adherent cells express one or more of the following cell surface markers, as determined by flow cytometry or transcriptome analysis: CD50, CD352, CD31, integrin α6β1, integrin β7, CD49e, CD122, CD314, HLA-DR, CD134, CD245, CD105 (endoglin), CD366, CD39, integrin β5, CD71, CD164, CD10, CD63, XCR1, CD298, CD201, CD151, CD325, CD324, CD147, SSEA-3, TRA-1-81, TRA-2-54, podoplanin, CD9, CD340, CD24, CD90, CD326, SSEA-5, SSEA-4, TRA-1-60-R. In another embodiment, at least about 15% to about 80%, at least about 20% to about 75%, at least about 25% to about 75%, at least about 30% to about 50%, at least about 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, or about 80% of T cell-derived adherent cells express one or more of the aforementioned cell surface markers, as determined using assays known in the art, such as flow cytometry, gene expression, or transcriptome analysis. The expression levels of these markers and the percentage of positive cells vary depending on the number of days of partial reprogramming.
[0179] In certain embodiments, partial reprogramming may result in a partial loss of certain identity markers of immune cells (e.g., T cells). For example, in certain embodiments, partial reprogramming of T cells may result in a loss or reduction of expression of one or more of the following: CD3, CD4, and CD8 (e.g., CD8αα, and / or CD8αβ). In certain embodiments, the reduction in expression may mean a reduction of about 10% to about 95% in the expression of the marker as measured by flow cytometry. In certain embodiments, the reduction in expression is a reduction of about 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, or 2log in the mean fluorescence intensity (MFI) of at least a portion of T cell-derived adherent cells.
[0180] In a particular embodiment, T cells are transiently exposed to one or more reprogramming factors for a period of time sufficient to form T cell-derived adherent cells. In a particular embodiment, T cells are transiently exposed to one or more reprogramming factors for a period of time sufficient to form adherent cell colonies, and at least a portion of the adherent cells express one or more of the following cell surface markers: CD50, CD352, CD31, integrin α6β1, integrin β7, CD49e, CD122, CD314, HLA-DR, CD134, CD245, CD105 (endoglin), CD366, CD39, integrin β5, CD71, CD164, CD10, CD63, XCR1, CD298, CD201, CD151, CD325, CD324, CD147, SSEA-3, TRA-1-81, TRA-2-54, podoplanin, CD9, CD340, CD24, CD90, CD326, SSEA-5, SSEA4, TRA-1-60-R. The expression of such markers can be determined using flow cytometry, gene expression analysis, RNA-seq, or other techniques known in the art.
[0181] In a particular embodiment, T cells are transiently exposed to one or more reprogramming factors for a period of time sufficient to form adherent cell colonies, and at least a portion of the adherent cells express integrin α6β1, CD9, CD90, and / or SSEA4.
[0182] In certain embodiments, at least a portion of T cell adherent cells express integrin α6β1, CD9, CD90, or SSEA4, or any combination thereof. In certain embodiments, at least a portion of T cell adherent cells express integrin α6β1, or at least a portion of T cell adherent cells express integrin α6β1 and SSEA4, or at least a portion of T cell adherent cells express integrin α6β1, SSEA4 and CD9, or at least a portion of T cell adherent cells express integrin α6β1, SSEA4, CD9 and CD90. In certain embodiments, at least a portion of T cell adherent cells express SSEA4, or SSEA4 and CD9, or SSEA4, CD9 and CD90.
[0183] In certain embodiments, at least a subset of T cell-derived adherent cells express CD9 and / or CD90, which are early markers of the partial reprogramming process. CD9, also known as tetraspanin-29, has four transmembrane domains. It is involved in cell adhesion, signaling, and cell differentiation. CD90, also known as THY-1, is an immunoglobulin superfamily surface glycoprotein and a marker associated with mesenchymal stem cells. It is also involved in cell adhesion and signaling. Thy-1 is commonly expressed in mouse T cells, but T cell Thy-1 expression in human T cell lineages is limited to specialized populations in the thymic cortex and some CD4 Th17 T cells.
[0184] In certain embodiments, at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or more T cell-derived adherent cells express CD9 and / or CD90.
[0185] In certain embodiments, T cell-derived adherent cells express one or more of the integrins α6β1, CD164, CD9, CD63, CD90, CD71, CD326, TRA-1-81, and TRA-1-60-R, and are compared in certain embodiments with stimulated and unstimulated T cells. In other embodiments, T cell-derived adherent cells have reduced expression of CD352 and CD31 compared with stimulated or unstimulated T cells.
[0186] In certain embodiments, at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or more T cell-derived adherent cells express one or more of CD164, CD9, CD63, CD90, CD71, CD326, TRA-1-81, and TRA-1-60-R.
[0187] In a particular embodiment, the disclosure provides a population of T cell-derived adherent cells whose epigenetic age is at least 5% younger than the chronological age of the starting population of the associated control T cells or isolated T cells. In another embodiment, the disclosure provides a population of T cell-derived adherent cells whose epigenetic age is at least 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or at least 80% younger than the chronological age of the source isolated T cells (i.e., isolated T cells contacted with a reprogramming factor).
[0188] In certain embodiments, when T cell-derived adherent cells are exposed to a T cell activator (e.g., anti-CD3, anti-CD28, one or more cytokines, e.g., IL2, IL7, IL15), the cells exhibit increased growth capacity compared to control T cells. In certain embodiments, partially reprogrammed T cells grow at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 100, 500, 100, 1500, or 2000 times greater than partially reprogrammed control T cells. In certain embodiments, partially reprogrammed T cells grow at least 50 to 2000 times, at least 50 to 1000 times, at least 50 to 900 times, at least 50 to 800 times, at least 50 to 700 times, at least 50 to 600 times, at least 50 to 500 times, at least 100 to 400 times, at least 150 to 500 times, at least 200 to 500 times, or at least 300 to 500 times greater than partially reprogrammed control T cells. In certain embodiments, partially reprogrammed T cells grow faster than partially reprogrammed T cells. In certain embodiments of this disclosure, the partial reprogramming method is carried out under conditions suitable for the maintenance of isolated T cells and / or partially reprogrammed T cells (T cell-derived adherent cells). Conditions suitable for the maintenance and proliferation of particular cell types will be apparent to those skilled in the art. Specialized culture media may be obtained from commercial sources, or factors necessary or desirable to improve proliferation may be added to standard culture media. For example, additional factors and drugs may be added to the culture medium to induce the expression of inducible elements in the cells or to inhibit the growth of cells sensitive to a particular drug.
[0189] In certain embodiments, isolated T cells are cultured in a T cell culture medium (TCM) containing a commercially available medium optimized for T cell culture, such as TexMACS medium or OpTmizer basic medium, with the addition of one or more supplements such as OpTmizer Cell Supplement; in certain embodiments, with the addition of an immune cell serum substitute (e.g., T cell serum substitute) and / or other supplements, such as L-glutamine, GlutaMAX, and / or cytokines, such as IL-2, IL-7, and / or IL-15.
[0190] In certain embodiments, the partial reprogramming step of the method herein is carried out using a medium optimized for cell reprogramming, such as STEMFIT medium (Amsbio, Abington, UK), mTESR2 (Stem Cell Technologies), and ESSENTIAL 6 or 8 (Life Technologies), STEMPRO hESC SFM (Gibco), TESR, Clone-R, dMEM F12, KSR, etc.
[0191] In another embodiment, partial reprogramming is performed in a medium consisting of 50% T cell medium and 50% stem cell medium (e.g., STEMFIT or Essential 8, mTESR, TESR, clone-R, dMEM F12, KSR), optionally supplemented with one or more cytokines such as IL2, IL7 and / or IL15. In a particular embodiment, partial reprogramming is performed in the first medium for a first period, and then in the second medium for a second period. For example, in a particular embodiment, the first medium is the 50 / 50 medium described above, optionally supplemented with one or more cytokines, for a period of 1, 2, 3, 4, 5, 6 days or more, followed by cell culture in a second medium, which is stem cell medium (e.g., STEMFIT or Essential 8), for 1, 2, 3, 4, 5, 6, 7, 8, 9 days or more. In certain embodiments, the first medium is 50 / 50 and used for 1, 2, or 3 days, and the second medium is a stem cell medium (e.g., STEMFIT or Essential 8) and is used starting from day 2, day 3, or day 4 until the formation and reactivation of T cell-derived adherent cells as further described herein. In certain embodiments of the partial reprogramming method, T cells are cultured in the first medium for a first period and then in the second medium for a second period. In certain embodiments of the partial reprogramming step of the method herein, T cells contacted with one or more reprogramming factors (e.g., one or more of KLF4, OCT3 / 4, SOX2, C-MYC, and SV40) are cultured in a suitable medium in a culture vessel coated with recombinant human laminin 511-E8 fragments such as iMatrix.
[0192] 3. Reactivation of partially reprogrammed T cell-derived adherent cells In various embodiments, partially reprogrammed T cell-derived adherent cells are reactivated in an activation medium that allows reprogrammed immune cells (e.g., T cells) to regain T cell identity and functionality.
[0193] In various embodiments of this disclosure, T cell-derived adherent cells are reactivated immediately after partial reprogramming using one or more T cell stimulating agents and / or co-stimulating agents in a suitable T cell culture medium.
[0194] In certain embodiments of the present disclosure, T cell-derived adherent cells are reactivated immediately after partial reprogramming in a T cell culture medium supplemented with one or more cytokines such as IL2, IL7, IL15, and IL21, with or without the presence of one or more T cell activators and / or one or more co-stimulators.
[0195] In certain embodiments, T cell-derived adherent cells are reactivated with one or more T cell activators and / or co-stimulators and / or immunomodulators as described elsewhere herein, in a medium suitable for T cell culture, such as a T cell culture medium (TCM) containing a commercially available medium optimized for T cell culture, such as TexMACS medium or OpTmizer basic medium, with the addition of one or more supplements such as OpTmizer Cell Supplement, or in certain embodiments, with the addition of an immune cell serum substitute (e.g., a T cell serum substitute) and other supplements, such as L-glutamine, GlutaMAX, cytokines, such as IL-2, IL-7, and / or IL-15.
[0196] In some embodiments, the conditions or agents for stimulation or activation used herein may be used for the pre-activation, reactivation, and / or augmentation steps of the method herein. T cells are generally, for example, U.S. Patent Nos. 5,858,358, 5,883,223, 6,352,694, 6,534,055, 6,797,514, 6,867,041, 6,692,964, 6,887,466, 6,905,680, and 6,905,6 These can be activated and amplified using the methods described in Nos. 81, 6,905,874, 7,067,318, 7,144,575, 7,172,869, 7,175,843, 7,232,566, 7,572,631, and 10,786,533. In certain embodiments, a T cell activating agent and / or a co-stimulatory agent that delivers a primary activation signal is brought into contact with the T cells. The agent that delivers the primary activation signal is known in the art and includes, for example, an antibody or its antigen-binding fragment or ligand or its target-binding fragment that binds to the CD3 cell surface receptor expressed on T cells (e.g., an anti-CD3 antibody). Agents that induce co-stimulatory signals are known in the art and include, but are not limited to, antibodies or ligands that bind to CD28, OX-40, 4-1BB / CD137, CD2, CD7, CD27, CD30, CD40, etc. In certain embodiments, the activating agent includes one or more agents, e.g., ligands, capable of activating the intracellular signaling domain of the TCR complex. In some embodiments, the agent initiates or starts the primary TCR / CD3 intracellular signaling cascade in T cells, such as an agent suitable for delivering a primary signal to initiate the activation of ITAM-inducible signaling, such as one specific to a TCR component. In other embodiments, the activating agent is provided in combination with, or simultaneously with, an agent that promotes co-stimulatory signals.Suitable agents that promote costimulatory signaling are known in the art and include antibodies or ligands that promote signaling of CD28, OX-40, 4-1BB / CD137, CD2, CD7, CD27, CD30, CD40, inducible T cell costimulatory factor (ICOS), lymphocyte function-associated antigen-1 (LFA-1 (CD11a / CD18), CD247, CD276 (B7-H3), Ig alpha (CD79a), DAP-10, Fc gamma receptor, or any combination thereof). In certain embodiments, the activation step of the method described herein is Stimulant and co-stimulant agents for the cell culture include, for example, anti-CD3, anti-CD28, anti-41-BB, or anti-CD27 antibodies and / or one or more cytokines conjugated to a solid support such as beads. In certain embodiments, the agent includes ligands for activating or co-stimulant receptors, e.g., peptide / MHC complexes and / or CD27 ligands (e.g., CD70 or its trimerized version), CD80, CD86, etc. Stimulant and co-stimulant agents include anti-CD3 / anti-CD28 beads (e.g., DYNABEADS M-450 CD3 / CD28 T Cell Expander and / or ExpACT beads). In some cases, stimulation and / or activation may include adding anti-CD3 antibodies and / or anti-CD28 antibodies to the culture medium. In some embodiments, the stimulant agent includes IL-2, IL-7, and / or IL-15.
[0197] In various embodiments, the activating agent is a tumor antigen, in particular the tumor antigens disclosed herein.
[0198] In some embodiments, the activating agents and / or co-stimulating agents described herein may be coated or adsorbed onto one or more surfaces. Such surfaces include, for example, solid surfaces, porous surfaces, semi-porous surfaces, spherical surfaces, non-spherical surfaces, rod-shaped surfaces, and polymer surfaces.
[0199] In certain embodiments, T cells are activated using a commercially available reagent such as TRANSACT (Miltenyi Biotec) (for example, in the pre-activation, reactivation, or augmentation steps of the method herein). In various embodiments, partially reprogrammed T cells are activated by using TRANSACT in a ratio that allows T cell-derived adherent cells to regain their T cell identity. In various embodiments, partially reprogrammed T cells are activated with TRANSACT at a ratio of 1:10, 1:50, 1:100, 1:150, 1:200, 1:250, 1:300, 1:350, 1:400, 1:450, 1:500, 1:550, 1:600, 1:650, 1:700, 1:750, 1:800, 1:850, 1:900, 1:1,000, 1:2000, 1:3000, 1:4000, or 1:10,000. In various embodiments, T cell-derived adherent cells are activated in a suitable T cell activation medium and cultured for a sufficient amount of time to allow the T cell-derived adherent cells to regain their identity. In various embodiments, partially reprogrammed cells are activated and cultured in T cell activation medium for approximately 1, 2, 3, 4, 5, 6, or 7 days or longer. In certain embodiments, partially reprogrammed cells are activated and cultured for approximately 1–20 days, 2–20 days, 3–20 days, 4–20 days, 5–20 days, 6–20 days, 7–20 days, 8–20 days, 9–20 days, or 10–20 days. In certain embodiments, partially reprogrammed cells are activated and then cultured for approximately 1–15 days, 2–15 days, 3–15 days, 4–15 days, 5–15 days, 6–15 days, 7–15 days, 8–15 days, 9–15 days, or 10–15 days.
[0200] In certain embodiments, T cell-derived adherent cells are retargeted or reactivated with an antigen or antigen-expressing cells, such as autologous cells expressing a tumor antigen or a tumor antigen. In certain embodiments, T cell-derived adherent cells are reactivated by co-culture with an APC expressing a tandem mini gene (i.e., tumors can be sequenced from fragments reexpressed from the tandem mini gene expressed and presented by the APC). All tumor antigens known to be associated with cancer are intended for use herein. Non-specific examples of antigens include AFP (alpha-fetoprotein), αvβ6 or another integrin, BCMA, BRAF, B7-H3, B7-H6, CA9 (carbonic anhydrase 9), (carcinoembryonic antigen), claudin 18.2, claudin 6, c-MET, DLL3 (delta-like protein 3), DLL4, ENPP3 (ectonucleotide pyrophosphatase / phosphodiesterase family member 3), EpCAM, EPG-2 (epithelial glycoprotein 2), EPG-40, ephrin B2, EPHa2 (ephrin receptor A2), ERBB dimer, estrogen receptor, ETBR (endothelin B receptor), FAP-α (fibroblast-activating protein α), fetal AchR (fetal acetylcholine receptor), FBP (folate-binding protein), FCRL5, FR-α (folate receptor alpha), and GCC (guanylic acid cyclamate). Glycoplasma C), GD2, GD3, GPC2 (Glypican-2), GPC3, gp100 (Glycoprotein 100), GPNMB (Glycoprotein NMB), GPRC5D (G protein-binding receptor 5D), HER2, HER3, HER4, Hepatitis B surface antigen, Melanoma-associated antigen (MAGE)-A1, MAGE-A3, MAGE-A6, MART-1 (Melan A), Mesothelin, Mucin 1 (MUC1), MUC16, MHC / Penetrate Peptide complexes (e.g., HLA-A complexed with peptides derived from AFP, KRAS, NY-ESO, MAGE-A, and WT1), NCAM (neuronal cell adhesion molecule), Nectin-4, NY-ESO, carcinoembryonic antigen, PRAME (preferentially expressed melanoma antigen), progesterone receptor, PSA (prostate-specific antigen), PSCA (prostate stem cell antigen), PSMA (prostate-specific membrane antigen), ROR1, ROR2,SIRPα (Signal Regulatory Protein Alpha), SLIT, SLITRK6 (NTRK-like Protein 6), Survivin, TAG72 (Tumor-associated Glycoprotein 72), TPBG (Trophoblast Glycoprotein), Trop-2, VEGFR1 (Vascular Endothelial Growth Factor Receptor 1), p53, p53 variants, Prostain, Survivin, Telomerase, PCTA-1 / Galectin 8, Melan A / MARTl, Ras variants, hTERT, Sarcoma Translocation Breakout, ML-IAP, ERG (TMPRSS2 ETS Fusion Gene), NA17, PAX3, Androgen Receptor, Cyclin Bl, MYCN, RhoC, TRP-2, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, RAGE-1, Human Telomerase Reverse Transcriptase, RU1, RU2, Intestinal Carboxylesterase, Mu This includes hsp70-2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5, IGLL1, CD2, CD3ε, CD4, CD5, CD7, the extracellular components of APRIL proteins, neoantigens, or any combination thereof.
[0201] In various embodiments, the activation medium for reactivating T cell-derived adherent cells may further contain immunomodulatory molecules such as cytokines. Examples of immunomodulatory molecules include lymphokines, monokines, and conventional polypeptide hormones. Cytokines include growth hormones such as human growth hormone, N-methionyl human growth hormone, and bovine growth hormone; parathyroid hormone; thyroxine; insulin; proinsulin; relaxin; prorelaxin; glycoprotein hormones such as follicle-stimulating hormone (FSH), thyroid-stimulating hormone (TSH), and luteinizing hormone (LH); hepatic growth factor (HGF); fibroblast growth factor (FGF); prolactin; placental lactogens; Müllerian duct inhibitors; mouse gonadotropin-related peptides; inhibin; activin; vascular endothelial growth factor; integrins; thrombopoietin (TPO); nerve growth factor (NGF) such as NGF-beta; platelet growth factor; TGF-alpha and TGF-beta, etc. These include transforming growth factors (TGF); insulin-like growth factors I and II; erythropoietin (EPO); bone induction factors; interferons such as interferon-alpha, beta, and gamma; colony-stimulating factors (CSFs), such as macrophage-CSF (M-CSF); granulocyte-macrophage-CSF (GM-CSF); and granulocyte-CSF (G-CSF); interleukins (ILs) such as IL-1, IL-1-alpha, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, and IL-15; tumor necrosis factors such as TNF-alpha or TNF-beta; and other polypeptide factors including LIF and kit ligand (KL). As used herein, the term cytokine includes proteins derived from natural sources or recombinant cell cultures, and biologically active equivalents of native sequence cytokines.
[0202] In certain embodiments, partially reprogrammed and reactivated T cells of this specification can be further stimulated and enlarged using the same methods as reactivation described herein. Such methods for activating and enlarging T cells are known in the Art.
[0203] In various embodiments, the methods described herein, which include partial reprogramming, subsequent reactivation, and optionally further augmentation, are sufficient to cause juvenile T cells to acquire one or more of the following characteristics:
[0204] In certain embodiments, the juvenified T cells possess one or more stem cell characteristics, including high epigenetic plasticity. Other advantageous phenotypic markers that juvenified cells may acquire include the expression of L-selectin (CD62L), IL-7Ra, CD132, CCR7, CD45RA, CD45RO, CD27, CD28, CD95, CXCR3, TCF7, and LFA-1. In certain embodiments, the juvenified T cells acquire T memory stem cell expression markers. For example, memory T cells expressing CD95, CD45RA, CCR7, and CD62L, possessing self-replicating stem cell-like ability and multipotency ability to reconstitute an entire range of memory T cells and effector T cells. In certain embodiments, the juvenified T cells are "central memory T cells" or "TCM cells," which are memory T cells expressing CD45RO, CCR7, and CD62L. In another embodiment, the juvenile T cells have effector memory T cell markers such as CD45RO expression, but lack CCR7 and CD62L expression. In a particular embodiment, the juvenile T cells described herein have a stem-like phenotype and improved proliferative capacity.
[0205] In certain embodiments, the immature T cells express CD45RA, CCR7, and CD62L, but do not express CD95, thus possessing the characteristics of naive T cells, or "TN cells."
[0206] In certain embodiments, juvenated T cells may exhibit the biological and phenotypic characteristics of younger T cells with respect to epigenetic signature, telomere length, and functionality.
[0207] In various embodiments, the partial reprogramming and reactivation described herein result in juvenated T cells that can be measured by evaluating the methylation status of various CpG sites in the cell's DNA. Such techniques are known in the art; see, for example, Horvath and Raj, 2018, Nature Reviews Genetics, 19:371-375. Various groups have established models, or "epigenetic clocks," that use the methylation status of cells to estimate the "biological age" of a cell or tissue, using mathematical algorithms that use values assigned to the methylation status of specific CpGs in the genome. In various embodiments, the methylation status of various CpG sites is used to determine whether partial reprogramming has occurred. In various embodiments, the methylation status of various CpG sites is used to predict the number of depleted CD8 T cells. In various embodiments, the methylation status of various CpG sites is used to determine whether a population of immune cells (e.g., T cells) is suitable for administration to a patient.
[0208] In various embodiments, the “Horvath clock” described by Horvath and Raj (2018, Nature Reviews Genetics, 19:371-375) is used to determine the epigenetic age of cells described herein, including juvenified immune cells (e.g., T cells). In various embodiments, the Horvath clock is used to determine whether partial reprogramming has occurred. In various embodiments, the Horvath clock is used to predict the number of depleted CD8 T cells. In various embodiments, the Horvath clock is used to determine whether a population of imm immune cells (e.g., T cells) is suitable for patient administration. In various embodiments, other epigenetic clocks or algorithms (e.g., Hannum clock or Levine clock) are used. See, for example, Hannum et al., 2013, Mol. Cell., 49:359-369 and Levine et al., 2018, Aging, 10(4):573-591.
[0209] In certain embodiments, juvenified T cells (partially reprogrammed and reactivated T cells as described herein) exhibit a reduced epigenetic age (eAge) compared to control T cells (e.g., T cells cultured without contact with one or more reprogramming factors). The eAge may be determined using known epigenetic clock determination methods, such as the Horvath clock, as described elsewhere herein. In certain embodiments, the eAge of the juvenified T cells described herein is reduced by approximately 5%–75%, 10%–75%, 10%–50%, 15%–75%, 15%–50%, 20%–75%, or 20%–50% compared to the eAge of appropriate control T cells (e.g., T cells from the original donor sample before partial reprogramming and reactivation, or T cells with matched chronological age). In certain embodiments, the eAge of the juvenated T cells described herein is reduced by at least 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or more compared to appropriate control T cells (e.g., T cells from the original donor sample before partial reprogramming, or T cells with matched chronological age).
[0210] In certain embodiments, the disclosure provides a population of T cells whose epigenetic age is at least 5% younger than their chronological age. In other embodiments, the disclosure provides a population of T cells whose epigenetic age is at least 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or at least 80% younger than their chronological age. In certain embodiments, the disclosure provides a population of T cells whose epigenetic age is at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more younger than their chronological age. In this regard, epigenetic age can be measured using methods known in the art, such as measuring the Horvath epigenetic clock.
[0211] In certain embodiments, juvenified T cells (partially reprogrammed and reactivated T cells as described herein) exhibit an epigenetic age (eAge) of approximately 7–16 years. In certain embodiments, juvenified T cells exhibit an epigenetic age (eAge) reduced to approximately the age corresponding to puberty, compared to (e.g., compared to the chronological age of the starting cells) control T cells (e.g., T cells cultured without contact with one or more reprogramming factors). In certain embodiments, juvenified T cells have increased telomere length compared to control T cells. Telomere length can be measured using methods known in the art (e.g., see Rosenberg et al., 2011, Clin Cancer Res 17, 4550–4557) and commercially available kits (e.g., TELOTAGGG, Sigma-Aldrich). In certain embodiments, telomere length is elongated by approximately 0.1–3 kb. In one particular embodiment, the telomere length is elongated by approximately 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or approximately 1 kb. In another embodiment, the telomere is elongated by approximately 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, or 2 kb.
[0212] In certain embodiments, juvenile T cells exhibit increased growth potential. In certain embodiments, juvenile T cells grow 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, and 50 times greater than control T cells that are partially unreprogrammed or chronologically age-matched. In certain embodiments, juvenile T cells grow 25 to 1000 times greater than control T cells that are chronologically age-matched or partially unreprogrammed. In certain embodiments, juvenile T cells grow 25, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 225, 250, 275, 300, 350, 400, 450, and 500 times more than chronologically age-matched control T cells or partially unreprogrammed control T cells. In certain embodiments, juvenile T cells grow faster than partially unreprogrammed T cells.
[0213] In certain embodiments, the disclosure provides a population of T cells whose epigenetic age is at least 5% younger than their chronological age, and in which the T cells do not express any abnormal NK cell markers, T cell markers, or B cell markers.
[0214] In another embodiment, the disclosure provides a population of T cells whose epigenetic age is at least 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or at least 80% younger than the chronological age of a source T cell or a suitable control T cell, wherein the T cells do not express an abnormal NK cell marker, T cell marker, or B cell marker.
[0215] In another embodiment, the disclosure provides a population of T cells whose epigenetic age is at least 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or at least 80% younger than the chronological age of a source T cell or a suitable control T cell, wherein the T cells have a stem-like phenotype.
[0216] In another embodiment, the disclosure provides a population of T cells whose epigenetic age is at least 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or at least 80% younger than the chronological age of a source T cell or a suitable control T cell, wherein the T cells express CCR7, CD62L, and TCF7.
[0217] In another embodiment, the Disclosure provides a population of T cells whose epigenetic age is at least 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or at least 80% younger than the chronological age of a source T cell or a suitable control T cell, wherein the T cells express CCR7, CD62L, and TCF7 and have increased killing capacity compared to a suitable control T cell. Killing capacity can be measured using assays known in the Art, such as those described in the examples herein.
[0218] In a particular embodiment, the disclosure provides a population of T cells whose epigenetic age is at least 5% younger than the chronological age of the source T cells, wherein the T cells do not express NCAM1, NCR2, FCGR3A, KIR2DL4, or KIR2DS4.
[0219] In certain embodiments, the present disclosure provides a population of T cells in which the epigenetic age is at least 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or at least 80% younger than its chronological age, and the T cells do not express NCAM1, NCR2, FCGR3A, KIR2DL4, or KIR2DS4.
[0220] In certain embodiments, the present disclosure provides T cells in which the epigenetic age is at least 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or at least 80% younger than its chronological age (or a suitable control T cell), and in which, when determined by transcriptome analysis, gene sets for oxidative phosphorylation, fatty acid metabolism, glycolysis, and hypoxia are enriched in the T cells.
[0221] In certain embodiments, the present disclosure provides T cells or a population of such T cells in which the epigenetic age is at least 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or at least 80% younger than its chronological age (or a suitable control T cell), and in which, when determined by transcriptome analysis, gene sets for both oxidative phosphorylation and glycolysis are enriched in the T cells as compared to control T cells.
[0222] In certain embodiments, the present disclosure provides T cells in which the epigenetic age is at least 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or at least 80% younger than the chronological age of a suitable control T cell, and which have an increased TCR repertoire diversity as compared to control T cells.
[0223] In various embodiments, the present disclosure provides a population of T cells in which the epigenetic age is at least 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or at least 80% younger than its chronological age, and the T cells contain an incomplete set of V, D, and J segments of the T cell receptor gene.
[0224]
[0225] In certain embodiments, the present disclosure provides a population of T cells in which the epigenetic age is at least 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or at least 80% younger than the chronological age of the source T cells, the T cells do not express NCAM1, NCR2, FCGR3A, KIR2DL4, or KIR2DS4, and in the T cells, when determined by transcriptome analysis, gene sets for oxidative phosphorylation, fatty acid metabolism, glycolysis, and hypoxia are enriched.
[0226] In certain embodiments, the present disclosure provides a population of T cells in which the epigenetic age is at least 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or at least 80% younger than the chronological age of the source T cells, the T cells do not express NCAM1, NCR2, FCGR3A, KIR2DL4, or KIR2DS4, and in the T cells, when determined by transcriptome analysis, gene sets for both oxidative phosphorylation and glycolysis are enriched compared to control T cells.
[0227] In certain embodiments, the disclosure provides a population of T cells whose epigenetic age is at least 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or at least 80% younger than the chronological age of the source T cells, wherein the T cells do not express NCAM1, NCR2, FCGR3A, KIR2DL4, or KIR2DS4, and are enriched with both oxidative phosphorylation and glycolysis gene sets compared to control T cells, as determined by transcriptome analysis, and the T cells have increased TCR repertoire diversity compared to control T cells.
[0227] In certain embodiments, the Disclosure provides a population of T cells whose epigenetic age is at least 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or at least 80% younger than the chronological age of the source T cells, wherein the T cells do not express NCAM1, NCR2, FCGR3A, KIR2DL4, or KIR2DS4, and are enriched with both oxidative phosphorylation and glycolysis gene sets compared to control T cells, as determined by transcriptome analysis, the T cells have increased TCR repertoire diversity compared to control T cells, and the T cells contain an incomplete set of V, D, and J segments of the T cell receptor gene.
[0228] As those skilled in the art will recognize, the T cell receptor V, D, and J gene segments are rearranged during T cell development to form complete variable domain exons. This rearrangement of these genes occurs in the thymus. The juvenile T cells produced herein are produced from isolated T cells that possess the rearranged TCR locus and express the TCR. Therefore, in certain embodiments, the juvenile T cells produced herein are distinguished from the isolated T cells by being epigenetically younger than the source isolated T cells, but possessing a functional TCR (i.e., an incomplete set of the V, D, and J segments of the T cell receptor gene).
[0229] In certain embodiments, the metabolic state of juvenile T cells is improved (see, e.g., Cell Metabolism 14, 264-271). In certain embodiments, metabolic gene sets corresponding to oxidative phosphorylation, fatty acid metabolism, glycolysis, and hypoxia are enriched in the juvenile T cells described herein compared to appropriate controls (see, e.g., Nishimura 2019 Int.J.Mol.Sci.20:2254). In certain embodiments, the juvenile T cells described herein have upregulated glycolytic enzymes and downregulated electron transport chain subunits. In certain embodiments, the juvenified T cells described herein exhibit one or more of the following characteristics: a metabolic switch that converts somatic cellular oxidative metabolism to a glycolysis flow-dependent, mitochondrial-independent state; downregulation of the expression of senescence-related stress response genes in the p53 tumor suppressor pathway, including p16INK4a, p21CIP1, Atf3, and Gadd45B; downregulation of senescence-related metalloproteinases MMP13 and interleukin-6; reduced senescence-related β-galactosidase activity; reduced production of mitochondrial reactive oxygen species (ROS); and restoration of levels of H3K9me3 and H4K20me3 (epigenetic modifications involved in heterochromatin maintenance) (e.g., Ocampo, Cell. 2016, 167(7):1719-1733, Benayoon BA, Nat Rev Mol Cell Biol. 2015; 16:593-610, Liu B, Nat). See Commun.2013,4:1868, Database,Volume 2016,baw100;doi.org / 10.1093 / database / baw100).
[0230] In certain embodiments, the juvenified T cells described herein are enriched with stem cell gene signatures compared to unjuvenated control T cells (see, for example, Gattinoni et al., 2011 Nature Medicine 17(10):1290-1297).
[0231] II. Treatment Methods In various embodiments, the Disclosure provides a method for treating a patient in need of a population of juvenile T cells produced by a partial reprogramming and reactivation method disclosed herein. A method for treating a disease or disorder, including cancer, is provided by administering a composition comprising the juvenile T cells described herein. In various embodiments, the Disclosure provides a method for treating a patient in need of a population of T cells produced by a method comprising (a) transiently contacting T cells with at least one reprogramming factor selected from the group consisting of KLF4, OCT3 / 4, SOX2, and C-MYC, and optionally SV40, for a time sufficient to form T cell-derived adherent cell colonies, and (c) contacting the T cell-derived adherent cells with a culture medium containing one or more cytokines such as anti-CD3, anti-CD28, and / or IL-2, which are T cell-activating and / or co-stimulating agents. In some embodiments, the T cells are engineered to express cell surface receptors that recognize specific antigenic portions on the surface of target cells. In various embodiments of the Disclosure, the target cells are cancer cells.
[0232] In certain embodiments, this disclosure relates to a method for treating patients in need with a population of juvenile T cells described herein.
[0233] In various embodiments, the Disclosure relates to a method for treating a patient in need of a population of juvenile immune cells (e.g., T cells) produced by a method disclosed herein. Methods are provided for treating diseases or disorders, including cancer, infectious diseases, or autoimmune diseases. In various embodiments, the Disclosure relates to a method for treating a patient in need of a population of immune cells (e.g., T cells) produced by a method comprising: (a) isolating a plurality of immune cells (e.g., T cells) from a source; (b) transiently contacting the plurality of immune cells (e.g., T cells) with at least one reprogramming factor selected from the group consisting of KLF4, OCT3 / 4, SOX2, and C-MYC; and (c) contacting the immune cells (e.g., T cells) with a culture medium containing IL-2, wherein the immune cells (e.g., T cells) are in contact with at least one reprogramming factor for a period of at least about 4 days. In some embodiments, multiple immune cells (e.g., T cells) are engineered to express cell surface receptors that recognize specific antigens on the surface of target cells. In various embodiments of this disclosure, the target cells are cancer cells.
[0234] In various embodiments, the disclosure includes pharmaceutical compositions comprising a plurality of juvenile T cells produced by the methods described herein. In certain embodiments, the pharmaceutical composition comprises juvenile T cells produced by a method comprising (a) transiently contacting a plurality of T cells with at least one reprogramming factor selected from the group consisting of KLF4, OCT3 / 4, SOX2, and C-MYC for a period of time sufficient to allow partially reprogrammed cells to adhere to the surface of a culture vessel, and (b) contacting the reprogrammed and adhered T cells with a culture medium containing a T cell activator. In some embodiments, the pharmaceutical composition further comprises additional activators.
[0235] In some embodiments, the disclosure includes a pharmaceutical composition comprising at least one juvenile T cell as described herein and a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition further comprises an additional activator.
[0236] It will be understood that the target dose of juvenified T cells may be in the range of approximately 1 × 10⁶ to approximately 2 × 10¹⁰ cells / kg, preferably 2 × 10⁶ cells / kg. For certain subjects, doses above and below this range may be appropriate, and it will be understood that the appropriate dose level may be determined by the healthcare provider as needed. In various embodiments, the target dose is 1 × 10⁵. In various embodiments, the target dose is 1 × 10⁶. In various embodiments, the target dose is 1 × 10⁷. In various embodiments, the target dose is 1 × 10⁸. In various embodiments, the target dose is 1 × 10⁹. In various embodiments, the target dose is 1 × 10¹⁰. In various embodiments, the target dose is 2 × 10¹⁰. Furthermore, multiple doses of cells can be provided in accordance with this disclosure. In various embodiments, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses of cells are administered to a patient who needs them.
[0237] Also provided are methods for reducing tumor size in a subject, including administering the juvenile T cells of this disclosure to the subject. In some embodiments, the subject has a solid tumor or a hematological malignancy such as lymphoma or leukemia. In some embodiments, juvenile immune cells (e.g., T cells) are delivered to the tumor bed. In some embodiments, the cancer is present in the bone marrow of the subject.
[0238] As used herein, the terms “subject” or “patient” mean an individual. In some embodiments, the subject is a mammal, such as a human. In some embodiments, the subject may be a non-human primate. Non-human primates include, to name a few, marmosets, monkeys, chimpanzees, gorillas, orangutans, and gibbons. The term “subject” also includes domesticated animals, such as cats and dogs, livestock (e.g., llamas, horses, cattle), wild animals (e.g., deer, elk, moose), laboratory animals (e.g., mice, rabbits, rats, gerbils, guinea pigs), and bird species (e.g., chickens, turkeys, ducks). Preferably, the subject is a human subject. More preferably, the subject is a human patient.
[0239] The method described herein may further include administering one or more chemotherapeutic agents. In certain embodiments, the chemotherapeutic agent is a lymphodepletion (preconditioning) chemotherapeutic agent. Beneficial preconditioning treatment regimens, along with corresponding beneficial biomarkers, are described in U.S. Provisional Patent Applications 62 / 262,143 and 62 / 167,750. These describe, for example, methods for conditioning patients requiring T-cell therapy, which include administering to the patient specific beneficial doses of cyclophosphamide (200 mg / m² / day to 2000 mg / m² / day) and specific doses of fludarabine (20 mg / m² / day to 900 mg / m² / day). A preferred dosing regimen includes treating the patient by administering to the patient approximately 500 mg / m² / day of cyclophosphamide and approximately 60 mg / m² / day of fludarabine daily for three days prior to administering to the patient a therapeutically effective dose of immature T cells.
[0240] In other embodiments, the juvenile T cells and the chemotherapy agent are each administered in an effective amount to treat the target disease or condition.
[0241] In certain embodiments, compositions comprising the juvenile immune cells (e.g., T cells) disclosed herein may be administered in combination with any number of chemotherapeutic agents. Examples of chemotherapeutic agents include alkylating agents, e.g., thiotepa and cyclophosphamide (CYTOXAN®); alkyl sulfonates, e.g., busulfan, improsulfan and pigosulfan; aziridines, e.g., benzodopa, carbocone, metsuredopa and uredopa; ethyleneimines and methylamelamamines (including altretamine, triethylenemelamamine, triethylenephosphoramide, triethylenethiophosphoramide and trimethylolomelamamine resume); nitrogen mustard, For example, chlorambucil, chlornafadin, chlorophosphamide, estramustine, ifosfamide, mechloretamine, oxidized mechloretamine hydrochloride, melphalan, nobembicin, fenestrine, prednimustine, trophosphamide, uracil mustard; nitrosourea, for example, carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine; antibiotics, for example, acrasinomycin, actinomycin, ausramycin, azaserin, bleomycin, kacchinomycin, calycephalone Amycin, Carabicin, Carminomycin, Cardinophilin, Chromomycin, Dactinomycin, Daunorubicin, Detorubicin, 6-Diazo-5-Oxo-L-Norleucine, Doxorubicin, Epirubicin, Esolubicin, Idarubicin, Marcelomycin, Mitomycin, Mycophenolic Acid, Nogaramycin, Olibomycin, Peplomycin, Potophyllomycin, Puromycin, Keramycin (que-lamycin), Rhodolubicin, Streptonigrin, Streptozocin, Tuberculin Zin, ubenimex, dinostatin, zolubicin; antimetabolites, e.g., methotrexate and 5-fluorouracil (5-FU); folic acid analogs, e.g., denopterin, methotrexate, pteropterin, trimethrexate; purine analogs, e.g., fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs, e.g., ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, 5-FU;Androgens, e.g., carsterone, dromostanolone propionate, epithiostanol, mepitiostane, testolactone; anti-adrenal drugs, e.g., aminoglutethimide, mitotane, trilostane; folic acid supplements, e.g., frolinic acid; acegraton; aldofamide glycoside; aminolevulinic acid; amsacrin; bestrabusil; bisanthren; edatraxate; dehofamine; demecolsin; diazicon; elformitin; eriptinium acetate; etogluside; gallium nitrate; hydroxyurea; lentinan; ronidamin; mitogluazone; mitoxantrone; mopidamol; nitracrin; pentostatin; fenamet; pirarubicin; podophyllic acid; 2-ethylhydrazine Do; Procarbazine; PSK®; Lazoxane; Schizophyllan; Spirogermanium; Tenuazonic acid; Triadicone; 2,2',2”-Trichlorotriethylamine; Urethane; Vindesine; Dacarbazine; Mannomustine; Mitobronitol; Mitractol; Pipobroman; Gacitosine; Arabinoside ("Ara-C"); Cyclophosphamide; Thiotepa; Taxoids, e.g., paclitaxel (Taxol®, Bristol-Myers Squibb) and doxetaxel (Taxotere®, Rhone-Poulenc) Rorer); Chlorambucil; Gemcitabine; 6-Thiogunine; Mercaptopurine; Methotrexate; Platinum analogs, e.g., cisplatin and carboplatin; Vinblastine; Platinum; Etoposide (VP-16); Ifosfamide; Mitomycin C; Mitoxantrone; Vincristine; Vinorelbine; Navelbine; Novantrone; Teniposide; Daunomycin; Aminopterin; Xeloda; Ibandronate; CPT-11; Topoisomerase inhibitor RFS2000; Difluoromethylomitine (DMFO); Retinoic acid derivatives, e.g., Targretin (trademark) (Bexarotene), Panretin (trademark) (Alitretinoin); Ontak (trademark) (Denileukin difutytox); Esperamicin; Capecitabine;This also includes any pharmaceutically acceptable salts, acids, or derivatives of the above. This definition also includes anti-estrogens, such as tamoxifen, raloxifene, the aromatase inhibitor 4(5)-imidazole, 4-hydroxytamoxifen, trioxyfen, keoxyfen, LY117018, onapristone, and toremifene (Fareston), as well as anti-androgens, such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin, and anti-hormonal agents that act to modulate or inhibit the hormonal effects on tumors, such as any pharmaceutically acceptable salts, acids, or derivatives of the above. CHOP, i.e., combinations of chemotherapeutic agents including but not limited to cyclophosphamide (Cytoxan®), doxorubicin (hydroxydoxorubicin), fludarabine, vincristine (Oncovin®), and prednisone, may also be administered as appropriate.
[0242] In some embodiments, the chemotherapeutic agent is administered simultaneously with or within one week after the administration of the engineered cells or nucleic acids. In other embodiments, the chemotherapeutic agent is administered 1 to 4 weeks, 1 week to 1 month, 1 week to 2 months, 1 week to 3 months, 1 week to 6 months, 1 week to 9 months, or 1 week to 12 months after the administration of the engineered cells or nucleic acids. In other embodiments, the chemotherapeutic agent is administered at least one month before the administration of the cells or nucleic acids. In some embodiments, the method further includes administering two or more chemotherapeutic agents.
[0243] Various additional therapeutic agents may be used in conjunction with the compositions described herein. For example, potentially useful additional therapeutic agents include PD-1 (or PD-L1) inhibitors such as nivolumab (Opdivo®), pembrolizumab (Keytruda®), pembrolizumab, pidilizumab, and atezolizumab (Tecentriq®).
[0244] Additional therapeutic agents suitable for use in combination with the present disclosure include, but are not limited to, Ibrutinib (Imbruvica®), Ofatumumab (Arzerra®), Rituximab (Rituxan®), Bevacizumab (Avastin®), Trastuzumab (Herceptin®), Trastuzumab Emtansine (KADCYLA®), Imatinib (Gleevec®), Cetuximab (Erbitux®), Panitumumab (Vectibix®), Catumaxomab, Ibritumomab, Ofatumumab, Tositumomab, Brentuximab, Alemtuzumab, Gemtuzumab, Erlotinib, Gefitinib, Vandetanib, Afatinib, Lapatinib, Neratinib, Axitinib, Masitinib, Pazopanib, Sunitinib, Sorafenib, Toceranib, lestaurtinib, Axitinib, Cediranib, Lenvatinib, Nintedanib, Pazopanib, Regorafenib, Semaxanib, Sorafenib, Sunitinib, Crenolanib, Toceranib, Vandetanib, Enzastaurtinib, Cabozantinib, Imatinib, Dasatinib, Nilotinib, Ponatinib, Radotinib, Bosutinib, lestaurtinib, Luxitinib, Pacritinib, Cobimetinib, Selumetinib, Trametinib, Binimetinib, Alectinib, Ceritinib, Crizotinib, aflibercept, adipotide, denileukin diftitox, mTOR inhibitors such as everolimus and temsirolimus, Hedgehog inhibitors such as sonidegib and vismodegib, CDK inhibitors such as CDK inhibitor (palbociclib).[[ID=A]] [[ID=B]]
[0245] [[ID=C]] In additional embodiments, compositions containing juvenified T cells may be administered together with anti-inflammatory agents. Anti-inflammatory agents include, but are not limited to, steroids and glucocorticoids (including betamethasone, budesonide, dexamethasone, hydrocortisone acetate, hydrocortisone, hydrocortisone, methylprednisolone, prednisolone, prednison, and triamcinolone), non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin, ibuprofen, naproxen, methotrexate, sulfasalazine, leflunomide, anti-TNF agents, cyclophosphamide, and mycophenolates. Exemplary NSAIDs include ibuprofen, naproxen, naproxen sodium, Cox-2 inhibitors, and sialic acid salts. Exemplary analgesics include acetaminophen, oxycodone, and tramadol (propoxifen hydrochloride). Examples of glucocorticoids include cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, or prednisone. Examples of biological response modifiers include molecules directed towards cell surface markers (e.g., CD4, CD5), cytokine inhibitors such as TNF antagonists (e.g., etanercept (ENBREL®), adalimumab (HUMIRA®), and infliximab (REMICADE®)), chemokine inhibitors, and adhesion molecule inhibitors. Biological response modifiers include monoclonal antibodies and recombinant forms of molecules. Examples of DMARDs include azathioprine, cyclophosphamide, cyclosporine, methotrexate, penicillamine, leflunomide, sulfasalazine, hydroxychloroquine, gold preparations (oral (auranofin) and intramuscular), and minocycline.
[0246] In certain embodiments, the compositions described herein are administered in conjunction with cytokines. In some embodiments, the cytokines may include proteins derived from natural sources or recombinant cell cultures, and bioactive equivalents of native sequence cytokines.
[0247] III. Formulations and Pharmaceutical Preparations Various known techniques can be used in the preparation of polynucleotides, polypeptides, vectors, antigen-binding molecules, immune cells (e.g., T cells), compositions, etc., according to this disclosure.
[0248] After isolation using known methods, isolated T cells may be genetically modified, or they may be partially reprogrammed, activated, and enlarged in vitro before genetic modification. In another embodiment, T cells are genetically modified with recombinant TCR or CAR and then rejuvenated using the partial reprogramming and reactivation methods described herein. In certain embodiments, the rejuvenated cells described herein are further activated and / or enlarged in vitro. Methods for activating and enlarging immune cells (e.g., T cells) are known in the art and are described, for example, in U.S. Patents 6,905,874, 6,867,041, 6,797,514, and WO2012 / 079000. Generally, such methods involve contacting T cells with a stimulating (e.g., activating) agent (referred to as a T cell activating compound in certain embodiments) (e.g., an agent that stimulates the CD3 / TCR complex (e.g., an anti-CD3 antibody or CD3 agonist) and a co-stimulating agent (an agent such as an antibody or ligand that stimulates CD28, ICOS, CD27, HVEM, LIGHT, CD40, 4-1BB, OX40, DR3, GITR, CD30, TIM1, CD2, CD226, or any combination thereof). In certain embodiments, the stimulating and co-stimulating agents are attached to beads or other surfaces in a culture medium containing a suitable cytokine such as IL-2.
[0249] In other embodiments, juvenile T cells may be activated and stimulated to proliferate by feeder cells and appropriate antibodies and cytokines using methods such as those described in U.S. Patent No. 6,040,177, U.S. Patent No. 5,827,642, and WO / 2012129514.
[0250] Certain methods for constructing the constructs and engineered T cells described herein are described in PCT application PCT / US2015 / 14520.
[0251] In certain embodiments, the disclosure provides a method for storing juvenile T cells as described herein. This includes cryopreserving T cells so that they remain viable upon thawing. Cryopreserving a portion of T cells by methods known in the art can provide a permanent source of such cells for future treatment of patients with malignant tumors. If necessary, the cryopreserved T cells can be thawed, grown, and further augmented.
[0252] As used herein, “cryopreservation” refers to the preservation of cells by cooling them to a sub-zero temperature, typically such as 77 Kelvin or 196°C (the boiling point of liquid nitrogen). At sub-zero temperatures, cryoprotective agents are often used to prevent damage to the cells being preserved by freezing at low temperatures or by warming to room temperature. Cryoprotective agents and an optimal cooling rate can prevent cell damage. Cryoprotective agents that may be used in accordance with this disclosure include, but are not limited to, dimethyl sulfoxide (DMSO) (Lovelock & Bishop, Nature, 1959, 183, 1394-1395; Ashwood-Smith, Nature, 1961, 190, 1204-1205), glycerol, polyvinylpyrrolidone (Rinfret, Ann. NYAcad. Sci., 1960, 85, 576), and polyethylene glycol (Sloviter & Ravdin, Nature, 1962, 196, 48). The preferred cooling rate is 1°C to 3°C per minute.
[0253] The term “substantially pure” is used to indicate the presence of a particular component at a high level. This component is preferably the main component present in the composition. Preferably, it is present at levels greater than 30%, greater than 50%, greater than 75%, greater than 90%, or even greater than 95%, where such levels are determined on a dry weight / dry weight basis with respect to the entire composition considered. At very high levels (e.g., greater than 90%, greater than 95%, or greater than 99%), the component can be considered to be in “pure form.” The biologically active substances of this disclosure (including polypeptides, nucleic acid molecules, antigen-binding molecules, and moieties) may be provided in a form substantially free of one or more impurities that the substance might otherwise be associated with. When a composition is substantially free of a particular impurity, that impurity is present at a low level (e.g., less than 10%, less than 5%, or less than 1% on a dry weight / dry weight basis as presented above).
[0254] In some embodiments, the cells described herein are prepared by first harvesting them from the culture medium, then washing the cells, and concentrating them in a treatment-effective amount in a medium and container system suitable for administration ("pharmaceutically acceptable" carrier). Suitable infusion media may be any isotonic medium preparation, typically physiological saline, Normosol® (Abbott), or Plasma-Lyte® A (Baxter), but a 5% dextrose aqueous solution or Ringer's lactate solution may also be used. The infusion medium may be supplemented with human serum albumin.
[0255] The desired treatment dose of cells in a composition is generally at least 2 cells, or more typically, greater than 102 cells, up to 106, up to 108 or 109 cells, and may exceed 1010 cells. The number of cells depends on the desired use for which the composition is intended and the type of cells contained in the composition. The desired cell density is typically greater than 106 cells / ml, generally greater than 107 cells / ml, and generally greater than 108 cells / ml. A clinically appropriate number of immune cells (e.g., T cells) can be allocated to multiple infusions that cumulatively equal or exceed 105, 106, 107, 108, 109, 1010, 1011, or 1012 cells. In some aspects of this disclosure, in particular, since all injected cells are redirected to a specific target antigen, smaller numbers of cells in the range of 106 / kilogram (106–1011 per patient) may be administered. Treatment with juvenile T cells may be administered multiple times in doses within these ranges. The cells can be autologous, allogeneic, or heterogeneous for the patient receiving the therapy.
[0256] The juvenile T cells of this disclosure may be administered alone or as part of a pharmaceutical composition in combination with diluents and / or other components or cell populations, such as IL-2 or other cytokines. The pharmaceutical compositions of this disclosure may comprise the juvenile T cell population described herein in combination with one or more pharmaceutically or physiologically acceptable carriers, diluents, or excipients. Such compositions may comprise buffers such as neutral buffered saline or phosphate buffered saline; carbohydrates such as glucose, mannose, sucrose, or dextran, or mannitol; proteins; amino acids such as polypeptides or glycine; antioxidants; chelating agents such as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide); and preservatives. The compositions of this disclosure are preferably formulated for intravenous administration. Treatment may also include treatment with one or more corticosteroids such as dexamethasone and / or methylprednisolone.
[0257] The compositions of this application may include, essentially consist of, or comprise the disclosed components.
[0258] The pharmaceutical compositions (solutions, suspensions, etc.) of this disclosure may comprise one or more of the following: a sterile diluent, e.g., water for injection, saline solution, preferably physiological saline, Ringer's solution, isotonic sodium chloride; a fixative oil, e.g., a synthetic monoglyceride or diglyceride, polyethylene glycol, glycerin, propylene glycol, or other solvent that can function as a solvent or suspension medium; an antimicrobial agent, e.g., benzyl alcohol or methylparaben; an antioxidant, e.g., ascorbic acid or sodium bisulfate; a chelating agent, e.g., ethylenediaminetetraacetic acid; a buffer, e.g., acetic acid, citric acid, or phosphoric acid; and an agent for adjusting the tonicity, e.g., sodium chloride or dextrose. Parenteral preparations may be sealed in ampoules, disposable syringes, or glass or plastic multi-dose vials. The injectable pharmaceutical compositions are preferably sterile.
[0259] It will be understood that adverse events can be minimized by transduction of suicide genes into immune cells (e.g., T cells). Suitable “kill switches” are described, for example, in WO2021 / 189008. It may also be desirable to incorporate inducible “on” or “accelerator” switches into immune cells (e.g., T cells). These techniques may utilize dimerization domains and optionally selected activators of such domain dimerization. These techniques include, for example, those utilizing the FKBP / Rapalog dimerization system in certain cells, as described by Wu et al., Science 2014, 350(6258). Additional dimerization techniques are described, for example, in Fegan et al. Chem. Rev. 2010, 110, 3315-3336 and in U.S. Patents 5,830,462, 5,834,266, 5,869,337, and 6,165,787. Additional dimerization pairs may include cyclosporine-A / cyclophylline receptors, estrogen / estrogen receptors (using tamoxifen in some cases), glucocorticoid / glucocorticoid receptors, tetracycline / tetracycline receptors, and vitamin D / vitamin D receptors. Further examples of dimerization techniques can be found, for example, in WO2014 / 127261, WO2015 / 090229, US2014 / 0286987, US2015 / 0266973, US2016 / 0046700, US Patent No. 8,486,693, US2014 / 0171649, and US2012 / 0130076.
[0260] Preferred techniques for the genetic modification of juvenile cells as described herein include the use of inducible caspase-9 (U.S. Patent Publication No. 2011 / 0286980) or thymidine kinase before, after, or concurrently with the genetic modification of cells to express a CAR or other engineered TCR. Additional methods for introducing suicide genes and / or "on" switches include CRISPR, TALENS, MEGATALEN, zinc fingers, RNAi, siRNA, shRNA, antisense techniques, and other techniques known in the art.
[0261] IV. Kit The scope of this disclosure also includes kits, such as pharmaceutical kits, that include at least one reprogramming factor for contacting one or more T cells in vitro. A kit typically includes a label indicating the intended use of the kit's contents and instructions for use. The term “label” includes any written or recorded material in the kit, supplied with the kit, or otherwise accompanying the kit.
[0262] In various embodiments, the Disclosure provides a kit for preparing one or more T cells for T cell therapy for subjects requiring T cell therapy, the kit comprising at least one reprogramming factor selected from the group consisting of KLF4, OCT3 / 4, SOX2, and C-MYC, and optionally SV40. In various embodiments, the Disclosure provides a kit for preparing one or more T cells for T cell therapy for subjects requiring T cell therapy, the kit comprising at least one expression vector capable of expressing at least one reprogramming factor selected from the group consisting of KLF4, OCT3 / 4, SOX2, and C-MYC. In various embodiments, the Disclosure provides a kit for preparing one or more T cells for T cell therapy for subjects requiring T cell therapy, the kit comprising at least one Sendai virus vector capable of expressing at least one reprogramming factor selected from the group consisting of KLF4, OCT3 / 4, SOX2, and C-MYC. In various embodiments, the kit further comprises a Sendai virus vector capable of expressing SV40.
[0263] In various embodiments, the present disclosure provides a kit for preparing one or more T cell vectors for T cell therapy for subjects requiring T cell therapy, the kit comprising: Expression vectors encoding KLF4, OCT3 / 4, and SOX2. Expression vectors encoded as KLF4, An expression vector encoding C-MYC, and An expression vector encoding SV40.
[0264] In various embodiments, the present disclosure provides a kit for preparing one or more T cell vectors for T cell therapy for subjects requiring T cell therapy, the kit comprising: Sendai virus encoding KLF4, OCT3 / 4, and SOX2, Sendai virus encoding KLF4, Sendai virus encoding C-MYC, and The Sendai virus that codes for SV40.
[0265] In various embodiments, the Disclosure provides a kit for preparing one or more T cell vectors for T cell therapy for subjects requiring T cell therapy, the kit comprising a multi-cistronic Sendai virus vector encoding KLF4, OCT3 / 4, SOX2, C-MYC and optionally SV40.
[0266] In various embodiments, the kit may further comprise a T cell activating compound or drug. In various embodiments, the T cell activating compound or drug is an anti-CD3 antibody. In various embodiments, the kit comprises a co-stimulatory drug such as an anti-CD28 antibody. In various embodiments, the kit comprises both an anti-CD3 antibody and an anti-CD28 antibody. In various embodiments, the kit may further comprise one or more suitable culture media for culturing and / or partially reprogramming T cells. In various embodiments, the kit may further comprise one or more cytokines. Such cytokines include, but are not limited to, IL-2, IL-7, IL-15, and IL-12.
[0267] V. Further Embodiments The present invention can be characterized by one or more of the following clauses that define the various embodiments described herein.
[0268] In a first embodiment, the present invention relates to [1].
[0269] [1] An in vitro method for producing at least one juvenile T cell comprises (a) contacting a population of T cells with at least one reprogramming factor selected from the group consisting of KLF4, OCT3 / 4, SOX2, C-MYC, and SV40 for a period of time sufficient to form T cell-derived adherent cells, wherein the T cells are not transformed into iPS or totipotent cells; and (b) contacting the T cell-derived adherent cells with at least one T cell activating compound.
[0270] In a second embodiment, the present invention relates to [2].
[0271] [2] An in vitro method for producing at least one T cell, comprising: (a) contacting a population of T cells in a first culture medium in a culture vessel with at least one reprogramming factor selected from the group consisting of KLF4, OCT3 / 4, SOX2, C-MYC, and SV40 for a period of time sufficient to cause the T cells to form at least one colony attached to the surface of the culture vessel, such that the T cells are not transformed into iPS cells or pluripotent cells; and (b) contacting the at least one attached colony with at least one T cell activating compound.
[0272] In a third embodiment, the present invention relates to [3].
[0273] [3] An in vitro method for producing at least one T cell, comprising: (a) contacting a population of T cells in a first culture medium with at least one reprogramming factor selected from the group consisting of KLF4, OCT3 / 4, SOX2, C-MYC, and SV40 for a period of at least about 5 days and no more than about 10 days, wherein the T cells are not transformed into iPS cells or pluripotent cells; and (b) contacting the T cells with at least one T cell activating compound.
[0274] In a fourth embodiment, the present invention relates to [4].
[0275] [4] An in vitro method for producing at least one T cell, comprising: (a) contacting a population of T cells with at least one reprogramming factor selected from the group consisting of KLF4, OCT3 / 4, SOX2, C-MYC, and SV40 for a period of time sufficient to cause the T cells to express at least one marker selected from the group consisting of integrin α6β1, SSEA4, CD9, and CD90, wherein the T cells are not transformed into iPS cells or pluripotent cells; and (b) contacting the T cells with at least one T cell activating compound.
[0276] In further embodiments, the present invention relates to the following:
[0277] [5] The method according to any one of [1] to [4], wherein at least a portion of the T cells are exposed to the at least one reprogramming factor for a period of time sufficient to express CD3 and at least one marker selected from the group consisting of integrin α6β1, SSEA4, CD9, and CD90, preferably SSEA4 and CD3, more preferably CD3, CD9, and CD90, and even more preferably CD3, SSEA4, CD9, and CD90.
[0278] [6] The method according to any one of [1] to [5], wherein, before the T cells are brought into contact with the at least one reprogramming factor, the T cells are brought into contact with IL-2 and / or at least one agent capable of activating the T cells, preferably the agent capable of activating the T cells is a tumor antigen.
[0279] [7] The method according to any one of [1] to [6], wherein the T cells are TCRα+TCRβ+ cells, TCRg(gamma)+TCRd(delta) cells, CD4+CD8αβ+ double-positive cells, CD4+ mono-positive cells (Th1, Th2, Th17, Treg, etc.), naive T cells, central memory T cells, or effector memory T cells, or the T cells express an activation marker after co-culture with autologous tumor cells, the activation marker being 4-1BB(CD137), PD1, LAG3, CD45, CD39, TIGIT, TIM3, CD69, OX40, CD28, CD25, CD49d, and CTLA4.
[0280] [8] The T cells are isolated from a mammal, preferably a human, according to the method of any one of [1] to [7].
[0281] [9] The method according to any one of [1] to [8], wherein the T cells are brought into contact with KLF4, OCT3 / 4, SOX2, and C-MYC.
[0282]
[10] The method according to any one of [1] to [9], wherein the T cells are brought into contact with the at least one reprogramming factor, preferably KLF4, OCT3 / 4, SOX2 and C-MYC, for at least about 4 to 10 days, preferably at least about 4 to 7 days, and more preferably about 5 days.
[0283]
[11] The method according to any one of [1] to
[10] , wherein the at least one reprogramming factor is expressed in the T cell, preferably the at least one reprogramming factor is expressed using nucleic acids delivered to the cell using a non-integrated viral vector or nanoparticles, more preferably the vector is Sendai virus, and even more preferably the at least one reprogramming factor is KLF4, OCT3 / 4, SOX2 and C-MYC.
[0284] [11a] The method according to any one of [1] to
[11] , wherein the at least one reprogramming factor is expressed in the T cell to a) sufficient extent to cause the formation of T cell-derived adherent cells and for a period of time during which the isolated T cell is not transformed into an iPS or totipotent cell, b) about 4 to 10 days, c) about 4 to 11 days, d) about 4 to 12 days, e) about 4 to 13 days, or f) about 4 to 14 days.
[0285]
[12] The method according to any one of [1] to [11a], wherein the at least one reprogramming factor is constitutively expressed, and then its expression is inhibited by the addition of a T cell activating agent or a compound that inhibits the expression of the at least one reprogramming factor, preferably the compound is a small molecule inhibitor that specifically inhibits the expression of the at least one reprogramming factor, more preferably the compound is an siRNA or shRNA molecule that specifically inhibits the expression of the at least one reprogramming factor, and even more preferably the at least one reprogramming factor is KLF4, OCT3 / 4, SOX2 and C-MYC.
[0286]
[13] The method according to any one of [1] to
[12] , further comprising contacting the T cells with at least one cytokine selected from the group consisting of IL-2, IL-7, IL-15, and IL-12.
[0287]
[14] The method according to any one of [1] to
[13] , wherein the at least one T cell activating compound comprises an antibody that binds to CD3, or an antibody that binds to CD28, or both, and / or the at least one T cell activating compound is a tumor antigen.
[0288]
[15] The method according to any one of [1] to
[14] further comprises engineering the T cells to express a cell surface receptor, wherein the T cells are engineered before or after contacting the T cells with the at least one reprogramming factor, preferably the cell surface receptor is a chimeric antigen receptor, a T cell receptor, or a hybrid thereof, and more preferably the cell surface receptor recognizes a specific antigenic moiety on the surface of a target cell.
[0289]
[16] The method according to
[15] , wherein the antigenic moiety is MHC class I-dependent or MHC class I-independent.
[0290]
[17] The method according to any one of [1] to
[16] , wherein the obtained T cells contain an incomplete set of V, D, and J segments of the T cell receptor gene, and / or the epigenetic age of the obtained T cells is measured, preferably the epigenetic age of the obtained T cells is at least 5% younger than the population of T cells before reprogramming. The method according to any one of [1] to
[16] , wherein the obtained T cells contain an incomplete set of V, D, and J segments of the T cell receptor gene, and / or the epigenetic age of the obtained T cells is measured, preferably the epigenetic age of the obtained T cells is at least 5% younger than the population of T cells before reprogramming, and the T cells do not express NCAM1, NCR2, FCGR3A, KIR2DL4, or KIR2DS4.
[0291]
[18] The method according to any one of [1] to
[17] , wherein the partially reprogrammed T cells can increase in size by at least 25 times compared to the T cells before contact with the at least one reprogramming factor.
[0292]
[19] The method according to any one of [1] to
[18] , wherein the isolated T cells are brought into contact with the at least one reprogramming factor, thereby reducing the expression of CD3 and CD8.
[0293] In further embodiments, the present invention relates to
[20] .
[0294]
[20] An in vitro method for producing T cells, comprising: culturing T cells in a first medium containing IL-2; activating the T cells with at least one antibody specific to CD3 or CD28 or both; contacting the activated T cells with KLF4, OCT3 / 4, SOX2 and C-MYC in a second culture medium not containing antibodies specific to IL-2 or CD3 or CD28 for a period of about 5 to about 10 days, wherein the T cells are not fully reprogrammed into iPSC cells; and replacing the second culture medium with a third culture medium containing IL-2 and at least one antibody specific to CD3 and / or CD28, wherein the T cells are cultured in the third culture medium for at least about 5 days.
[0295] In further embodiments, the present invention relates to one or more of the following:
[0296]
[21] The method according to
[20] , further comprising increasing the T cells.
[0297]
[22] The method according to
[20] or
[21] , wherein the T cells are TCRα+TCRβ+ cells, TCRg(gamma)+TCRd(delta) cells, CD4+CD8αβ+ double-positive cells, CD4+ mono-positive cells (Th1, Th2, Th17, Treg), naive T cells, central memory T cells, or effector memory T cells.
[0298]
[23] The method according to any one of
[20] to
[22] , further comprising contacting the activated T cells with SV40.
[0299]
[24] The method according to any one of
[20] to
[23] , wherein the T cells express an activation marker after co-culture with autologous tumor cells, the activation marker being 4-1BB(CD137), PD1, LAG3, CD45, CD39, TIGIT, TIM3, CD69, OX40, CD28, CD25, CD49d, and CTLA4.
[0300]
[25] The method according to any one of [1] to
[24] , wherein the T cells are tumor-infiltrating lymphocytes (TILs) obtained from a tumor.
[0301] In further embodiments, the present invention relates to
[26] .
[0302]
[26] A population of T cells whose epigenetic age is at least 5% younger than their chronological age, preferably at least 25% younger.
[0303] In further embodiments, the present invention relates to
[27] .
[0304]
[27] A population of T cell-derived adherent cells, wherein at least 70% of the cells express both CD3 and SSEA4.
[0305] In further embodiments, the present invention relates to the following:
[0306]
[28] The population according to
[27] , wherein at least 30% of the cells express CD9 and / or at least 30% of the cells express CD90, preferably at least 30% of the cells express both CD9 and CD90.
[0307]
[29] A population of T cells produced by any one of the methods described in [1] to
[25] .
[0308]
[30] A population of T cells according to any one of
[26] to
[29] , wherein the T cells are brought into contact with at least one factor selected from the group consisting of KLF4, OCT3 / 4, SOX2, C-MYC, and SV40, resulting in a reduction in CD3 and CD8 expression.
[0309]
[31] The population according to any one of
[26] to
[30] , wherein the T cells are TILs, and at least 50% of the TILs express both CCR7 and CD62L, or at least 50% of the TILs express both CCR7 and TCF7.
[0310]
[32] The T cells are a population of immature TILs as described in any one of
[26] to
[31] .
[0311]
[33] A population of T cells as described in any one of
[26] to
[32] , for use in therapy.
[0312]
[34] A population of T cells as described in any one of
[26] to
[32] , for use in a method for treating cancer, viral conditions, or autoimmune disorders.
[0313]
[35] The cancers mentioned above include acute lymphoblastic carcinoma, acute myeloid leukemia, alveolar rhabdomyosarcoma, bone cancer, brain cancer, breast cancer, cancer of the anus, anal canal, or anorectal cancer, eye cancer, intrahepatic cholangiocarcinoma, joint cancer, cancer of the neck, gallbladder, or pleura, head and neck cancer (e.g., cancer of the nose, nasal cavity, or middle ear, or oral cancer), vulvar cancer, chronic lymphoblastic leukemia, chronic myeloma, colon cancer, esophageal cancer, cervical cancer, and gastrointestinal carcinoid tumors. Populations of T cells for use as described in
[34] , which are Hodgkin lymphoma, hypopharyngeal cancer, kidney cancer, laryngeal cancer, liver cancer, lung cancer, malignant mesothelioma, melanoma, multiple myeloma, nasopharyngeal cancer, non-Hodgkin lymphoma, ovarian cancer, pancreatic cancer, cancer of the peritoneum, retinoplasm, and mesentery, pharyngeal cancer, prostate cancer, rectal cancer, kidney cancer (e.g., renal cell carcinoma (RCC)), small intestine cancer, soft tissue cancer, gastric cancer, testicular cancer, thyroid cancer, ureteral cancer, or bladder cancer.
[0314] In further embodiments, the present invention relates to the following:
[0315]
[37] A method for producing juvenile T cells, comprising: contacting a population of T cells for a period of time sufficient to cause at least 20% of the contacted T cells to express α6β1 integrin; (i) at least one reprogramming factor selected from the group consisting of KLF4, OCT3 / 4, SOX2 and C-MYC, and (ii) optionally SV40, such that the contacted T cells are not transformed into iPS cells; isolating the at least 20% of the contacted T cells with a binding molecule that specifically binds to α6β1 integrin; and (b) contacting the isolated cells with a T cell activating agent and / or a T cell costimulating agent to produce juvenile T cells.
[0316] In further embodiments, the present invention relates to the following:
[0317]
[38] A method for producing at least one juvenile T cell, comprising: transiently contacting the population of T cells with (i) at least one reprogramming factor selected from the group consisting of KLF4, OCT3 / 4, SOX2 and C-MYC, and (ii) optionally SV40 for a period of time sufficient to form T cell-derived adherent cells, wherein the T cells are not transformed into iPS or totipotent cells; isolating a subpopulation of T cell-derived adherent cells expressing either or both a6(CD49f) or b1(CD29) integrins; and contacting the isolated subpopulation with at least one T cell activating compound.
[0318] In further embodiments, the present invention relates to the following:
[0319]
[39] A population of juvenile T cells, produced by a method comprising contacting the population of T cells with (i) at least one reprogramming factor selected from the group consisting of KLF4, OCT3 / 4, SOX2 and C-MYC, and (ii) SV40 for a period of time sufficient to form T cell-derived adherent cells, wherein the T cells are not transformed into iPS or totipotent cells; isolating a subpopulation of T cell-derived adherent cells expressing a6 integrin, b1 integrin, or both; and contacting the subpopulation of T cell-derived adherent cells with at least one T cell activating compound.
[0320] In further embodiments, the present invention relates to the following:
[0321]
[40] A population of T cell-derived adherent cells in which at least 70% of the cells express integrin α6 or integrin β1, or
[0322]
[41] A population of T cell-derived adherent cells, wherein at least 50% of the cells express both integrin α6 and integrin β1.
[0323] In further embodiments, the present invention relates to the following:
[0324]
[42] A population of T cell-derived adherent cells, wherein at least 70% of the cells express both integrin α6 and integrin β1.
[0325] In further embodiments, the present invention relates to the following:
[0326]
[43] T cells whose epigenetic age is at least 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or at least 80% younger than their chronological age (or appropriate control T cells), wherein the T cells are enriched with gene sets for oxidative phosphorylation, fatty acid metabolism, glycolysis, and hypoxia, as determined by transcriptome analysis.
[0327]
[44] T cells whose epigenetic age is at least 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or at least 80% younger than their chronological age (or appropriate control T cells), wherein the T cells are enriched with both oxidative phosphorylation and glycolysis gene sets compared to control T cells, as determined by transcriptome analysis.
[0328]
[45] T cells whose epigenetic age is at least 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or at least 80% younger than their chronological age (or appropriate control T cells), and which do not express an unconventional NK cell marker, T cell marker, or B cell marker (e.g., NCAM1, NCR2, FCGR3A, KIR2DL4, or KIR2DS4).
[0329] In further embodiments, the present invention relates to the following:
[0330]
[46] A method for producing juvenile T cells, comprising: a) contacting a population of T cells with (i) at least one reprogramming factor selected from the group consisting of KLF4, OCT3 / 4, SOX2 and C-MYC, and (ii) optionally SV40 for a period of time sufficient to cause at least 20% of the contacted T cells to express α6β1 integrin, wherein the contacted T cells are not transformed into iPS cells; b) isolating at least 20% of the contacted T cells with a binding molecule that specifically binds to α6β1 integrin; and c) contacting the cells from (b) with a T cell activator and / or T cell costimulator to produce juvenile T cells;
[47] the method wherein the binding molecule that specifically binds to α6β1 integrin is selected from laminin-511, laminin-511E8, an anti-CD29 antibody, and an anti-Cd49f antibody.
[0331] In further embodiments, this disclosure relates to the following:
[0332]
[48] A method for producing juvenile T cells, comprising: a) transiently contacting a population of T cells with (i) at least one reprogramming factor selected from the group consisting of KLF4, OCT3 / 4, SOX2 and C-MYC, and (ii) optionally SV40 for a period of time sufficient to form T cell-derived adherent cells, wherein the T cells are not transformed into iPS or totipotent cells; b) isolating a subpopulation of T cell-derived adherent cells expressing either or both a6(CD49f) or b1(CD29) integrins; and c) contacting the subpopulation with at least one T cell activating compound.
[0333] In further embodiments, this disclosure relates to the following:
[0334]
[48] A population of juvenile T cells, produced by a method comprising: a) contacting the population of T cells with (i) at least one reprogramming factor selected from the group consisting of KLF4, OCT3 / 4, SOX2 and C-MYC, and (ii) SV40 for a period of time sufficient to form T cell-derived adherent cells, wherein the T cells are not transformed into iPS or totipotent cells; b) isolating a subpopulation of T cell-derived adherent cells expressing a6 integrin, b1 integrin, or both; and c) contacting the subpopulation of T cell-derived adherent cells with at least one T cell activating compound.
[0335]
[49] A population of juvenile T cells as described in any one of the items
[46] to
[48] , wherein in the subpopulation, at least 20% of the cells express integrin α6 or integrin β1, or
[50] in the subpopulation, at least 50% of the cells express integrin α6 or integrin β1, or
[51] in the subpopulation, at least 20% of the cells express both integrin α6 and integrin β1, or
[52] in the subpopulation, at least 50% of the cells express both integrin α6 and integrin β1.
[0336]
[50] A population of T cell-derived adherent cells, wherein at least 70% of the cells express integrin α6 or integrin β1, or
[51] at least 50% of the cells express both integrin α6 and integrin β1, or
[52] at least 70% of the cells express both integrin α6 and integrin β1.
[0337]
[53] A method of treating a patient in need using a population of T cells described in any one of the embodiments of [1] to
[52] . [Examples]
[0338] The following examples are not limiting and are provided to provide further information and support for the present invention. The following examples demonstrate that transient exposure of T cells to cell reprogramming conditions (in this case, using Sendai virus possessing four Yamanaka factors) yields partially reprogrammed T cells with high proliferative capacity, retained antigen specificity, and reduced epigenetic age. The treated T cells begin to dedifferentiate, express markers more typically found in stem cells (e.g., SSEA4), and adhere to the surface of the culture vessel to form epithelial colonies. Simultaneously, the treated cells begin to lose T cell identity (loss of CD3 and CD8 expression). Subsequent activation can induce these “T cell-derived adherent cells” to regain T cell identity and exhibit remarkably increased growth capacity (250-fold in 6 days).
[0339] Example 1: Conditions for partial reprogramming of T cells This experiment investigated reprogramming conditions for rejuvenating and improving the biological characteristics of T cells. CD8-positive T cells isolated from a 21-year-old male PBMC (donor 11360; cells purchased from Allcells, Alameda, CA) using MACS magnetic beads (Miltenyi Biotec) were stimulated for 3 days with soluble CD3 (catalog number 317325, BioLegend) and CD28 in T cell culture medium (TCM) containing 60 IU / ml IL-2 (TCM: OpTmizer basic medium (1000 mL bottle); OpTmizer Cell Supplement (supplement #02); immune cell serum substitute (CTS SR); L-glutamine 200 mM (100x); GlutaMAX 200 mM (100x); IL-2 (1 ug = 2.1 × 10 e4 IU)** RS 50 ug in 105 ul; (1 ug = 4.5 × 10 e5 IU)** RS 25 ug in 1125 ul). All T cell culture media described in this experiment contained 60 IU / ml of IL-2. This activation process was performed to enhance the efficiency of Sendai virus transduction. The Sendai virus (Cytotune iPS 2.0 Sendai Reprogramming Kit, ThermoFisher) consisted of three vectors: 1) encoding KLF4-OCT3 / 4-SOX2 (KOS), 2) encoding KLF4, and 3) encoding C-MYC. These are collectively known as the "Yamanaka factor" and are referred to as "4 factors" or "4F" in the diagram. Furthermore, to enhance reprogramming efficiency, a Sendai virus vector encoding SV40 was used.
[0340] Activated CD8 T cells were divided into four groups. Group 1 was the control group, in which T cells were cultured in T cell culture medium throughout the entire process. Group 2 was also cultured from day 1 in IL-2-free stem cell medium (SCM) (StemFit Basic02, Ajinomoto, containing bFGF) without transduction of Sendai virus. Cells from groups 1 and 2 were seeded in triplicate at 50,000 cells per well in 96-well plates. Group 3 was transduced with 23 MOI EmGFP Sendai virus (Cytotune EmGFP Sendai fluorescent reporter, Thermo) and 5 MOI SV40 Sendai virus. Cells from group 3 were plated in triplicate at a density of 50,000 cells per well in 24-well plates coated with recombinant human laminin 511-E8 fragment (iMatrix-511, catalog number T304, Takara) according to the manufacturer's protocol. Group 4 was transduced with 10 MOI KOS Sendai vector, 10 MOI KLF4 vector, 3 MOI cMyc vector, and 5 MOI SV40 vector. Cells were cultured in IL2-free SCM from day 1 and plated at a density of 80,000 cells per well in a 24-well plate coated with iMatrix-511 in a quad-tray configuration. See Figure 1 and Table 2 for the complete experimental design. [Table 2]
[0341] Group IV T cells began colony formation on day 3 or 4. See Figure 2. Cells adhering to the bottom of the covered plate and forming colonies are not seen in normal T cell culture. T cells under other conditions did not show colony formation and did not adhere to the bottom of the culture plate. Figure 3 compares the appearance of Group IV (expressing four Yamanaka factors) adherent cells with that of Group 3 (not expressing Yamanaka factors, but instead expressing GFP). The adherent cells showed colony formation and were larger than the Group 3 T cells. This suggests that the T cell-derived adherent cells had lost T cell identity. Group IV T cell-derived adherent cells were also larger than standard activated T cells (Figure 3D). The panels in Figures 3A–3F show T cells cultured under various conditions as follows: 3A, 3C, 3E: Group IV adherent colonies; 3B: Group 3 cells; 3D: T cells cultured under standard T cell activation conditions; 3F: Standard iPS cell colonies. As is evident from Figure 3, partially reprogrammed cells exhibit a unique morphology. Furthermore, flow cytometry analysis showed decreased CD3 marker expression in cells from groups 2, 3, and 4, all of which were placed in IL2-free stem cell medium from day 1. See, for example, Figure 4. CD3 is an important marker of T cell identity in lymphocytes. This reduction was particularly pronounced in T cell-derived adherent cells of group 4. This also suggests that the adherent cells of group 4 had lost T cell identity. Notably, this differs from studies by other groups that have shown that transient expression of Yamanaka factor does not interfere with cell fate but can still reverse aging and improve the efficacy of certain cell types. See, for example, Sarkar et al., 2020, Nat Commun 11, 1545. Based on their finding that the expression of MyoD, a myogenic marker, did not change after transient reprogramming, Sarkar et al. demonstrated that "transient reprogramming does not interfere with myogenic fate but may enhance the likelihood of myogenicity." Here, T cell identity was altered, at least partially. Furthermore, as shown by FSC / SSC FACS analysis, adherent cells in group 4 were slightly larger and had a more complex structure (see Figures 5 and 6).
[0342] Example 2: Reactivation of partially reprogrammed T cells Next, partially reprogrammed T cells were reactivated on day 5 in a 96-well plate for 2 days using T cell TRANSACT® (Miltenyi Biotec) diluted 1:100 in T cell culture medium. On day 5, cells under the conditions of Group 4 were divided into two wells. Suspension cells were transferred to one well, cells that had adhered after exposure to the reprogramming conditions were detached from the container surface, washed, and transferred to the other well. Many cells in Group 3 died, likely due to the toxicity of the Sendai virus. It can be hypothesized that the Yamanaka factor expressed in Group 4 was able to rescue cells from the toxicity of the Sendai virus. All cells were cultured in T cell culture medium for a further 5 days after activation. As shown in Figure 5, cells that had lost CD3 and CD8 expression on day 5 of reprogramming regained expression of these genes on day 12. See, for example, Figure 7.
[0343] In addition to restoring CD3 expression on day 12, the reactivated T cells showed expression of CCR7 and CD62L, T cell homing markers suggestive of a naive T cell population. See, for example, Figure 8.
[0344] To evaluate T cell growth, cells were counted by counting beads (123 count eBeads Counting beads, Thermo) using flow cytometry on days 0, 5, and 12. Adherent cells in group 4 showed an abnormal appearance and reduced CD3 expression on day 5, but exhibited robust cell growth after activation. As shown in Figure 9, the ratio of change in cell number from day 5 to day 12 showed increased cell growth in group 4 compared to group 1. This indicates that the partial reprogramming method described herein increases the T cell growth capacity, particularly in adherent cells.
[0345] In a similar experiment, PBMC-derived CD8 T cells were stimulated with TRANSACT for 1 day as described above. The following day, reprogramming factors (Yamanaka factor + SV40) were introduced into the T cells by Sendai virus transduction, also as described above. The infected T cells were transferred to iMatrix-coated dishes on day 1 and cultured for 3 days in (a) T cell medium + 60 IU / ml IL2 or (b) iPS cell medium + 60 IU / ml IL2, after which they were switched to iPS cell medium without IL2 from day 4. On day 8, suspension and adherent cells were collected for flow cytometry analysis. In particular, the expression of SSEA4 and CD3 was analyzed to more accurately monitor T cell reprogramming. SSEA4 is a carbohydrate epitope that is considered a broad stem cell marker expressed from partially reprogrammed somatic cells to pluripotent stem cells. Notably, no adherent colonies were detected under condition (a), suggesting that culture conditions may affect T cell reprogramming. As shown in Figure 10, FACS analysis on day 8 showed that 71.9% of adherent cells were positive for both CD3 and SSEA4, indicating that adherent cells express both T cell lineage markers and stem cell markers. A population of cells that were high in SSEA4 and negative for CD3 was observed. Compared to adherent cells, there were few suspension cells expressing SSEA4 under condition (b), and no SSEA4-high CD3- population was observed. As expected, no SSEA4+ cells were observed after culture condition (a) (standard T cell culture conditions). This data strongly suggests that partially reprogrammed T cells (T cell-derived adherent cells) that form adherent colonies dedifferentiate (i.e., partially dedifferentiate) and express SSEA4. Our observations were consistent with previous reports using fibroblasts for reprogramming into iPS cells (see, e.g., Biol Open. 2017 Jan 15;6(1):100-108).
[0346] Example 3: Measurement of Epigenetic Age Horvath et al. showed that the “epigenetic age” (eAge) of cells can be estimated using a method that analyzes the methylation status at various DNA CpG sites in the cell genome (Horvath et al., Aging, 10(7):1758-1775). In this example, the eAge of T cells before and after partial reprogramming was calculated using the technique described by Horvath et al. Before partial reprogramming, the eAge of all experimental groups described in Examples 1 and 2 and outlined in Table 1 was estimated to be 21.5 years, which is consistent with the donor’s chronological age. After reprogramming and subsequent T cell activation, the calculated eAge of cells in group 1 was 20.8 years, while the calculated eAge of adherent cells in group 4 was 10.0 years (note that cells that adhere to the container surface during the partial reprogramming process detach from the surface at or immediately after activation. Such cells are referred to as “detached” cells to distinguish them from suspension cells). This indicates that the partial reprogramming process resulted in the rejuvenation of cells from an eAge of 21.5 years to approximately 10 years. Suspension cells in group 4 had an eAge of 14.5 years, and T cells in group 2 also had an eAge of 14.6 years, despite not being transduced with the four Yamanaka factors. This suggests that the stem cell culture medium itself (StemFit, Ajinomoto) contains components that contribute to some cell rejuvenation, although the contents of these components have not been published. The results are summarized in Table 3 below. [Table 3]
[0347] Example 4: Non-conventional T cells were generated by partial reprogramming from day 10 onwards. In this example, various time points of the second stimulation (reactivation) were investigated. The experimental overview is shown in Table 4 below. Sendai virus transduction was performed using KOS 10 MOI, KLF4 10 MOI, cMyc 3 MOI, and SV40 5 MOI in TCM containing 60 IU / ml IL2. Reprogramming culture conditions were 3 days in 50 / 50 TCM / iPS medium (Stemfit) containing 60 IU / ml IL2, followed by culture in Stemfit without IL2 until the second activation. After reprogramming over the indicated period, suspension and adherent cells were collected. The cells were then activated with TRANSACT at a ratio of 1:100 in TCM + 60 IU / ml IL2. Seven days after the second stimulation, the cells were analyzed by flow cytometry for the expression of the following markers: CD3, CD4, CD8α, and CD8β. Figure 11 is a schematic diagram summarizing the process for PBMC-derived CD8 T cells (see also Table 4). [Table 4]
[0348] Generally, conventional cytotoxic T cells express the CD8α-CD8β heterodimer. Non-conventional T cells, such as intraepithelial lymphocytes (IELs) and gamma delta T cells, express the CD8αα homodimer. Therefore, in this experiment, FACS was used to determine whether T cells generated using a partial rejuvenation process could express the canonical CD8 T cell marker. The absence of CD8αβ expression after stimulation may indicate that the partially rejuvenated T cells are not conventional cytotoxic T cells.
[0349] As shown in Figures 12A and 12B, T cell-derived adherent cell colonies reactivated by TCM between days 6 and 10 express CD8α and CD8β, indicating a return to the normal CD8 T cell phenotype. Delaying reactivation after day 10 in current reprogramming methods for restoring dedifferentiated T cells to the T cell phenotype resulted in an increase in the CD4-CD8- population (see Figure 12A, upper and lower panels on day 10, where CD8α expression is shifted to the left (lower MFI)). As mentioned above, CD8α-negative cells are not mature T cells. After day 10, gating in the CD8α-positive population resulted in the observation of more CD8β-negative cells (CD8αα+ atypical T cells) (see Figure 12B, FACS plot on day 13).
[0350] Example 5: Cytokine production assays and degranulation assays of juvenile NY-ESO-1 TCR transduced T cells demonstrate T cell functionality. To test whether partially reprogrammed T cells retain antigen specificity, we partially reprogrammed genetically modified CD8+ T cells expressing a NY-ESO-1 specific TCR, stimulated them with T cell activating molecules, and measured their response to target cells pulsed with the NY-ESO-1 peptide.
[0351] Peripheral blood-derived CD8+ T cells from a 42-year-old male were purchased from Allcells (Alameda, CA). The cells were thawed and stimulated with TRANSACT (1 / 100) in TCM containing IL-2 (60 IU / ml) as described in Example 4. The following day, the T cells were transduced with the NY-ESO-1 TCR by lentiviral vector transduction as follows.
[0352] For lentiviral transduction, T cells were stimulated with a 1:100 dilution of T cell TRANSACT (Miltenyi) for 30 hours. The virus was then added to the T cells and left for 24 hours. Next, 7 times the volume of fresh medium without TRANSACT was added to terminate the stimulation and viral infection. The cells were then cultured for a further 7 days on a Grex-24 plate (Wilson Wolf) and cryopreserved at 3 × 10⁷ cells / ml in a CryoStor CS10 (STEMCELL Technologies) (see also Robbins 2008 J Immunol, 180(9) 6116-6131). Control T cells were stimulated similarly without transduction.
[0353] For partial reprogramming and reactivation, NY-ESO-1 specific T cells were thawed and stimulated with TRANSACT (1 / 100) in TCM containing IL-2 (60 IU / ml). On day 2, the T cells were infected with Sendai virus containing four Yamanaka factors (KOSM MOI=10) and SV40 large T antigen (MOI=3). Then, on day 9, the cells were stimulated with TRANSACT to obtain juvenile NY-ESO-1 specific T cells as described above (second stimulation). For functional assays, the juvenile NY-ESO-1 specific T cells were again stimulated with TRANSACT on day 16 (third stimulation) to increase their size (see Figure 13).
[0354] On day 26, cytokine production and degranulation assays were performed as follows: Control non-transduced T cells and NY-ESO-1 specific TCR transduced T cells were thawed and stimulated with TRANSACT (1 / 500) in TCM containing IL-2 (60 IU / ml) for 1 week to increase their size. Non-transduced T cells, NY-ESO-1 specific TCR transduced T cells, and juvenile NY-ESO-1 specific TCR T cells were compared to effector cells. Target cells T2 were cultured in T2 medium (RPMI, 20% FCS and P / SM). T2 cells were pre-cultured for 1 hour with or without NY-ESO-1 peptide (SLLMWITQC) (10 nM), washed, and counted. Each well contained 5 × 10⁴ effector cells and 1 × 10⁵ target cells (E:T ratio 2:1). As a positive control, PMA / ionomycin (Biolegend Cell Activation Cocktail) was added according to the manufacturer's instructions. GolgiPlug and GolgiStop (BD Biosciences) were added according to the manufacturer's instructions. Anti-CD107a Ab-BV421 was also added to the culture medium (1 μl / well). Cells were cultured for 6 hours in cytokine-free TCM. Co-cultured cells were then stained for surface antigens (PE-NY-ESO-1 tetramer, BUV395-CD8, BUV496-CD4, and BUV805-CD3). Live / dead eFluor 780 was also added to eliminate dead cells. Cells were washed after 20 minutes. Cells were fixed and permeabilized using the BD cytofix / cytoperm kit according to the manufacturer's instructions. Cells were then stained for intracellular cytokine expression (FITC-IFNg, APC-IL-2, and BV785-TNFa). After a 30-minute incubation, the cells were washed twice and analyzed by flow cytometry using a ZE5 instrument. FACS results were analyzed using FlowJo software. For NY-ESO-1 Tg T cells, gating was performed as follows: single cell > live cell > CD3+ > CD8+CD4-> NY-ESO-1 tetramer+ cell. For mock control T cells, gating was performed as follows: single cell > live cell > CD3+ > CD8+CD4-> NY-ESO-1 tetramer- cell.The frequencies of IFNg+, TNFa+, IL-2+, and CD107a+ were calculated as shown in Figure 14. The results indicated that the juvenile NY-ESO-1+ transduced T cells retained their functionality and were antigen-specific.
[0355] Example 6: Surface protein profiling of T cells, iPS cells, and partially reprogrammed T cells In this example, cell surface protein profiling was performed on activated T cells, unstimulated T cells, iPS cells, and attached partially reprogrammed T cells (T cell-derived adherent cells) on day 5. The objective of this screening was to identify intermediate cells and markers expressed in partially reprogrammed cells that can be used to characterize the partial reprogramming process and the cells produced using this method.
[0356] T cell culture medium (TCM) was prepared as described above. For the initial screening, CD4+ and CD8+ T cells (Allcells cell ID 3046087I&K) were thawed. T cells were stimulated for 3 days with 100 ng / ml anti-CD3 and 2 ug / ml anti-CD28 (BioLegend, San Diego, CA anti-human CD3 OKT3 and CD28 CD28.2 antibodies) supplemented with 60 IU IL-2. Umbilical cord blood-derived iPS cell line NL5GFP and tumor-infiltrating lymphocyte (TIL)-derived iPS cell line hi4095#8 were cultured in Stemfit and harvested. T cells and iPS cells were stained with BioLegend LEGENDScreen (BioLegend, San Diego, CA) and anti-CD8, CD4, CD3, SSEA4, and Live / Dead, and the expression levels of 371 markers were determined using flow cytometry.
[0357] The initial screening identified 39 candidate markers, selected based on their expression levels in T cells and iPS cells. Markers were selected that showed significantly higher levels in stimulated or unstimulated T cells compared to iPS cells, or that exhibited different expression patterns between iPS cells and T-iPS cells. These markers, along with their relative expression levels in stimulated or unstimulated T cells compared to iPS cells, are ranked in Table 5 below. This data is also graphically represented in waterfall plots in Figure 15 (stimulated T cells vs. NL5iPS cells) and Figure 16 (unstimulated T cells vs. T-iPS cells). [Table 5-1] [Table 5-2]
[0358] In the second screening, CD4+ and CD8+ T cells (Allcells cell ID 3046087I&K) were thawed and stimulated with 100 ng / ml anti-CD3 and 2 ug / ml anti-CD28, supplemented with 60 IU of IL-2. Three days later, 10 MOI KOS Sendai vector, 10 MOI KLF4 vector, 3 MOI cMyc vector, and 5 MOI SV40 vector were transduced into the T cells as described in previous examples. Five days later, adherent cells were harvested and screened for surface expression of the markers identified in the first screening as described above. Unstimulated T cells, stimulated T cells, NL5 iPS cells, and hi4095 iPS cells were used as controls.
[0359] The expression of CD164, CD9, CD63, CD90, CD71, CD326, TRA-1-81, and TRA-1-60-R was increased in partially reprogrammed adherent cells on day 5 compared to stimulated and unstimulated T cells, while CD352 and CD31 were found to be downregulated. As shown in Figure 17, this second screening identified CD9 and CD90 as potential indicators of early transition during partial reprogramming, although the expression levels of the known iPS cell markers SSEA3 and SSEA4 were not significantly altered on day 5. CD9, also known as tetraspanin-29, has four transmembrane domains. It is involved in cell adhesion, signaling, and cell differentiation. CD90, also known as THY-1, is an immunoglobulin superfamily surface glycoprotein and a marker associated with mesenchymal stem cells. It is also involved in cell adhesion and signaling. Therefore, the expression of these two markers may explain the adhesion characteristics acquired in dedifferentiated T cells. The expression of these two markers also suggests that partially reprogrammed T cells are dedifferentiating into an unknown cell type, which, to the best of our knowledge, has not been identified as a differentiated cell stage corresponding to the T cell lineage hierarchy.
[0360] Example 7: Stimulus signaling is important for the survival and proliferation of immature T cells. To determine whether stimulus signaling is important for improved survival and proliferation, T cell adherent cells were activated with various concentrations of TRANSACT® (Miltenyi Biotec).
[0361] First, T cells were partially reprogrammed using the method described in Example 1. Briefly, CD8-positive T cells were stimulated for 3 days with soluble CD3 and CD28 TRANSACT® (Miltenyi Biotec) in T cell culture medium containing 60 IU / ml IL2. After 3 days, 10 MOI KOS Sendai vector, 10 MOI KLF4 vector, 3 MOI cMyc vector, and 5 MOI SV40 vector were transduced into the T cells. Cells were cultured in IL2-free SCM from day 1 and plated at a density of 80,000 cells per well in 24-well plates coated with iMatrix-511 in a quad-tray configuration.
[0362] On day 7, adherent cells were detached from the container surface, washed, and transferred to another well. The T cell-derived adherent cells were then reactivated with T cell TRANSACT® (Miltenyi Biotec) diluted to a concentration of 1:500 or 1:1000, or incubated without any stimulating medium. All cells were cultured for an additional 9 days after activation in T cell culture medium (TCM with 60 IU / ml IL2 added). As shown in Figure 18A, T cell-derived adherent cells showed significant loss of CD3 and CD8a expression. However, on day 22, only 8.4% of cells cultured in TCM without TRANSACT expressed CD3 and CD8a, whereas 93%–94% of cells activated with TRANSACT at any concentration regained expression of the conventional T cell markers CD3 and CD8a. Furthermore, as shown in Figures 18C and 18D, activated T cells showed significantly higher viability and proliferation compared to partially reprogrammed T cells cultured in T cell medium without TRANSACT®.
[0363] Example 8: Immature T cells exhibit an effector phenotype after prolonged growth in the presence of IL-2. In this example, the ability of juvenile T cells from different donors to survive and proliferate over time was investigated. Peripheral blood-derived CD8+ T cells from three donors (a 42-year-old male, a 37-year-old female, and a 52-year-old male) were purchased from Allcells, Alameda, CA. The cells were thawed and stimulated with TRANSACT® (Miltenyi Biotec) at a concentration of 1:500 in TCM containing IL-2 (60 IU / ml).
[0364] On day 2, T cells were infected with Sendai virus containing four Yamanaka factors (KOSM MOI=10) and SV40 large T antigen (MOI=3). Subsequently, on day 9, the cells were stimulated with TRANSACT® (1:500). Additional aliquots of CD8+ T cells from each donor were thawed and stimulated on day 9 with TRANSACT® (1:500) in a TCM containing IL-2 (60 IU / mL) ("Control 1"), or, after thawing, stimulated on day 0 with TRANSACT® (1:500) in a TCM containing IL-2 (60 IU / mL) and cultured in a TCM containing IL-2 (60 IU / mL) ("Control 2"). On day 9, Control 2 cells were stimulated with TRANSACT® (1:500). The juvenile T cells were grown in vitro for 42 days. The growth of non-immature T cells plateaued after approximately 3 weeks of growth in vitro. See Figure 19A. Immature T cells showed significant growth that continued for up to 42 days in culture. See Figure 19B. This growth was cytokine-dependent, and the immature T cells began to die within 6 days after IL-2 discontinuation. See Figures 20B and 20C.
[0365] On day 36, cytokine production and degranulation assays were performed as follows: Cells were cultured in cytokine-free TCM with or without PMA / ionomycin (Biolegend Cell Activation Cocktail). GolgiPlug and GolgiStop (BD Biosciences) were also added according to the manufacturer's instructions. Co-cultured cells were then stained for surface antigens (BUV395-CD8, BUV496-CD4, and BUV805-CD3). Live / dead eFluor 780 was added to eliminate dead cells. After 20 minutes, the cells were washed. Cell fixation and permeabilization were performed using the BD cytofix / cytoperm kit according to the manufacturer's instructions. Cells were then stained for intracellular cytokine expression (FITC-IFNg and APC-IL-2). After a 30-minute incubation, the cells were washed twice and analyzed by flow cytometry using a ZE5 instrument. FACS results were analyzed using FlowJo software. For all cells, gating was performed as follows: single cell > viable cell > CD3+ > CD8+CD4- cell. The frequencies of IFNg+ and IL-2+ were calculated as shown in Figure 21. The results showed that the juvenile T cells retained functionality. Normally, effector T cells express IFNg but do not express large amounts of IL2. Therefore, these results suggest that the juvenile cells after 36 days of culture have not yet reached the full effector phenotype.
[0366] Cell surface expression of CD3, CD8b, CD45RA, CCR7, and CD62L was measured by flow cytometry on days 7 and 26. See Figures 22 and 23. Reprogrammed detached T cells show decreased CD3+CD8b+ expression but increased CD45RA and CCR7+CD62L+ expression levels. By day 26, immature T cells show normal levels of CD3+CD8b+ expression, as well as decreased levels of CD45RA+ and CCR7+CD62L+ cells. See Figures 22 and 23.
[0367] In summary, these data suggest that, after long-term in vitro culture, the rejuvenated cells possess high proliferative capacity and are multifunctional (Figures 19-23). While the rejuvenated cells continue to express IL2, an indicator of stem cell characteristics, they exhibit an effector phenotype, as indicated by cell surface markers. Therefore, despite long-term culture and growth, the rejuvenated cells still appear to possess stem cell characteristics.
[0368] Example 9: Developed NY-ESO-1 TCR transduced T cells recognize NY-ESO-1 expressing tumor cells. To test whether juvenile T cells retain antigen specificity against tumor cells, we partially reprogrammed genetically modified CD8+ T cells expressing a NY-ESO-1 specific TCR, stimulated them with T cell activating molecules, and measured their response to target cells pulsed with the NY-ESO-1 peptide.
[0369] Peripheral blood-derived CD8+ T cells from two different donors (#3 a 42-year-old male, #4 a 37-year-old female) were purchased from Allcells (Alameda, CA). 2 × 10⁶ cells were thawed, and each donor's cells were stimulated in one well of a 24-well plate with TRANSACT™ (1:100) in TCM containing IL-2 (60 IU / mL), as described in Example 4. The following day, the T cells were transduced with the NY-ESO-1 TCR by lentiviral vector transduction as follows: First, the T cells were stimulated with T cell TRANSACT (Miltenyi) at a 1:100 dilution for 30 hours. Then, the virus (MOI: 5) and LentiBOOST™ A&B (Sirion Biotech) were added to the T cells and left for 24 hours. Finally, stimulation and viral infection were terminated by adding 7 ml of TCM containing IL-2 (60 IU / L). On the second day, T cells were infected with Sendai virus containing four Yamanaka factors (KOS 10MOI, KLF 10MOI, cMyc 3MOI, SV40 5MOI) and SV40 large T antigen (MOI=3). Control cells were continued to be cultured in TCM containing IL-2 (60 IU / mL).
[0370] After 16 hours, the infected T cells were washed and transferred to iMatrix-coated dishes on day 1. The culture medium was then changed to Stemfit (2 mL / well) without IL-2. Sample #3 had a density of 2.6 × 10⁵ cells / well, and sample #4 had a density of 1.76 × 10⁵ cells / well. The procedure was performed in triplicate. On day 3, Stemfit was added (2 mL / well, 4 mL total).
[0371] On day 5, suspension cells were removed and adherent cells were collected according to the following protocol. The medium was aspirated and washed twice with 2 mL of PBS per well. 1 mL of EDTA was added and the mixture was incubated at 37°C for 5 minutes. Cells were collected by P1000 pipetting, and the final densities were 6.1 × 10⁵ cells in 3 wells for #3 and 1.9 × 10⁶ cells in 1 well for #4. This yielded approximately 2 × 10⁵ cells / well in a 96-well U-bottom microplate. The cells were then activated with TRANSACT at a ratio of 1:500 in TCM containing IL-2 (60 IU / mL). Control Sendai uninfected NY-ESO-1 Tg cells were similarly restimulated.
[0372] On day 6, the cell density was too high, so the cells were divided into two wells of a 96-well microplate. TCM containing IL-2 (60 IU / mL) was added. On day 8, the cells from the two wells of the 96-well microplate were combined into one well of a 48-well plate, and TCM containing IL-2 (60 IU / mL) was added. On day 12, the cells were transferred to a 24-well plate to achieve a cell density of 2 × 10⁶ cells / well. TCM containing IL-2 (60 IU / mL) was added to each well. The cells were counted every 3-4 days, and the rate of change was calculated. See Figure 24. The cell count was adjusted to approximately 2 × 10⁶ cells / well, and TCM containing IL-2 (60 IU / mL) was added to achieve a volume of 2 mL / well.
[0373] On day 19 (14 days after the second stimulation), target cells, T2 and Mel624 HLA-A*02:01-positive tumor cells expressing endogenous NYESO1, were cultured in T2 medium (RPMI, 20% FCS and P / SM). T2 cells were pre-cultured for 1 hour with or without NY-ESO-1 peptide (SLLMWITOC) (10 nM), washed, and counted. Each well contained 5 × 10⁴ effector cells and 1 × 10⁵ target cells (E:T ratio 1:2). As a positive control, PMA / ionomycin (Cell Activation Cocktail by Biolegend) was added according to the manufacturer's instructions. GolgiPlug and GolgiStop (BD Biosciences) were added according to the manufacturer's instructions. Anti-CD107a Ab-BV421 was also added to the culture medium (1 μL / well). Cells were cultured for 6 hours in cytokine-free TCM. Co-cultured cells were then stained for surface antigens (PE-NY-ESO-1 tetramer, BUV395-CD8, BUV496-CD4, and BUV805-CD3). Live / dead eFluor 780 was added to eliminate dead cells. After 20 minutes, the cells were washed. Cell fixation and permeabilization were performed using the BD cytofix / cytoperm kit according to the manufacturer's instructions. Cells were then stained for intracellular cytokine expression (FITC-IFNg, APC-IL-2, and BV785-TNFa). After a 30-minute incubation, cells were washed twice, and cell surface marker expression for CD45RA, CD45RO, CCR7, and CD62L was analyzed by flow cytometry using a ZE5 instrument. FACS results were analyzed using FlowJo software. For NY-ESO-1 Tg T cells, gating was performed as follows: single cell > live cell > CD3+ > CD8+CD4-> NY-ESO-1 tetramer-cell. For mock control T cells, gating was performed as follows: single cell > live cell > CD3+ > CD8+CD4-> NY-ESO-1 tetramer-cell (Figure 25). The frequencies of IFNg+, TNFa+, IL-2+, and CD107a+ were calculated as shown in Figures 26A-26D.This experiment confirms that juvenile NYESO1 T cells are antigen-specific and recognize NYESO1-positive T2 and Mel624 target cells (Figures 24-26) (see also Figure 14). These data also confirm that juvenile cells continue to express IL2, an indicator of stem cell characteristics, but possess an effector phenotype as indicated by cell surface markers.
[0374] Example 10: NY-ESO-1 TCR transduced T cells are rejuvenated by antigen-specific stimulation. To test whether antigen-specific T cells can be juvenated using antigen-specific stimulation, CD8+ T cells are isolated from one or more donors genetically modified to express the NY-ESO-1 specific TCR. Donor cells are thawed and stimulated with TRANSACT® in TCM containing IL-2 (60 IU / mL) in one well of a 24-well plate for each donor. After 1 day, lentivirus expressing the NY-ESO-1 T cell receptor is transduced into the T cells. Then, NY-ESO-1 specific T cells are co-cultured with T2 cells pulsed with the NY-ESO-1 peptide (T2+NY-ESO-1 cells). Next, the cells are enriched for NY-ESO-1 specific T cells (Group 1) or maintained as a heteromix of NY-ESO-1 specific T cells and untransduced T cells (Group 2). During reprogramming, the cells are again co-cultured with T2+NY-ESO-1 cells. Next, cells are infected with Sendai virus containing four Yamanaka factors (KOS 10MOI, KLF 10MOI, cMyc 3MOI, SV40 5MOI) and the SV40 large T antigen (MOI=3). Control cells are kept cultured in TCM containing IL-2 (60 IU / mL) in co-culture with T2+NY-ESO-1 cells.
[0375] NY-ESO-1 specific T cells can form T cell-derived adherent cells in the presence of T2+NY-ESO-1 cells and in the absence of further stimulation. Adherent cells were harvested according to the protocol described in Example 9 and then reactivated by co-culturing with T2+NY-ESO-1 cells.
[0376] Example 11: Dejuvenation improved the T cell stem cell characteristics of tumor-infiltrating lymphocytes. In this example, tumor-infiltrating lymphocytes (TILs) were isolated from a 66-year-old donor and juvenated as follows: TILs were enriched by culturing tumor fragments in T cell culture medium for two weeks. T cells were activated by co-culturing them overnight with autologous antigen-presenting cells derived from the tumor. Subsequently, FACS sorting of T cells was performed, and CD137(4-1BB) positive cells were isolated. After 1 day (day 0), the cells were either left undisturbed or transduced with four Sendai viruses expressing KOS(KLF4, OCT3 / 4, SOX2), KLF4, cMyc, and SV40 as described above. The cells were then transferred to stem cell medium (StemFit) and cultured for 7 days. T cell-derived adherent cells were harvested on day 7 and reactivated for a further 2 days with TransAct(1:500) in T cell culture medium. From day 9 onwards, the cells were cultured in standard T cell culture medium. On day 21, juvenile cells or control cells (following the same procedure except that the cells were not transduced with four Sendai viruses) were evaluated for CD62L, CCR7, and TCF7 expression using flow cytometry. Juvenile TILs showed improved proliferation (Figure 27A) and improved expression of stem cell phenotype markers (Figure 27B) compared to non-juvenile controls. In this experiment, 73.0% of juvenile TILs co-expressed CCR7 and CD62L, and 64.5% of juvenile TILs co-expressed CCR7 and TCF7, which was significantly higher than the non-juvenile TIL population, where only 2.94% showed co-expression of CCR7 and CD62L, and only 3.07% showed co-expression of CCR7 and TCF7. These data suggest that TILs, typically characterized by phenotypic markers of low proliferative capacity and depletion, can be successfully rejuvenated to enhance proliferative and stem cell properties.
[0377] Example 12: Dynamic analysis of the epigenetic clock during T cell juvenation In this example, CD8+ T cells from 53-year-old, 55-year-old, and 50-year-old males were stimulated with T cell TransAct®, human (Miltenyi Biotec) at a 1:500 dilution in T cell culture medium (TCM) containing 60 IU / ml of IL-2, at a cell density of 1 million cells / ml in 48-well plates. All TCMs described below contain 60 IU / ml of IL-2. After 26.5 hours of activation, the cells were divided into two groups. One group was subjected to a juvenation protocol, and the other group was used as a control. Both groups were cultured in TCM without any viral manipulation throughout the process.
[0378] Sendai virus (SeV) containing Yamanaka factor and SV40 was transduced into juvenile samples at concentrations of 10 MOI for KLF4-OCT3 / 4-SOX2, 10 MOI for KLF4, 3 MOI for cMyc, and 5 MOI for SV40 (Day 0), and then cultured at 37°C. After 16.5 hours, the cells were washed and suspended in stem cell medium. Cells were plated into iMatrix-511 coated 24-well plates at 50,000 cells / well (corresponding to the count of 50,000 on Day 0) and cultured at 37°C (Day 1). 500 μl of SCM was added on Days 3 and 5.
[0379] On day 7, 1 ml of TrypLE Express (Thermo catalog number 12604013) was added to detach adherent cells, and the cells were incubated at 37 degrees Celsius for 10 minutes. The detached cells were then collected by pipetting. Suspended cells in the supernatant were also retained and mixed with the detached cells. A portion of the cells was set aside for DNA, and the eAge was determined. 500,000 cells each from both the control and juvenation samples were activated with T cell TransAct, human diluted 1:500 in 500 ul of TCM at a density of 1 million cells / ml in 48-well plates. On day 9, the cells were transferred to 12-well plates, and 1 ml of TCM was added to each well. On day 11, the cells were transferred to 6-well plates. The cells were then cultured in the 6-well plates.
[0380] Cell samples were collected for SeV transduction before the pre-activation step, and for epigenetic clock analysis on days 7, 13, and 18. Cells at each time point were pelletized and kept at -20°C until DNA extraction. DNA was extracted from the frozen cell pellets using the PureLink Genomic DNA mini kit (Invitrogen, K182002). Each extracted DNA was divided into three tubes for technical repeat tests of methylome analysis. Due to insufficient DNA, the control conditions for donor 1 on day 18 and donor 3 on days 7 and 18 consisted of only two technical repeat tests. Samples were prepared for epigenetic analysis using an Illumina Infinium array. CpG methylation status data was analyzed using the Horvath method (described in Horvath et al., 2018, Aging 10, 1758-1775 and Horvath and Raj, 2018, Nature Reviews Genetics, 19:371-375) to obtain skin and blood clock values.
[0381] Cells were stained with fluorescently conjugated antibodies and viability-determinating dyes, and the cell phenotype was obtained by flow cytometry using Cytek Aurora.
[0382] Following the juvenation protocol shown in Figure 28, CD8-positive T cells from three male donors (ages 53, 55, and 50) were transduced with Yamanaka factor and SV40 and compared with controls under non-transduced conditions at each time point. Juvenated cells showed reduced CD3 and CD8b expression on day 7. After detachment and stimulation, the expression of conventional T cell markers was fully restored in juvenated cells on days 13 and 18 (Figures 29A and 29B). Thus, partially reprogrammed cells regained the expression of conventional T cell markers just 6 days after reactivation.
[0383] To investigate epigenetic age (eAGE) at four time points in the juvenation protocol, DNA samples from three male donors were analyzed using epigenetic clocks (a highly accurate age estimation method) on the skin and blood (Figures 30A-30C).
[0384] The eAge of Donor 1, whose chronological age was 53 years (y / o), was 45.1 years before activation for Sev transduction. While the eAge of non-juvenated control cells after TransAct activation did not change [ranging from 43.3 to 45.7 years (a variation of 2.4 years)], the eAge of Sendai virus transduction cells (juvenated cells) on day 7 was the youngest at 30.9 years, which gradually increased to 46.2 years on day 18. The difference between the control eAGE and juvenated eAGE on day 7 was 12.9 years. This represents a decrease of approximately 24.3% in age as measured by Horvath clock analysis.
[0385] The eAge of control cells from donor 2, whose chronological age was 55 years, ranged from 43.8 to 50.0 years (a variation of 6.2 years). Again, the youngest age was achieved by rejuvenation on day 7, at 34.4 years (12.9 years younger than the control eAGE on day 7). Consistent with the results for donor 1, the eAge gradually increased.
[0386] Donor 3 had a chronological age of 50 years. The eAge of non-immature control cells fluctuated from 46.0 to 51.4 (a fluctuation of 5.4 years), but the youngest age was 31.5 years for the immature cells on day 7, which was 19.9 years younger than the control eAge on day 7. In summary, in all three donors, the immature cells showed the youngest eAge on day 7, after which the eAge gradually increased. The eAge of the immature cells in Donor 1 reached the control level on day 18, but in the other two donors, the immature cells remained younger than the control.
[0387] As demonstrated by the results described above, partially reprogrammed T cells lose common T cell markers (e.g., CD3 and CD8b) according to measurements on detachment day (i.e., day 7). However, after restorative stimulation on day 7 and culture in T cell medium, T cell adherent cells fully regained T cell markers by day 13, or on day 13. The epigenetic clock showed the youngest epigenetic age on day 7 in three test donors (aged 50, 53, and 55, respectively). The results in this case demonstrate that although an increase in eAge was observed after day 7, the immature cells remained younger than the controls on day 13, when they exhibited a complete T cell phenotype.
[0388] Example 13: Developing immature NY-ESO-1 transduced T cells This example demonstrates that T cells can be genetically engineered using the methods described herein to express a TCR specific to a desired target (e.g., NYESO1) and to be rejuvenated.
[0389] Activation of healthy donor CD4 / CD8 T cells: On day 1, healthy human donor CD4 and CD8 T cells from two male donors (ages 24 and 35) were thawed, washed once, and resuspended in preheated complete TCM + IL-2 (60 IU / ml) (-3 days). The cells were diluted to 2e6 cells / ml. Transact was added at a dilution of 10 ul / ml (1 / 100) to stimulate the CD4 and CD8 T cells (see Figure 31). On day 2, the stimulated CD8+ and CD4+ T cells were counted, and 7.5e+5 cells were suspended in 0.75 ml of TCM + IL-2. Using a standard protocol, lentiviral vectors encoding NYESO1-specific TCRs were constructed. NYESO1-encoding lentiviral supernatant (7.5 ul, MOI; 10) and LentiBoost A & B (7.5 ul each) were added. The following day, 5.25 ml of new TCM + IL-2 was added (total 6 ml).
[0390] Reprogramming and collection of NY-ESO-1 transgenic (Tg) T cells: 4e+5 cells were collected on day 0 and resuspended in TCM+IL-2 in a 48-well plate. The Cytotune® Sendai reprogramming kit was used for reprogramming (KOS:MOI=10, KLF4:MOI=10, C-MYC:MOI=3, and SV40:MOI=5). The following day (i.e., day 1), cells were collected, resuspended in stem cell culture medium, and seeded in iMatrix coated 6-well plates (2 wells per condition). Fresh stem cell culture medium was added on day 3, and half of the medium was refreshed with fresh stem cell culture medium on day 5. Control cells were kept under culture in TCM+IL-2. On day 7, suspension cells were collected, the wells were washed with PBS, TrypLE was added, and adherent cells were detached. The number of cells in all collected cells (i.e., suspension cells + detached cells) was counted. Exfoliated cells were restimulated with Transact (1 / 500 dilution) in 500 μl of TCM+IL-2 (in a 48-well plate). Cells were collected on day 11, resuspended in 1 ml of fresh TCM+IL-2, and transferred to a 6-well plate. Cell counting and medium changes were performed every 3-4 days. On day 13, 1 / 20 of the cells were stained for surface expression with antibodies for CD3, CD62L, CD45RO, HLA-A02:01 NYESO1 MHC tetramer, Cd197, CD4, CD8a, and CD45RA, and intracellularly stained for TCF1. Fixation and permeabilization were performed using the Foxp3 staining kit as described in the manufacturer's protocol, stained with Tcf7 antibody, and analyzed by FACS. See, for example, Figures 32A and 32B. Genomic DNA was extracted from 1e+6 cells per condition using the PureLink Genomic DNA Mini Kit as described. The DNA was treated with RNAse and evaluated for epigenetic age analysis as described above.
[0391] T2 cell stock vials were thawed, washed once, and cultured in complete RP10 medium for 1 week. 5e+6 cells were resuspended in complete RP10 with or without 10nM NY-ESO1 peptide in a 5% CO2 incubator for 2 hours. After 2 hours, the cells were washed and resuspended in TCM.
[0392] On day 19, control and juvenile NY-ESO-1 TCR Tg T cells were analyzed for their ability to generate cytokines during co-culture with target cells. 5e+4 T cells were co-cultured with 1e+5 T2 cells, with or without the NY-ESO-1 peptide. Wells without target cells and wells containing PMA / ionomycin (Cell Activation Cocktail) were added as negative and positive controls, respectively. CD107a antibody was added to the culture medium. After 6 hours of co-culture, cells were stained with a surface antibody mix, fixed and permeabilized using a BD kit as described in the manufacturer's protocol, stained with an intracellular antibody mix, and analyzed by FACS (Cytek Aurora). Data were analyzed using Flowjo software. The gating strategy was as follows: Lymphocytes > Single Cells > Live / Dead -> CD3 + NY-ESO-1 Tetramer +.
[0393] On day 19, continuous stimulation was used to analyze the target cell killing capacity of control and juvenile NY-ESO-1 TCR Tg T cells. Specifically, control and juvenile T cells were counted. In 24-well plates, 50,000 NY-ESO-1 tetramer+ T cells were co-cultured with 200,000 NY-ESO-1+ HLA A02:01+ target cells (A375-Nuclight Red (NLR) or H1703-NLR) in a 1:4 E:T ratio. Every 3-4 days, 25% of the culture was transferred to a new plate plated with fresh target cells at the initial seeding density. Target clearance was quantified using Incucyte.
[0394] The results showed that juvenile NY-ESO-1 TCR Tg T cells exhibited a poorly differentiated phenotype. In particular, juvenile NY-ESO-1 TCR transduction T cells on day 13 (detected by NY-ESO-1 tetramer binding) contained a higher percentage of CCR7+CD62L+ and Tcf1+ populations and showed a poorly differentiated phenotype. See, for example, Figures 32A and 32B. Control and juvenile NY-ESO-1 TCR Tg T cells were kept in culture with TCM+IL-2 for extended periods. The medium was changed every 3-4 days, and the cells were maintained at a concentration of 1-2e+6 / ml. Juvenile NY-ESO-1 TCR Tg T cells took longer to initiate proliferation, which may be due to recovery from the reprogramming process. However, they proliferated more than 100-fold over time compared to non-juvenile control cells. See, for example, Figure 33. The epigenetic ages of control and juvenile NY-ESO-1 TCR Tg T cells were analyzed as shown in Figure 34. Compared to control T cells, juvenile cells at day 19 showed a phenotype approximately 8–18 years younger. More specifically, in the first donor (Figure 34A), the epigenetic age of juvenile CD4 T cells (T cell-derived adherent cells) at day 7 showed a 68% reduction in age compared to the eAge of control cells (eAge at day 19). Juvenile CD4+ T cells at day 19 showed a 33% reduction in age compared to control cells. The epigenetic age of juvenile CD8 T cells at day 7 showed a 70% reduction in age compared to control cells. Juvenile CD8 T cells at day 19 showed a 45% reduction in age compared to control cells. In the second donor (Figure 34B), the epigenetic age of juvenile CD4 T cells (T cell-derived adherent cells) at day 7 showed a 62% reduction in age compared to control cells. Juvenile CD4+ T cells at day 19 showed a 27% reduction in age compared to control cells. The epigenetic age of juvenile CD8 T cells (T cell-derived adherent cells) at day 7 showed a 68% reduction in age compared to control cells. Juvenile CD8 T cells at day 19 showed a 67% reduction in age compared to control cells.
[0395] Furthermore, it was observed that juvenile NY-ESO-1 TCR Tg T cells produced more cytokines (IL-2, IFNg, and TNFα) when co-cultured with target cells in the presence of the NY-ESO-1 peptide (Figure 35). Cytokine (IL-2, TNFα, IFNg) production by control and juvenile NY-ESO-1 TCR Tg T cells was analyzed by co-culturing them with T2 cells (HLA A02:01+) with or without the NY-ESO-1 peptide, as described above. Both control and juvenile NY-ESO-1 TCR Tg T cells did not produce cytokines when co-cultured with T2 cells without the peptide. When co-cultured with T2 cells in the presence of the NY-ESO-1 peptide, a higher percentage of juvenile NY-ESO-1 TCR Tg T cells produced IL-2, IFNg, and TNFα. See, for example, Figure 35.
[0396] Please refer to Figures 31-37. Figure 31 shows the experimental results for the juvenation of NY-ESO-1 Tg CD4 and CD8 T cells. CD4 or CD8 T cells were stimulated with Transact and transduced with NY-ESO-1 TCR before reprogramming. Cells were cultured under iPS cell culture conditions from day 1 to day 7. On day 7, cells were collected, counted, restimulated with Transact, and kept under TCM+IL-2 culture. On day 19, control and juvenated cells were analyzed for cytokine production and cytotoxic activity. Juvenated CD4 and CD8 T cells were mixed under serial killing assay conditions to investigate their synergistic effects.
[0397] Figures 32A and 32B show that juvenile NY-ESO-1 Tg CD4 (Figure 32A) and CD8 T cells (Figure 32B) exhibited a poorly differentiated phenotype. On day 13, control and juvenile NY-ESO-1 Tg CD4 and CD8 T cells were analyzed by FACS for surface markers and intracellular Tcf1 expression. Cells were gated as lymphocytes > single cells > Live / Dead -> NY-ESO-1 tetramer + and plotted as CD4×CD8a, CCR7×CD62L, and CCR7×Tcf1.
[0398] Figure 33 shows that juvenile NY-ESO-1 Tg CD4 and CD8 T cells proliferated more significantly than control NY-ESO-1 Tg CD4 and CD8 T cells. NY-ESO-1 Tg CD4 and CD8 T cells were juvenated and cultured as described above, and cell counts were recorded every 3-4 days. The graphs show the rate of change over time, 7 days after transduction with reprogramming factors, and compared to their corresponding control cells. These are representative data from four different donors.
[0399] Figure 34 shows that juvenile NY-ESO-1 Tg CD4 and CD8 T cells exhibited a younger phenotype than control NY-ESO-1 Tg CD4 and CD8 T cells, as well as the donor's chronological age, based on epigenetic age analysis. The graph shows the mean and standard deviation of age values analyzed from the methylation status of a specific CpG site.
[0400] Figure 35 shows that juvenile NY-ESO-1 Tg CD4 and CD8 T cells produced more cytokines (IFNg, IL-2, and TNFα) when co-cultured with T2 cells containing the NY-ESO-1 peptide. On day 19, control or juvenile NY-ESO-1 Tg CD4 and CD8 T cells were cultured alone or with T2 cells containing or without PMA / ionomycin and the NY-ESO-1 peptide in the presence of Golgi transporter inhibitors. After staining surface antigens, cells were fixed, permeabilized, and stained with intracellular antibodies. The frequency of cytokine-positive NY-ESO-1 tetramer+ cells is shown.
[0401] Figure 36 shows that juvenile NY-ESO-1 Tg CD8 T cells, when repeatedly co-cultured with NY-ESO-1 expressing target cells (A375-NLR), persisted longer and retained cytotoxic activity than control cells. Control or juvenile NY-ESO-1 Tg CD8 T cells were co-cultured with the A375-NLR cell line. Every 3-4 days, 25% of the previous culture was transferred to a new plate containing fresh targets. Target growth was monitored using the Incucyte® live cell analysis system and analyzed using the Base Software Analysis Module. The graph shows the number of A375-NLRs / image for each condition. These are representative data from two different donors. NLR: Nuclight Red.
[0402] Figure 37 illustrates the increased cytotoxicity of juvenile NY-ESO-1 Tg CD8 T cells resulting from the addition of juvenile NY-ESO-1 Tg CD4 T cells. Juvenile NY-ESO-1 Tg CD4 and CD8 T cells were co-cultured with the A375-NLR cell line at E:T = 1:4. Under one condition, exogenous IL-2 (10 IU / ml) was added. Under another condition, juvenile CD4 and CD8 T cells were mixed in a 1:1 ratio and co-cultured with the A375-NLR cell line at E:T = 1:2. Every 3-4 days, 25% of the previous culture was transferred to a new plate containing fresh target cells. Target cell growth was monitored using the Incucyte® live cell analysis system and analyzed using the Base Software Analysis Module. The graph shows the A375-NLR cell count / image for each condition. Representative data are from two different donors.
[0403] From this example, it can be concluded that juvenile NY-ESO-1 TCR Tg T cells exhibited a poorly differentiated phenotype and proliferated significantly compared to control NY-ESO-1 TCR Tg T cells. Furthermore, the epigenetic age of juvenile NY-ESO-1 TCR Tg T cells was lower than that of control NY-ESO-1 TCR Tg T cells. Juvenile NY-ESO-1 TCR Tg T cells also produced more cytokines (IL-2, IFNg, and TNFα) when co-cultured with target cells pulsed with the appropriate NYESO1 peptide. In addition, juvenile NYESO1 TCR+ cells retained cytotoxic activity for a longer period than non-juvenile control cells after repeated exposure to target antigen cells. Furthermore, the activity of juvenile NY-ESO-1 TCR Tg CD8 T cells was enhanced by the addition of IL-2 or juvenile NY-ESO-1 TCR Tg CD4 T cells.
[0404] Example 14: Identification of cytokines This example was performed to evaluate cytokine production by juvenile T cells.
[0405] PBMC juvenation. On day 2, 1 × 10⁶ donor cells were thawed and incubated in a 24-well plate with 1 mL of TCM + IL-2 (60 IU / ml) per well for 24 hours. The following day (i.e., day 1), cells were counted, and T cells were activated with T Cell TransAct.Human(Miltenyi)REA107 1:500, followed by incubation for 24 hours. On day 0, Sendai vector transduction (MOI: KOS 10, KLF4 10, c-MYC 3, SV40 5) was performed, and plates coated with the substrate (iMatrix 511) were prepared by diluting iMatrix 511 (57.6 μl iMatrix + 9 ml PBS). 500 μl of diluted iMatrix was added to each well of the 24-well plate and maintained at 37°C for more than 1 hour. On day 1, cells were pelleted and dispensed into iMatrix-coated plates with 500 μL of stem cell culture medium + bFGF per well. On day 3, 500 μL of fresh stem cell culture medium and bFGF were added to each well of a 24-well plate. On day 7, all suspension cells were collected without suspension and detached by adding 1 mL of TrypLE Express. The cells were incubated at 37°C for 10 minutes, then diluted by adding 500 μL of PBS to each well. The cells were collected and 1 mL of PBS was added. The cells were resuspended and collected, and the suspension cells were combined with the detached cells. The cells were counted, pelleted, resuspended in TCM + IL-2 (60 IU / ml), and reactivated with T Cell TransAct. Human (Miltenyi) (1:500). The supernatant was collected and frozen. On days 11, 14, and 18, the cells were pelleted, harvested, and resuspended in fresh TCM + IL-2 (60 IU / ml).
[0406] Quantitative analysis of adaptive immunity-related cytokines. Supernatants from both control and juvenile cells on days 7, 11, 14, and 18 were analyzed using an Isoplexis Codeplex adaptive immunity selectome chip. The results are shown in Figures 38A and 38B. In both donors, T cell-derived adherent cells on day 7 (D7) showed relatively low expression levels of GM-CSF, IFN-γ, IL-5, IL-13, MIP-1α, and MIP-1β. The expression of these cytokines gradually increased to levels comparable to control cells by day 18 (D18). The expression patterns of IL-6, I...
Claims
[Claim 1] The invention described herein and in the drawings.
